



(43) International Publication Date
25 February 2016 (25.02.2016)

(10) International Publication Number
WO 2016/029146 A1

- (51) **International Patent Classification:**
C07D 403/12 (2006.01) *C07D 487/04* (2006.01)
C07D 471/04 (2006.01)
- (21) **International Application Number:**
PCT/US2015/046357
- (22) **International Filing Date:**
21 August 2015 (21.08.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/040,899 22 August 2014 (22.08.2014) US
62/130,967 10 March 2015 (10.03.2015) US
- (71) **Applicant:** UNIVERSITY OF WASHINGTON
[US/US]; 4311 11th Avenue NE, Suite 500, Seattle, WA
98105-4608 (US).
- (72) **Inventors:** BUCKNER, Frederick, S.; c/o University of
Washington, 4311 11th Avenue NE, Suite 500, Seattle,
WA 98105-4608 (US). ALVAREZ, Ximena, Barros; c/o
University of Washington, 4311 11th Avenue NE, Suite
500, Seattle, WA 98105-4608 (US). FAN, Erkang; c/o
University of Washington, 4311 11th Avenue NE, Suite
500, Seattle, WA 98105-4608 (US). GILLESPIE, John,
Robert; c/o University of Washington, 4311 11th Avenue
NE, Suite 500, Seattle, WA 98105-4608 (US). HOL, Wil-
helmus, G.J.; c/o University of Washington, 4311 11th
Avenue NE, Suite 500, Seattle, WA 98105-4608 (US).
HUANG, Wenlin; c/o University of Washington, 4311
11th Avenue NE, Suite 500, Seattle, WA 98105-4608
(US). KOH, Cho, Yeow; c/o University of Washington,
4311 11th Avenue NE, Suite 500, Seattle, WA 98105-4608
(US). RANADE, Ranae, M.; c/o University of Washing-
ton, 4311 11th Avenue NE, Suite 500, Seattle, WA 98105-

4608 (US). SHIBATA, Sayaka; c/o University of Wash-
ington, 4311 11th Avenue NE, Suite 500, Seattle, WA
98105-4608 (US). VERLINDE, Christophe, L.M.; c/o
University of Washington, 4311 11th Avenue NE, Suite
500, Seattle, WA 98105-4608 (US). ZHANG, Zhong-
sheng; c/o University of Washington, 4311 11th Avenue
NE, Suite 500, Seattle, WA 98105-4608 (US).

- (74) **Agent:** LEONARD, Nicholas, M.; McDonnell Boehnen
Hulbert & Berghoff LLP, 300 South Wacker Drive, Chica-
go, IL 60606 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE

(57) **Abstract:** The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treat-
ing diseases that are ameliorated by the inhibition of MetRS.



WO 2016/029146 A1

SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE

[0001] The present application claims priority to U.S. Provisional Application No. 62/040,899 filed August 22, 2014, and U.S. Provisional Application No. 62/130,967 filed March 10, 2015, the disclosure of which are explicitly incorporated by reference herein.

STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under R01 AI084004 and AI097177 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Field of the Invention

[0003] The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of methionyl-tRNA synthetase (MetRS).

Description of Related Art

[0004] Anti-bacterial compounds kill or inhibit the growth of bacteria by interfering with major processes of cellular function that are essential for survival. The β -lactams (penicillins and cephalosporins) and the glycopeptides (vancomycin and teicoplanin) inhibit synthesis of the cell wall. Macrolides (erythromycin, clarithromycin, and azithromycin), clindamycin, chloramphenicol, aminoglycosides (streptomycin, gentamicin, and amikacin) and the tetracyclines inhibit protein synthesis. Also inhibiting protein synthesis are synthetic oxazolidinones. Rifampin inhibits RNA synthesis, the fluoroquinolones (such as ciprofloxacin) inhibit DNA synthesis indirectly by inhibiting the enzymes that maintain the topological state of DNA. Trimethoprim and the sulfonamides inhibit folate biosynthesis directly and DNA synthesis indirectly by depleting the pools of one of the required nucleotides (Chambers, H. F. and Sande, M. A. (1996) antimicrobial agents. Goodman & Gilman's the pharmacological basis of therapeutics, McGraw-Hill, New York). The disclosure of this reference, and of all other patents, patent applications, and publications referred to herein, are incorporated by reference herein in their entirety.

[0005] Antibiotic resistance is increasingly common. These circumstances have prompted efforts to develop new antibiotics that overcome the emerging antibiotic-resistant bacteria. MetRS has emerged as an attractive target for the development of new antibiotics,

since compounds that inhibit this enzyme have the ability to circumvent existing resistance mechanisms.


DETAILED DESCRIPTION OF THE INVENTION

[0006] The following description provides specific details for a thorough understanding of, and enabling description for, embodiments of the disclosure. However, one skilled in the art will understand that the disclosure may be practiced without these details. In other instances, well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the disclosure.

[0007] In view of the present disclosure, the compounds described herein can be configured by the person of ordinary skill in the art to meet the desired need. In general, the disclosed compounds provide improvements in treatment of diseases that are ameliorated by the inhibition of MetRS. For example, in certain aspects, the compounds of the disclosure are effective against bacterial infection. In certain embodiments the bacterial infection is in the form an infection from Gram positive cocci, including but not limited to *Staphylococcus aureus* and *Enterococcus faecalis*. In certain embodiments, the compounds of the present disclosure are effective in treating or ameliorating infections from *Staphylococcus* (including MRSA), *Enterococcus* (including VRE), *Streptococcus*, *Clostridium*, and others. In certain embodiments, the compositions are effective in treating Mycobacterial infections, including infections from *Mycobacterium tuberculosis*, *Mycobacterium avium complex*, *Mycobacterium fortuitum*, and others. In certain embodiments, the compositions are effective in treating protozoan infections, including infections caused by *Trypanosoma*, *Leishmania*, *Giardia*, *Trichomonas*, and others.

[0008] In certain embodiments, the present disclosure provides pyridine-imidazole (PI) containing compounds capable of blocking protein synthesis by inhibiting MetRS. An important advance of these compounds over related compounds in the literature is their favorable pharmacokinetic profile (as shown in rodents) that potentially makes them suitable for oral administration. The addition of fluorine to the pyridine ring improves the permeability properties.


[0009] In a first aspect, the present disclosure provides compounds of formula (I)



or a pharmaceutically acceptable salt thereof, wherein

R₂ is a aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphanyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl;

Z is N or CR₆, wherein R₆ selected from H, C₁₋₁₂ alkyl, C₁₋₁₂ halogen-alkyl, C₁₋₁₂ alkenyl, C₁₋₁₂ alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclic, optionally substituted heterocyclic, C₁₋₁₂ alcohol, halogen, cyano, ether, thio ether, ester, amine, amide, carbamate, and urea groups; and



wherein

R₁ is an aryl or heteroaryl ring, each optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C1-6)alkenyl (C3-7)cycloalkyl, C(1-6)alkoxy, amino;

X is absent or a linker selected from one of the optionally substituted groups consisting of C₁₋₆ alkanes, C₁₋₆ alkenes, C₁₋₆ alkynes, C₁₋₆ alcohols, ethers, thio ethers, amines, amides, carbamates, ureas and combinations thereof;

E is absent or a 3- to 8-membered cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl group wherein A and B disposed in the 1,2-, 1,3-, or 1,4- positions are independently selected from the group consisting of -C-, -CH-, -CH₂-, -N- or -N(R⁷), where R⁷ is H or C₁₋₁₂ alkyl,

wherein E is optionally substituted with (C1-6)alkyl, -O-(C1-6)alkyl, aryl -O-aryl, heteroaryl, -O-heteroaryl, heterocycloalkyl, -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -NH-aryl, -NH-heteroaryl, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, halogen, nitrile or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and


heteroaryl are optionally substituted with -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, nitrile, heteroaryl, halogen, or (C1-6)alkyloxy; and

Y is absent or a linker selected from the group consisting of C₁₋₃ alkyl, secondary and tertiary amine, thiol, thiol ether, alcohol, ether, ester, amine, amide, carbamate, and urea groups and combinations thereof; provided that

1) when E is absent, Z is NH and R₂ is unsubstituted heteroaryl, unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-NH-, -CH₂-NH-CH₂-CH₂-CH₂-NH- or -CH₂-NH-CH₂-CH₂-CH₂-CH₂-NH-;

2) when E is pyrimidine and Z is NH, R₂ is not phenyl;

or R is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -S(O)₂R⁷, -OC(O)R⁷, -OC(O)OR⁷, -OC(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)OR⁷, or -N(R⁷)C(O)N(R⁷)₂, wherein each R⁷ is independently hydrogen or C₁₋₆ alkyl,



wherein

R³ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -S(O)₂R⁷, -OC(O)R⁷, -OC(O)OR⁷, -OC(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)OR⁷, or -N(R⁷)C(O)N(R⁷)₂, wherein each R⁷ is independently hydrogen or C₁₋₆ alkyl; and

R⁴ is hydrogen, halogen, C₁₋₆ alkyl, or -OR⁸, where R⁸ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₂ cycloalkyl,







heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -S(O)₂R⁷, -OC(O)R⁷, -OC(O)OR⁷, -OC(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)OR⁷, or -N(R⁷)C(O)N(R⁷)₂, wherein each R⁷ is independently hydrogen or C₁₋₆ alkyl.

[0010] In some embodiments, the present disclosure provides compounds of formula (I), provided that:

when Z is NH and R₂ is unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;


[0011] In some embodiments of the first aspect, the compound of formula (I) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):

No.	Chemical Structure	Chemical Name
1575		N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
1576		3-([(3,5-dichlorophenyl)methyl]amino)-N-{1H-imidazo[4,5-b]pyridin-2-yl}propanamide
1599		N1-(3,5-dichlorobenzyl)-N3-(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine

1614		[(3,5-dichlorophenyl)methyl][3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]amine
1634		1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
1641		N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine
1655		(S)-N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine
1673		[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)-2-methylpropyl]amine
1683		N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide

WHAT IS CLAIMED:


1. A compound of the formula (I):



or a pharmaceutically acceptable salt thereof, wherein

R_2 is a aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl;

Z is N or CR_6 , wherein R_6 selected from H, C_{1-12} alkyl, C_{1-12} halogen-alkyl, C_{1-12} alkenyl, C_{1-12} alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclic, optionally substituted heterocyclic, C_{1-12} alcohol, halogen, cyano, ether, thio ether, ester, amine, amide, carbamate, and urea groups; and



wherein

R_1 is an aryl or heteroaryl ring, each optionally substituted with from 1 to 4 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C1-6)alkenyl (C3-7)cycloalkyl, C(1-6)alkoxy, amino;

X is absent or a linker selected from one of the optionally substituted groups consisting of C_{1-6} alkanes, C_{1-6} alkenes, C_{1-6} alkynes, C_{1-6} alcohols, ethers, thio ethers, amines, amides, carbamates, ureas and combinations thereof;

E is absent or a 3- to 8-membered cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl group wherein A and B disposed in the 1,2-, 1,3-, or 1,4- positions are independently selected from the group consisting of -C-, -CH-, -CH₂-, -N- or -N(R⁷), where R⁷ is H or C₁₋₁₂ alkyl, wherein E is optionally substituted with (C1-6)alkyl, -O-(C1-6)alkyl, aryl, -O-aryl, heteroaryl, -O-heteroaryl, heterocycloalkyl, -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -NH-aryl, -NH-heteroaryl, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, halogen, nitrile or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and heteroaryl are optionally substituted with -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, nitrile, heteroaryl, halogen, or (C1-6)alkyloxy; and


Y is absent or a linker selected from the group consisting of C₁₋₃ alkyl, secondary and tertiary amine, thiol, thiol ether, alcohol, ether, ester, amine, amide, carbamate, and urea groups and combinations thereof;

provided that

- 1) when E is absent, Z is NH and R₂ is unsubstituted heteroaryl, unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
- 2) when E is pyrimidine and Z is NH, R₂ is not phenyl;

or R is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl,

-OR⁸, -SR⁸, -N(R⁸)₂, -C(O)R⁸, -C(O)OR⁸, -C(O)N(R⁸)₂, -S(O)₂R⁸, -OC(O)R⁸, -OC(O)OR⁸, -OC(O)N(R⁸)₂, -N(R⁸)C(O)R⁸, -N(R⁸)C(O)OR⁸, or -N(R⁸)C(O)N(R⁸)₂, wherein each R⁸ is independently hydrogen or C₁₋₆ alkyl,




wherein

R³ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl; and

R⁴ is hydrogen, halogen, C₁₋₆ alkyl, or -OR⁸, where R⁸ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl.

2. The compound of claim 1, provided that when Z is NH and R₂ is unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
3. A compound of the formula (II):



or a pharmaceutically acceptable salt thereof,
wherein

R₁ is an aryl or heteroaryl ring, each optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C1-6)alkenyl (C3-7)cycloalkyl, C(1-6)alkoxy, amino;

R₂ is a aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl;

X is absent or a linker selected from the optionally substituted groups consisting of C₁₋₆ alkanes, C₁₋₆ alkenes, C₁₋₆ alkynes, C₁₋₆ alcohols, ethers, thio ethers, amines, amides, carbamates, ureas and combinations thereof;

E is absent or a 3- to 8-membered cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl group wherein A and B disposed in the 1,2-, 1,3-, or 1,4- positions are independently selected from the group consisting of -C-, -CH-, -CH₂-, -N- or -N(R⁷), where R⁷ is H or C₁₋₁₂ alkyl,

wherein E is optionally substituted with (C1-6)alkyl, -O-(C1-6)alkyl, aryl -O-aryl, heteroaryl, -O-heteroaryl, heterocycloalkyl, -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -NH-aryl, -NH-heteroaryl, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, halogen, nitrile or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and heteroaryl are optionally substituted with -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, nitrile, heteroaryl, halogen, or (C1-6)alkyloxy;


Y is absent or a linker selected from the optionally substituted group consisting of C₁₋₃ alkyl, secondary and tertiary amine, thiol, thiol ether, alcohol, ether, ester, amine, amide, carbamate, and urea groups and combinations thereof; and

Z is N or CR₆, wherein R₆ selected from H, C₁₋₁₂ alkyl, C₁₋₁₂ halogen-alkyl, C₁₋₁₂ alkenyl, C₁₋₁₂ alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclic, optionally substituted heterocyclic, C₁₋₁₂ alcohol, halogen, cyano, ether, thio ether, ester, amine, amide, carbamate, and urea groups;

provided that


- 1) when E is absent, Z is NH and R₂ is unsubstituted heteroaryl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-NH-, -CH₂-NH-CH₂-CH₂-CH₂-NH- or -CH₂-NH-CH₂-CH₂-CH₂-CH₂-NH-;
 - 2) when E is pyrimidine and Z is NH, R₂ is not phenyl;
 - 3) when E is absent, Z is NH and R₂ is unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
 - 4) (a) when E is absent, Z is NH and R₂ is pyridinyl substituted with methyl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
 - (b) when E is absent and R₂ is pyridinyl or unsubstituted phenyl, X and Y, alone or in combination, do not form -O-CH₂-CH₂-C(O)-NH-CH₂- or -O-CH₂-CH₂-C(O)-N(Me)-CH₂-;
 - (c) when E is absent, R₁ is dichlorophenyl and R₂ is unsubstituted phenyl, X and Y, alone or in combination, do not form -O-CH=CH-C(O)-NH-CH₂-; and
 - (d) when E is absent and R₂ is pyridinyl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH(Me)-CH₂-NH-, -CH₂-NH-CH₂-CH(OH)-CH₂-NH-, -CH₂-NH-CH₂-C(Me)₂-CH₂-NH- or -CH₂-NH-CH₂-CH₂-C(O)-NH-.
4. The compound of claim 3, wherein E is optionally substituted with -O-aryl, heterocycloalkyl, -OH, halogen or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and heteroaryl are optionally substituted with heteroaryl, halogen, or (C1-6)alkyloxy

5. The compound of claim 3, having the formula (IIa):



or a pharmaceutically acceptable salt thereof.


6. The compound of claim 3, having the formula (IIb):



or a pharmaceutically acceptable salt thereof,


wherein A and B are in the 1,4-positions.

7. The compound of claim 3, having the formula (IIc):



or a pharmaceutically acceptable salt thereof.


8. The compound of claim 3, having the formula (IIId):



or a pharmaceutically acceptable salt thereof,

wherein A and B are in the 1,4-positions.

9. The compound of claim 3 having the formula (IIe):



or a pharmaceutically acceptable salt thereof.

10. The compound of any of claims 5-8, wherein A and B are independently -N- or -CH-.
11. The compound of any of claims 3-10, wherein R₁ is aryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy and amino), (C3-7)cycloalkyl and C(1-6)alkoxy.
12. The compound of claim 11, wherein R₁ is phenyl substituted with from 1 to 3 substituents independently selected from halogen and C(1-6)alkoxy.
13. The compound of claim 12, wherein R₁ is phenyl substituted with 2 substituents independently selected from halogen and C(1-6)alkoxy.
14. The compound of claim 13, wherein R₁ is phenyl substituted with 2 chloro groups.
15. The compound of any of claims 3-14, wherein R₂ is a 5 or 6-membered aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy.
16. The compound of claim 15, wherein R₂ is aryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy.
17. The compound of claim 16, wherein R₂ is phenyl optionally substituted with from 1 to 3 substituents independently selected from halogen, (C1-6)alkyl, perfluoro(C1-3)alkyl or amino.
18. The compound of claim 17, wherein R₂ is unsubstituted phenyl.

19. The compound of claim 17, wherein R₂ is phenyl substituted with two substituents independently selected from halogen, (C1-6)alkyl and perfluoro(C1-3)alkyl.
20. The compound of claim 19, wherein R₂ is phenyl substituted with one halogen.
21. The compound of claim 20, wherein the halogen is fluoro.
22. The compound of any of claims 3-14, wherein R₂ is heteroaryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy.
23. The compound of claim 22, wherein R₂ is pyridyl optionally substituted with from 1 to 3 substituents independently selected from halogen, (C1-6)alkyl, perfluoro(C1-3)alkyl or amino.
24. The compound of claim 23, wherein R₂ is unsubstituted pyridyl.
25. The compound of claim 23, wherein R₂ is pyridyl substituted with two substituents independently selected from halogen, (C1-6)alkyl and perfluoro(C1-3)alkyl.
26. The compound of claim 25, wherein R₂ is pyridyl substituted with one halogen.
27. The compound of claim 26, wherein the halogen is fluoro.
28. The compound of any of claims 3-6 and 9-27, wherein X is (C1-6)alkyl, -N(R₈)-, -(C1-6)alkyl-N(R₈)-, (C1-6)alkyl-N(R₈)-(C1-6)alkyl, -O-, -(C1-6)alkyl-O-, (C1-6)alkyl-O-(C1-6)alkyl, -(C1-6)alkenyl-O-, (C1-6)alkenyl-O-(C1-6)alkenyl, -S-, -(C1-6)alkyl-S-, (C1-6)alkyl-S-(C1-6)alkyl, -C(O)N(R₈)-, -C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-C(O)N(R₈)-, -(C1-6)alkyl-C(O)N(R₈)-(C1-6)alkyl-, -C(O)-, -(C1-6)alkyl-C(O)-, -(C1-6)alkyl-C(O)-(C1-6)alkyl-, -C(O)O-, -(C1-6)alkyl-C(O)O-, -C(O)O-(C1-6)alkyl-, -(C1-6)alkyl-C(O)O-(C1-6)alkyl-, -OC(O)N(R₈)-, -OC(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-OC(O)N(R₈)-, -(C1-6)alkyl-OC(O)N(R₈)-(C1-6)alkyl-,

-N(R₈)C(O)N(R₈)-, -N(R₈)C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-N(R₈)C(O)N(R₈)-(C1-6)alkyl-,

wherein R₈ is hydrogen, (C1-6)alkyl, -C(O)-(C1-6)alkyl, -C(O)O-(C1-6)alkyl, and wherein each (C1-6)alkyl is optionally substituted with (C1-6)alkyl, -N(R₈)₂, -OH or -O-(C1-6)alkyl.

29. The compound of claim 28, wherein X is -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂-N(R₈)-, -CH₂-N(R₈)-CH₂-, -CH₂CH₂-N(R₈)-, -CH₂CH₂-N(R₈)-CH₂CH₂-, -CH(CH₃)CH₂-N(R₈)-, -CH(OH)CH₂-N(R₈)-, -CH₂-O-, -CH₂-O-CH₂-, -CH₂CH₂-O-, -CH₂CH₂-O-CH₂CH₂-, -CH₂-C(O)-, -CH₂-C(O)-CH₂-, -CH₂CH₂-C(O)-, -CH₂CH₂-C(O)-CH₂CH₂-, -CH₂-C(O)N(R₈)-, -CH₂-C(O)N(R₈)-CH₂-, -CH₂CH₂-C(O)N(R₈)-, -CH₂CH₂-C(O)N(R₈)-CH₂CH₂-, -CH₂-C(O)O-, -CH₂-C(O)O-CH₂-, -CH₂CH₂-C(O)O-, -CH₂CH₂-C(O)O-CH₂CH₂-, wherein R₈ is hydrogen or -C(O)CH₃.

30. The compound of any of claims 4 and 7-27, wherein Y is (C1-6)alkyl, -N(R₈)-, -(C1-6)alkyl-N(R₈)-, (C1-6)alkyl-N(R₈)-(C1-6)alkyl, -O-, -(C1-6)alkyl-O-, (C1-6)alkyl-O-(C1-6)alkyl, -(C1-6)alkenyl-O-, (C1-6)alkenyl-O-(C1-6)alkenyl, -S-, -(C1-6)alkyl-S-, (C1-6)alkyl-S-(C1-6)alkyl, -C(O)N(R₈)-, -C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-C(O)N(R₈)-, -(C1-6)alkyl-C(O)N(R₈)-(C1-6)alkyl-, -C(O)-, -(C1-6)alkyl-C(O)-, -(C1-6)alkyl-C(O)-(C1-6)alkyl-, -C(O)O-, -(C1-6)alkyl-C(O)O-, -C(O)O-(C1-6)alkyl-, -(C1-6)alkyl-C(O)O-(C1-6)alkyl-, -OC(O)N(R₈)-, -OC(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-OC(O)N(R₈)-, -(C1-6)alkyl-OC(O)N(R₈)-(C1-6)alkyl-, -N(R₈)C(O)N(R₈)-, -N(R₈)C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-N(R₈)C(O)N(R₈)-(C1-6)alkyl-, wherein R₈ is hydrogen, (C1-6)alkyl, -C(O)-(C1-6)alkyl, -C(O)O-(C1-6)alkyl, and wherein each (C1-6)alkyl is optionally substituted with (C1-6)alkyl, -N(R₈)₂, -OH or -O-(C1-6)alkyl.

31. The compound of claim 30, wherein Y is -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂-N(R₈)-, -CH₂-N(R₈)-CH₂-, -CH₂CH₂-N(R₈)-, -CH₂CH₂-N(R₈)-CH₂CH₂-, -CH(CH₃)CH₂-N(R₈)-, -CH(OH)CH₂-N(R₈)-, -CH₂-O-, -CH₂-O-CH₂-, -CH₂CH₂-O-, -CH₂CH₂-O-CH₂CH₂-, -CH₂-C(O)-, -CH₂-C(O)-CH₂-, -CH₂CH₂-C(O)-, -CH₂CH₂-C(O)-CH₂CH₂-, -CH₂-C(O)N(R₈)-, -CH₂-C(O)N(R₈)-CH₂-, -CH₂CH₂-

C(O)N(R₈)-, -CH₂CH₂-C(O)N(R₈)-CH₂CH₂-, -CH₂-C(O)O-, -CH₂-C(O)O-CH₂-,
-CH₂CH₂-C(O)O-, -CH₂CH₂-C(O)O-CH₂CH₂-,

wherein R₈ is hydrogen or -C(O)CH₃.

32. The compound of claim 3, wherein the compound is:

2-[(3-[(3,5-dichlorophenyl)methyl]amino)propyl]amino]-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile

N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2,4-dichlorophenoxy)acetamide

2-(2,4-dichlorophenoxy)-N-(1H-indol-2-ylmethyl)acetamide

N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-2-(2,4-dichlorophenoxy)acetamide

benzyl N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl} carbamate

2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)carbamate

3-(1H-1,3-benzodiazol-2-ylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]urea

(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(4-fluorophenyl)butanamide

2-(2,4-dichlorophenyl)ethyl N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl} carbamate

2-(2,4-dichlorophenyl)ethyl N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)carbamate

[(3,5-dichlorophenyl)methyl][2,2-difluoro-3-({3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]amine

N-(3-[[1-(3,5-dichlorophenyl)cyclopropyl]amino]propyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine

(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide

(3S)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide

2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)-N-methylcarbamate

1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(2,4-dichlorophenyl)ethan-1-one

1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one

1-[3-(4-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one

1-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one

1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2-chlorophenyl)methyl]piperazin-2-one

1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3-chlorophenyl)methyl]piperazin-2-one

(3E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)but-3-enamide

N-[1-(1H-1,3-benzodiazol-2-yl)cyclopropyl]-3-(2,4-dichlorophenoxy)propanamide

1H-1,3-benzodiazol-2-ylmethyl N-[2-(2,4-dichlorophenyl)ethyl]carbamate

3-(2,4-dichlorophenoxy)-N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]propanamide

2-(2,4-dichlorophenyl)ethyl N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]carbamate
 2-(3,5-dichlorophenyl)-1-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]ethan-1-one
 1-[3-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
 1-[3-(5-chloro-6-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
 1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]piperazin-2-one
 1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3,5-dichlorophenyl)methyl]piperazin-2-one
 2-({1-[(2,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl} methyl)-1H-1,3-benzodiazole
 2-({1-[(3,5-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl} methyl)-1H-1,3-benzodiazole
 (5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-dione
 methyl (2S)-2-{{[(1H-1,3-benzodiazol-2-ylmethyl)carbamoyl]amino}-3-(2,4-dichlorophenyl)propanoate
 N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1-benzofuran-2-yl)acetamide
 1-[(3R)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
 1-[(3S)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
 3-(5-chloro-1H-1,3-benzodiazol-2-yl)-N-(3,5-dichlorophenyl)piperidine-1-carboxamide
 1-(1H-1,3-benzodiazol-2-ylmethyl)-4-(naphthalene-2-carbonyl)piperazin-2-one
 2-(3,5-dichlorophenyl)-1-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl)ethan-1-one
 1-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl)-2-(3,5-dichlorophenyl)ethan-1-one
 N-(1H-1,3-benzodiazol-2-ylmethyl)-3-[(2,4-dichlorophenyl)amino]propanamide
 N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1H-1,3-benzodiazol-2-yl)acetamide
 (2E)-N'-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enhydrazide
 (2E)-N-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enhydrazide
 [2-(6-chloro-1H-1,3-benzodiazol-2-yl)ethyl][(3,5-dichlorophenyl)methyl]amine
 (2E)-3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)prop-2-enamide
 3-[(1H-1,3-benzodiazol-2-ylmethyl)amino]-4-{{[(2,4-dichlorophenyl)methyl]amino}cyclobut-3-ene-1,2-dione
 (2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-{2,4-dichloro-6-[(methylamino)methyl]phenoxy}prop-2-enamide
 (2-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine

3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} -N-[(3,5-dichlorophenyl)methyl]piperidine-1-carboxamide

N-(3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} cyclohexyl)-2-(3,5-dichlorophenyl)acetamide

2-amino-1-[(3S)-3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one

3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} -N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine

N-(3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide

1-(2- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} morpholin-4-yl)-2-(3,5-dichlorophenyl)ethan-1-one

N-(2-amino-6-chloropyridin-3-yl)-4-[2-(3,5-dichlorophenyl)acetyl]piperazine-2-carboxamide

(4S)-1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]imidazolidin-2-one

3- {5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} -1-[(3,5-dichlorophenyl)methyl]urea

[1-(5-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine

2-amino-3-(1H-1,3-benzodiazol-2-yl)-N-[2-(2,4-dichlorophenyl)ethyl]propanamide

2-chloro-6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)pyrimidin-4-amine

6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2-[4-(pyrazin-2-yl)piperazin-1-yl]pyrimidin-4-amine

1-[2-(3,5-dichlorophenyl)ethyl]-3- {5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl} piperidine

(2S)-2-amino-1-[(3S)-3- {5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-1-yl]-3-(2,4-dichlorophenyl)propan-1-one

N-[(3,5-dichlorophenyl)methyl]-3- {5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl} cyclohexan-1-amine

N-[(3,5-dichlorophenyl)methyl]-N-(3- {5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl} cyclohexyl)acetamide

N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-[(2,4-dichlorophenyl)methyl]ethanediamide

N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-(2,4-dichlorophenyl)propanediamide

2-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]acetamide

[(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine

[(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine

(2S)-2-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide

(2S)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenyl)-2-(methylamino)propanamide

3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]cyclohexan-1-amine
 N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(2,4-dichlorophenyl)methyl]acetamide
 1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine
 3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[2-(3,5-dichlorophenyl)ethyl]piperidine
 5-chloro-2-[(3S)-1-[(3,5-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole
 3-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-[(3,5-dichlorophenyl)methyl]piperidine
 3-(1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
 N-[3-(1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
 N-[(3,5-dichlorophenyl)methyl]-3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexan-1-amine
 N-[(3,5-dichlorophenyl)methyl]-N-(3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
 [1-(1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [(3,5-dichlorophenyl)methyl][1-(6-methyl-1H-1,3-benzodiazol-2-yl)propan-2-yl]amine
 [1-(6-bromo-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [1-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [1-(4,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [1-(6-chloro-5-fluoro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [(3,5-dichlorophenyl)methyl]({1-[6-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]propan-2-yl})amine
 [(3,5-dichlorophenyl)methyl](1-{1H-naphtho[2,3-d]imidazol-2-yl}propan-2-yl)amine
 [(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)butan-2-yl][(3,5-dichlorophenyl)methyl]amine
 [(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)-3-methylbutan-2-yl][(3,5-dichlorophenyl)methyl]amine
 {2-[(6-chloro-1H-1,3-benzodiazol-2-yl)amino]ethyl}[(3,5-dichlorophenyl)methyl]amine
 N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-[[[(3,5-dichlorophenyl)methyl]amino]acetamide
 (2S)-N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-[[[(3,5-dichlorophenyl)methyl]amino]propanamide
 [3-(6-chloro-1H-1,3-benzodiazol-2-yl)propyl][(3,5-dichlorophenyl)methyl]amine
 N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]acetamide
 N-[(3,5-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-

yl}propyl)acetamide

N-[(2,4-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide

5-chloro-2-[(3S)-1-[(2,4-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole

5-chloro-2-[(3R)-1-[(3,5-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole

N-[(3,5-dichlorophenyl)methyl]-3-(5-fluoro-1H-1,3-benzodiazol-2-yl)cyclohexan-1-amine

3-(5-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine

3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine

N-(3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide

(2-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine

(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine

(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine

(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine

(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine

[2-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino]ethyl[(3,5-dichlorophenyl)methyl]amine

[2-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)amino]ethyl[(3,5-dichlorophenyl)methyl]amine

N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide

N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide

[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine

(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine

(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine

1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]piperidin-3-amine

[(3,5-dichlorophenyl)methyl](3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}propyl)amine

N-[(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide

N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)cyclohexyl]acetamide
 N-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
 3,5-dichloro-N-[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]aniline
 N-[(1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]-3,5-dichloroaniline
 1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
 1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
 1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-4-[(3,5-dichlorophenyl)methyl]piperazine
 1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-4-amine
 (3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dichlorophenyl)methyl]piperidine
 (3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(2,4-dichlorophenyl)methyl]piperidine
 (3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,4-dichlorophenyl)methyl]piperidine
 (3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dibromophenyl)methyl]piperidine
 (3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dimethoxyphenyl)methyl]piperidine
 N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide
 N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide
 N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
 N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
 N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
 N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
 N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
 N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
 (3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}propyl)[(3,5-dichlorophenyl)methyl]amine
 (2-{6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
 6-(2-chloro-4-methoxyphenoxy)-2-N,4-N-bis({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazine-2,4-diamine
 4,6-bis(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazin-2-amine

4-(2-chloro-4-methoxyphenoxy)-6-[(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]-1,3,5-triazin-2-ol

N-[(3,5-dichlorophenyl)methyl]-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine

N-[(3,5-dichlorophenyl)methyl]-N-(1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)acetamide

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-(3,5-dichlorophenyl)piperidine-3-carboxamide

3,5-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]benzamide

3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl-1-(3,5-dichlorophenyl)urea

3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl-1-(2,4-dichlorophenyl)urea

{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl[2-(2,4-dichlorophenyl)ethyl]amine

5-chloro-N-(2-{[(3,5-dichlorophenyl)methyl]amino}ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine

6-bromo-5-chloro-N-(2-{[(3,5-dichlorophenyl)methyl]amino}ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine

N-(3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}propyl)-N-[(3,5-dichlorophenyl)methyl]acetamide

[2-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]ethyl[(3,5-dichlorophenyl)methyl]amine

N-[(3,5-dichlorophenyl)methyl]-N-[2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)amino]ethylacetamide

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-3-[(3,5-dichlorophenyl)methoxy]piperidine

6,8-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]-1,2,3,4-tetrahydroquinolin-4-amine

(3S)-N-[(3,5-dichlorophenyl)methyl]-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine

N-[(3,5-dichlorophenyl)methyl]-N-[(3S)-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]acetamide

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine

1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azepan-3-amine

(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-3-[(3,5-dichlorophenyl)methoxy]piperidine

(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine

(5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-diol

1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromophenyl)methyl]piperidin-3-amine

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-methoxyphenyl)methyl]piperidin-3-amine

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-ethoxyphenyl)methyl]piperidin-3-amine

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-methoxyphenyl)methyl]piperidin-3-amine

(3S)-N-[(3-bromo-5-chlorophenyl)methyl]-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine

N-(2-[(3,5-dichlorophenyl)methyl]amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine

N-[(3,5-dichlorophenyl)methyl]-N-[2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)(methyl)amino]ethyl]acetamide

[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}azetidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine

[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}pyrrolidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine

5-chloro-N-(2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine

N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine

N-(2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-ethoxyphenyl)methyl]piperidin-3-amine

2,4-dichloro-6-([(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]amino)methyl]phenol

3,5-dichloro-N-[(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]methyl]aniline

3,5-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]methyl]aniline

N-(1H-1,3-benzodiazol-2-ylmethyl)-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine

5-chloro-N-(2-[(3,5-dichloro-2-ethoxyphenyl)methyl]amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine

N-[2-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)(methyl)amino]ethyl]-N-[(3,5-dichlorophenyl)methyl]acetamide

(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-propoxyphenyl)methyl]piperidin-3-amine


(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-(prop-2-en-1-

yloxy)phenyl)methyl} piperidin-3-amine
 (3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-(cyclopropylmethoxy)phenyl)methyl} piperidin-3-amine
 (3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-cyclopropoxyphenyl)methyl} piperidin-3-amine
 (3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-(propan-2-yloxy)phenyl)methyl} piperidin-3-amine
 N-{(3,5-dichlorophenyl)methyl}-N-[(1R,3S)-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl]acetamide
 N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
 (4S)-1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-5-hydroxyimidazolidin-2-one
 3-(1H-1,3-benzodiazol-2-ylmethyl)-1-[(2S)-1-(2,4-dichlorophenyl)-3-hydroxypropan-2-yl]urea
 1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-1H-imidazol-2-ol
 (3S)-N-{(3-bromo-5-chloro-2-ethoxyphenyl)methyl}-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-amine
 N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-N-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]acetamide
 N-(2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl][2-({5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
 (3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-(ethylamino)phenyl)methyl} piperidin-3-amine
 N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2-chloro-4-methoxyphenoxy)aniline
 N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]propanamide
 N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]-N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)acetamide
 3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
 N-(1-acetyl-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]acetamide
 5-chloro-N-(2-[(3,5-dichlorophenyl)methyl]amino)ethyl)-N-ethyl-3H-imidazo[4,5-b]pyridin-2-amine
 N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2-chloro-4-methoxyphenoxy)pyridin-4-amine
 2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}sulfanyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
 3-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]aniline

3,5-dichloro-N-[3-(6-chloro-1H-1,3-benzodiazol-2-yl)phenyl]benzamide
3,5-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]-N-ethylpiperidin-3-amine
2,4-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
2-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
3-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]propanamide
N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]acetamide
4-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)pyridin-2-amine
4-[(2,4-dichlorophenyl)methyl]-1-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2,3-dihydro-1H-imidazol-2-one
methyl N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]carbamate
methyl N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]carbamate
methyl 2-[(3-[(3,5-dichlorophenyl)methyl](methoxycarbonyl)amino)propyl]amino]-5-fluoro-3H-imidazo[4,5-b]pyridine-3-carboxylate
3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]aniline
3,5-dichloro-N-[3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]-3-propanamidopropanamide
3-amino-3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-N-[(3,5-dichlorophenyl)methyl]acetamide
N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]-2-hydroxyacetamide
1-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-1-[(3,5-dichlorophenyl)methyl]urea
N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-2-hydroxyacetamide
1-[(3,5-dichlorophenyl)methyl]-1-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]urea
N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2-[(3,5-dichlorophenyl)amino]acetamide
3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-1-[(3,5-

dichlorophenyl)methyl]urea
 3-chloro-5-({[(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]amino} methyl)benzonitrile
 ({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)({2-[(3,5-dichlorophenyl)amino]ethyl})amine
 5-chloro-N-[3-(4,6-dichloro-1H-indol-1-yl)propyl]-3H-imidazo[4,5-b]pyridin-2-amine
 or a pharmaceutically acceptable salt thereof.


33. A pharmaceutical composition comprising one or more of compounds according to any of claims 1-32 and a pharmaceutically acceptable carrier, diluent, or excipient.
34. A method for treating diseases that are ameliorated by the inhibition of MetRS, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of claims 1-32 or a pharmaceutical composition of claim 33.
35. The method of claim 34, wherein the disease is selected from the group consisting of Protozoan, Mycobacterial, Staphylococcus, Enterococcus, Streptococcus, and Clostridium infections.
36. A compound of the formula (III):



or a pharmaceutically acceptable salt thereof, wherein

R is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁸, -SR⁸, -N(R⁸)₂, -C(O)R⁸, -C(O)OR⁸, -C(O)N(R⁸)₂, -S(O)₂R⁸, -OC(O)R⁸, -OC(O)OR⁸, -OC(O)N(R⁸)₂, -N(R⁸)C(O)R⁸, -N(R⁸)C(O)OR⁸, or -N(R⁸)C(O)N(R⁸)₂, wherein each R⁸ is independently hydrogen or C₁₋₆ alkyl.

37. A compound of the formula (IV):




or a pharmaceutically acceptable salt thereof, wherein

R³ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl,

-OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl; and

R⁴ is hydrogen, halogen, C₁₋₆ alkyl, or -OR¹⁰, where R¹⁰ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl.

38. A compound of the formula (V):



or a pharmaceutically acceptable salt thereof, wherein

R⁵ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl,

-OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -O

$C(O)OR^9$, $-OC(O)N(R^9)_2$, $-N(R^9)C(O)R^9$, $-N(R^9)C(O)OR^9$, or $-N(R^9)C(O)N(R^9)_2$,
wherein each R^9 is independently hydrogen or C_{1-6} alkyl.

39. A compound that is:

N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
 3-([(3,5-dichlorophenyl)methyl]amino)-N-(1H-imidazo[4,5-b]pyridin-2-yl)propanamide
 N1-(3,5-dichlorobenzyl)-N3-(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
 [(3,5-dichlorophenyl)methyl][3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propylamine
 1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
 N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine
 (S)-N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine
 [(3,5-dichlorophenyl)methyl][(2S)-3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]-2-methylpropylamine
 N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
 3-(2,4-dichlorophenoxy)-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)propanamide
 3-(2,4-dichlorophenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methylpropanamide
 (4R)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
 (R)-N1-(6,8-dichlorochroman-4-yl)-N3-(3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
 (4S)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
 (4R)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-1,2,3,4-tetrahydroquinolin-4-amine
 N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)-N-methylpropanamide
 (2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
 (2Z)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
 or a pharmaceutically acceptable salt thereof.

40. A compound that is:

[(3,5-dichlorophenyl)methyl][3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propylamine
 1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
 N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine

[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-2-methylpropyl]amine

3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide

(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine

(4S)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine

(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-1,2,3,4-tetrahydroquinolin-4-amine

or a pharmaceutically acceptable salt thereof.

41. A compound having the structure:

3- [{(3,5-dichlorophenyl)methyl}amino]-N-(1H-imidazo[4,5-b]pyridin-2-yl)propanamide

1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol

N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine

(S)-N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine

[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-2-methylpropyl]amine

N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide

3-(2,4-dichlorophenoxy)-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)propanamide

3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide

N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)-N-methylpropanamide

(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide

(2Z)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide

or a pharmaceutically acceptable salt thereof.

42. A compound having the structure:


[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-2-methylpropyl]amine

N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide


3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide

or a pharmaceutically acceptable salt thereof.






43. A pharmaceutical composition comprising one or more of compounds according to any one of claims 36-41 and a pharmaceutically acceptable carrier, diluent, or excipient.
44. A method for treating diseases that are ameliorated by the inhibition of MetRS comprising providing to a patient in need of such treatment a therapeutically effective amount of either a compound according to any one of claims 36-42 or a pharmaceutical composition of claim 43.
45. The method of claim 44, wherein the disease is selected from the group consisting of a bacterial infection.
46. The method of claim 45, wherein the bacterial infection is a Gram positive bacterial infection.
47. The method of claim 46, wherein the Gram positive bacterial infection is selected from one of Staphylococcus, Enterococcus, Streptococcus, Clostridium, Bacillus, Helicobacter pylori, and Listeria.
48. The method of claim 45, wherein the bacteria is a Gram negative bacteria.
49. The method of claim 48, wherein the Gram negative bacteria is Brucella.
50. The method of claim 45 wherein the disease is a Mycobacterium tuberculosis infection.
51. The method of claim 45, wherein the disease is a Trypanosomatid protozoa infection.
52. The method of claim 51, wherein the Trypanosomatid protozoa is one of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania species.
53. A compound having the structure of compound A or compound B:













54. A method for the synthesis of a compound of claim 1, wherein a compound having the structure of compound A or compound B:













is used as an intermediate.






1704		3-(2,4-dichlorophenoxy)-N-({3H-imidazo[4,5-b]pyridin-2-ylmethyl} propanamide
1705		3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide
1709		(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
1710		(R)-N1-(6,8-dichlorochroman-4-yl)-N3-(3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
1711		(4S)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine






1717		(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]-1,2,3,4-tetrahydroquinolin-4-amine
1727		N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)-N-methylpropanamide
1729		(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
1730		(2Z)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
1627		2-[(3-[(3,5-dichlorophenyl)methyl]amino)propylamino]-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile






1671		N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2,4-dichlorophenoxy)acetamide
1674		2-(2,4-dichlorophenoxy)-N-(1H-indol-2-ylmethyl)acetamide
1675		N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-2-(2,4-dichlorophenoxy)acetamide
1699		benzyl N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl} carbamate
1701		2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)carbamate






1702		3-(1H-1,3-benzodiazol-2-ylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]urea
1703		(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(4-fluorophenyl)butanamide
1706		2-(2,4-dichlorophenyl)ethyl N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)carbamate
1707		2-(2,4-dichlorophenyl)ethyl N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)carbamate
1708		[(3,5-dichlorophenyl)methyl][2,2-difluoro-3-(3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]amine






1716		N-(3-{[1-(3,5-dichlorophenyl)cyclopropyl]amino}propyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine
1720		(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide
1726		(3S)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide
1728		2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)-N-methylcarbamate
1731		1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(2,4-dichlorophenyl)ethan-1-one






1732		1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1733		1-[3-(4-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1734		1-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1735		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2-chlorophenyl)methyl]piperazin-2-one
1736		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3-chlorophenyl)methyl]piperazin-2-one






1737		(3E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)but-3-enamide
1738		N-[1-(1H-1,3-benzodiazol-2-yl)cyclopropyl]-3-(2,4-dichlorophenoxy)propanamide
1739		1H-1,3-benzodiazol-2-ylmethyl N-[2-(2,4-dichlorophenyl)ethyl]carbamate
1740		3-(2,4-dichlorophenoxy)-N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]propanamide
1741		2-(2,4-dichlorophenyl)ethyl N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]carbamate






1744		2-(3,5-dichlorophenyl)-1-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]ethan-1-one
1745		1-[3-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1746		1-[3-(5-chloro-6-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1747		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]piperazin-2-one
1748		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3,5-dichlorophenyl)methyl]piperazin-2-one






1752		2-({1-[(2,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-1H-1,3-benzodiazole
1753		2-({1-[(3,5-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-1H-1,3-benzodiazole
1754		(5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-dione
1755		methyl (2S)-2- {[(1H-1,3-benzodiazol-2-ylmethyl)carbamoyl]amino }-3-(2,4-dichlorophenyl)propanoate
1756		N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1-benzofuran-2-yl)acetamide






1757		1-[(3R)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1758		1-[(3S)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1759		3-(5-chloro-1H-1,3-benzodiazol-2-yl)-N-(3,5-dichlorophenyl)piperidine-1-carboxamide
1760		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-(naphthalene-2-carbonyl)piperazin-2-one
1761		2-(3,5-dichlorophenyl)-1-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl)ethan-1-one






1762		1-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethan-1-one
1763		N-(1H-1,3-benzodiazol-2-ylmethyl)-3-[(2,4-dichlorophenyl)amino]propanamide
1764		N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1H-1,3-benzodiazol-2-yl)acetamide
1765		(2E)-N'-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enehydrazide
1766		(2E)-N-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enehydrazide





1767		[2-(6-chloro-1H-1,3-benzodiazol-2-yl)ethyl][(3,5-dichlorophenyl)methyl]amine
1768		(2E)-3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)prop-2-enamide
1769		3-[(1H-1,3-benzodiazol-2-ylmethyl)amino]-4-{{(2,4-dichlorophenyl)methyl}amino}cyclobut-3-ene-1,2-dione
1779		(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-{2,4-dichloro-6-[(methylamino)methyl]phenoxy}prop-2-enamide
1780		(2-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine






1785		3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidine-1-carboxamide
1786		N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-2-(3,5-dichlorophenyl)acetamide
1787		2-amino-1-[(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1788		3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1789		N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide






1790		1-(2-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}morpholin-4-yl)-2-(3,5-dichlorophenyl)ethan-1-one
1791		N-(2-amino-6-chloropyridin-3-yl)-4-[2-(3,5-dichlorophenyl)acetyl]piperazine-2-carboxamide
1792		(4S)-1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]imidazolidin-2-one
1793		3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dichlorophenyl)methyl]urea
1794		[1-(5-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine






1795		2-amino-3-(1H-1,3-benzodiazol-2-yl)-N-[2-(2,4-dichlorophenyl)ethyl]propanamide
1796		2-chloro-6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)pyrimidin-4-amine
1797		6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2-[4-(pyrazin-2-yl)piperazin-1-yl]pyrimidin-4-amine
1798		1-[2-(3,5-dichlorophenyl)ethyl]-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidine
1799		(2S)-2-amino-1-[(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl]-3-(2,4-dichlorophenyl)propan-1-one






1800		N-[(3,5-dichlorophenyl)methyl]-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexan-1-amine
1801		N-[(3,5-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
1802		N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-[(2,4-dichlorophenyl)methyl]ethanediamide
1803		N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-(2,4-dichlorophenyl)propanediamide
1804		2-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]acetamide






1805		[(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1806		[(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1807		(2S)-2-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
1808		(2S)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenyl)-2-(methylamino)propanamide
1809		3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]cyclohexan-1-amine






1810		N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(2,4-dichlorophenyl)methyl]acetamide
1811		1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine
1812		3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[2-(3,5-dichlorophenyl)ethyl]piperidine
1813		5-chloro-2-[(3S)-1-[(3,5-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole
1814		3-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-[(3,5-dichlorophenyl)methyl]piperidine






1815		3-(1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1816		N-[3-(1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1817		N-[(3,5-dichlorophenyl)methyl]-3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexan-1-amine
1818		N-[(3,5-dichlorophenyl)methyl]-N-(3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
1819		[1-(1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine






1820		[(3,5-dichlorophenyl)methyl][1-(6-methyl-1H-1,3-benzodiazol-2-yl)propan-2-yl]amine
1821		[1-(6-bromo-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1822		[1-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1823		[1-(4,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1824		[1-(6-chloro-5-fluoro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine






1825		[(3,5-dichlorophenyl)methyl]({1-[6-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]propan-2-yl})amine
1826		[(3,5-dichlorophenyl)methyl]({1-{1H-naphtho[2,3-d]imidazol-2-yl}propan-2-yl})amine
1827		[(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)butan-2-yl][(3,5-dichlorophenyl)methyl]amine
1828		[(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)-3-methylbutan-2-yl][(3,5-dichlorophenyl)methyl]amine
1829		{2-[(6-chloro-1H-1,3-benzodiazol-2-yl)amino]ethyl}[(3,5-dichlorophenyl)methyl]amine

1830		N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-([(3,5-dichlorophenyl)methyl]amino)acetamide
1831		(2S)-N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-([(3,5-dichlorophenyl)methyl]amino)propanamide
1832		[3-(6-chloro-1H-1,3-benzodiazol-2-yl)propyl][(3,5-dichlorophenyl)methyl]amine
1833		N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]acetamide
1835		N-[(3,5-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}propyl)acetamide






1836		N-[(2,4-dichlorophenyl)methyl]- N-(3-{5-fluoro-1H-imidazo[4,5- b]pyridin-2- yl}cyclohexyl)acetamide
1837		5-chloro-2-[(3S)-1-[(2,4- dichlorophenyl)methyl]piperidin- 3-yl]-1H-1,3-benzodiazole
1838		5-chloro-2-[(3R)-1-[(3,5- dichlorophenyl)methyl]piperidin- 3-yl]-1H-1,3-benzodiazole
1839		N-[(3,5-dichlorophenyl)methyl]-3- (5-fluoro-1H-1,3-benzodiazol-2- yl)cyclohexan-1-amine
1840		3-(5-chloro-1H-1,3-benzodiazol-2- yl)-N-[(3,5- dichlorophenyl)methyl]cyclohexan- 1-amine






1841		3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1842		N-(3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1844		(2-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
1845		(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine
1846		(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine






1847		(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine
1848		(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine
1849		[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}amino)ethyl][(3,5-dichlorophenyl)methyl]amine
1850		[2-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}amino)ethyl][(3,5-dichlorophenyl)methyl]amine
1851		N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide






1852		N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide
1853		[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine
1854		(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1855		(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine
1856		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine






1857		1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]piperidin-3-amine
1858		[(3,5-dichlorophenyl)methyl](3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}propyl)amine
1859		N-[(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1860		N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)cyclohexyl]acetamide
1861		N-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide






1862		3,5-dichloro-N-[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]aniline
1863		N-[(1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]-3,5-dichloroaniline
1864		1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
1865		1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
1866		1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-4-[(3,5-dichlorophenyl)methyl]piperazine





1867		1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl])piperidin-4-amine
1868		(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dichlorophenyl)methyl]piperidine
1869		(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(2,4-dichlorophenyl)methyl]piperidine
1870		(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,4-dichlorophenyl)methyl]piperidine
1871		(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dibromophenyl)methyl]piperidine






1872		(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dimethoxyphenyl)methyl]piperidine
1873		N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide
1874		N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide
1875		N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1876		N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide

1877		N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1878		N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
1879		N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1880		N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
1881		(3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}propyl)[(3,5-dichlorophenyl)methyl]amine






1882		(2-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
1883		6-(2-chloro-4-methoxyphenoxy)-2-N,4-N-bis({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazine-2,4-diamine
1884		4,6-bis(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazin-2-amine
1885		4-(2-chloro-4-methoxyphenoxy)-6-[(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]-1,3,5-triazin-2-ol
1886		N-[(3,5-dichlorophenyl)methyl]-1-({5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine






1887		N-[(3,5-dichlorophenyl)methyl]-N-(1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)acetamide
1888		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-(3,5-dichlorophenyl)piperidine-3-carboxamide
1889		3,5-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]benzamide
1890		3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-(3,5-dichlorophenyl)urea
1891		3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-(2,4-dichlorophenyl)urea






1892		({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)[2-(2,4-dichlorophenyl)ethyl]amine
1893		5-chloro-N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1894		6-bromo-5-chloro-N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1895		N-(3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)propyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1896		[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} sulfanyl)ethyl][{(3,5-dichlorophenyl)methyl}amine






1897		N-[(3,5-dichlorophenyl)methyl]- N-[2-(5-fluoro-1H-imidazo[4,5- b]pyridin-2- yl)amino]ethyl]acetamide
1898		(3S)-1-{5-chloro-1H-imidazo[4,5- b]pyridin-2-yl}-3-[(3,5- dichlorophenyl)methoxy]piperidin e
1899		6,8-dichloro-N-[(3S)-1-{5-chloro- 1H-imidazo[4,5-b]pyridin-2- yl}piperidin-3-yl]-1,2,3,4- tetrahydroquinolin-4-amine
1900		(3S)-N-[(3,5- dichlorophenyl)methyl]-1-{5- fluoro-1H-imidazo[4,5-b]pyridin- 2-yl}piperidin-3-amine
1901		N-[(3,5-dichlorophenyl)methyl]- N-[(3S)-1-{5-fluoro-1H- imidazo[4,5-b]pyridin-2- yl}piperidin-3-yl]acetamide

1902		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine
1903		1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azepan-3-amine
1904		(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-3-[(3,5-dichlorophenyl)methoxy]piperidine
1905		(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine
1906		(5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-diol






1907		1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one
1908		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromophenyl)methyl]piperidin-3-amine
1909		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-methoxyphenyl)methyl]piperidin-3-amine
1910		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-ethoxyphenyl)methyl]piperidin-3-amine
1911		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-methoxyphenyl)methyl]piperidin-3-amine

1912		(3S)-N-[(3-bromo-5-chlorophenyl)methyl]-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine
1913		N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1914		N-[(3,5-dichlorophenyl)methyl]-N-[2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)(methyl)amino]ethyl]acetamide
1915		[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}azetidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine
1916		[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}pyrrolidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine






1917		5-chloro-N-(2-({[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]amino}ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1918		N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
1919		N-(2-({[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]amino}ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1920		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-ethoxyphenyl)methyl]piperidin-3-amine
1921		2,4-dichloro-6-({[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]amino}methyl)phenol






1922		3,5-dichloro-N-([(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]aniline
1923		3,5-dichloro-N-([(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]aniline
1924		N-(1H-1,3-benzodiazol-2-ylmethyl)-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
1925		5-chloro-N-(2-([(3,5-dichloro-2-ethoxyphenyl)methyl]amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1926		N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]acetamide






1927		(3S)-1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-propoxyphenyl)methyl])piperidin-3-amine
1928		(3S)-1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-(prop-2-en-1-yloxy)phenyl)methyl])piperidin-3-amine
1929		(3S)-1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-(cyclopropylmethoxy)phenyl)methyl])piperidin-3-amine
1930		(3S)-1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-cyclopropoxyphenyl)methyl])piperidin-3-amine
1931		(3S)-1-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-(propan-2-yloxy)phenyl)methyl])piperidin-3-amine






1932		N-[(3,5-dichlorophenyl)methyl]- N-[(1R,3S)-3-{5-fluoro-1H- imidazo[4,5-b]pyridin-2- yl}cyclohexyl]acetamide
1933		N-(1H-1,3-benzodiazol-2- ylmethyl)-4-(2-chloro-4- methoxyphenoxy)pyridin-2-amine
1934		(4S)-1-(1H-1,3-benzodiazol-2- ylmethyl)-4-[(2,4- dichlorophenyl)methyl]-5- hydroxyimidazolidin-2-one
1935		3-(1H-1,3-benzodiazol-2- ylmethyl)-1-[(2S)-1-(2,4- dichlorophenyl)-3-hydroxypropan- 2-yl]urea
1936		1-(1H-1,3-benzodiazol-2- ylmethyl)-4-[(2,4- dichlorophenyl)methyl]-2,3- dihydro-1H-imidazol-2-ol






1937		(3S)-N-[(3-bromo-5-chloro-2-ethoxyphenyl)methyl]-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine
1938		N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}(methylamino)ethyl)-N-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]acetamide
1939		N-(2-[[[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl][2-({5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}(methylamino)ethyl)amino]ethyl]-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1940		(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-(ethylamino)phenyl]methyl}piperidin-3-amine
1941		N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2-chloro-4-methoxyphenoxy)aniline






1942		N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]propanamide
1943		N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]-N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)acetamide
1944		3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
1945		N-(1-acetyl-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]acetamide
1949		5-chloro-N-(2-{{(3,5-dichlorophenyl)methyl}amino}ethyl)-N-ethyl-3H-imidazo[4,5-b]pyridin-2-amine





1950		N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2-chloro-4-methoxyphenoxy)pyridin-4-amine
1951		2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} sulfanyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1952		3-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]aniline
1953		3,5-dichloro-N-[3-(6-chloro-1H-1,3-benzodiazol-2-yl)phenyl]benzamide
1954		3,5-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]aniline

1955		(3S)-1-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl])-N-ethylpiperidin-3-amine
1956		2,4-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]aniline
1957		2-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}(methylamino)ethyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1958		3-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}(methylamino)ethyl)-N-[(3,5-dichlorophenyl)methyl]propanamide
1959		N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]acetamide


1960		4-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)pyridin-2-amine
1962		4-[(2,4-dichlorophenyl)methyl]-1-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2,3-dihydro-1H-imidazol-2-one
1963		methyl N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}(methylamino)ethyl)-N-[(3,5-dichlorophenyl)methyl]carbamate
1964		methyl N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]carbamate
1965		methyl 2-[(3-[[3,5-dichlorophenyl)methyl](methoxycarbonyl)amino]propylamino]-5-fluoro-3H-imidazo[4,5-b]pyridine-3-carboxylate

1966		3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]aniline
1967		3,5-dichloro-N-[3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
1968		3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]-3-propanamidopropanamide
1969		3-amino-3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
1970		2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-N-[(3,5-dichlorophenyl)methyl]acetamide

1971		N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]-2-hydroxyacetamide
1972		1-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}(methyl)amino)ethyl]-1-[(3,5-dichlorophenyl)methyl]urea
1973		N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]-2-hydroxyacetamide
1974		1-[(3,5-dichlorophenyl)methyl]-1-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]urea
1990		N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-[(3,5-dichlorophenyl)amino]acetamide

1991		3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-[(3,5-dichlorophenyl)methyl]urea
1992		3-chloro-5-({[(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]amino}methyl)benzonitrile
1994		(5-chloro-3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-[(3,5-dichlorophenyl)amino]ethylamine
1996		5-chloro-N-[3-(4,6-dichloro-1H-indol-1-yl)propyl]-3H-imidazo[4,5-b]pyridin-2-amine

[0012] In one embodiment, the compound has the structure of formula (II):


$$(II)$$

or a pharmaceutically acceptable salt thereof,

wherein

R₁ is an aryl or heteroaryl ring, each optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C1-6)alkenyl (C3-7)cycloalkyl, C(1-6)alkoxy, amino;

R₂ is a aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy, amino, mono to perfluoro(C1-3)alkyl, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl;

X is absent or a linker selected from the optionally substituted groups consisting of C₁₋₆ alkanes, C₁₋₆ alkenes, C₁₋₆ alkynes, C₁₋₆ alcohols, ethers, thio ethers, amines, amides, carbamates, ureas and combinations thereof;

E is absent or a 3- to 8-membered cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl group wherein A and B disposed in the 1,2-, 1,3-, or 1,4- positions are independently selected from the group consisting of -C-, -CH-, -CH₂-, -N- or -N(R⁷), where R⁷ is H or C₁₋₁₂ alkyl,

wherein E is optionally substituted with (C1-6)alkyl, -O-(C1-6)alkyl, aryl -O-aryl, heteroaryl, -O-heteroaryl, heterocycloalkyl, -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -NH-aryl, -NH-heteroaryl, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, halogen, nitrile or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and heteroaryl are optionally substituted with -OH, -NH₂, -NH(C1-6)alkyl, -N((C1-6)alkyl)₂, -N(H)C(O)(C1-6)alkyl, -C(O)N(H)(C1-6)alkyl, -C(O)N((C1-6)alkyl)₂, -N(H)C(O)O(C1-6)alkyl, -OC(O)N(H)(C1-6)alkyl, -OC(O)N((C1-6)alkyl)₂, -N(H)C(O)N(H)(C1-6)alkyl, -N(H)C(O)N((C1-6)alkyl)₂, nitrile, heteroaryl, halogen, or (C1-6)alkyloxy

Y is absent or a linker selected from the optionally substituted group consisting of C₁₋₃ alkyl, secondary and tertiary amine, thiol, thiol ether, alcohol, ether, ester, amine, amide, carbamate, and urea groups and combinations thereof; and


Z is N or CR₆, wherein R₆ selected from H, C₁₋₁₂ alkyl, C₁₋₁₂ halogen-alkyl, C₁₋₁₂ alkenyl, C₁₋₁₂ alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclic, optionally substituted heterocyclic, C₁₋₁₂ alcohol, halogen, cyano, ether, thio ether, ester, amine, amide, carbamate, and urea groups;

provided that

- 1) when E is absent, Z is NH and R₂ is unsubstituted heteroaryl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-NH-, -CH₂-NH-CH₂-CH₂-CH₂-NH- or -CH₂-NH-CH₂-CH₂-CH₂-CH₂-NH-;
- 2) when E is pyrimidine and Z is NH, R₂ is not phenyl;
- 3) when E is absent, Z is NH and R₂ is unsubstituted phenyl, or pyridinyl substituted with 1-2 fluoro groups, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
- 4) (a) when E is absent, Z is NH and R₂ is pyridinyl substituted with methyl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH₂-CH₂-NH-;
- (b) when E is absent and R₂ is pyridinyl or unsubstituted phenyl, X and Y, alone or in combination, do not form -O-CH₂-CH₂-C(O)-NH-CH₂- or -O-CH₂-CH₂-C(O)-N(Me)-CH₂-;
- (c) when E is absent, R₁ is dichlorophenyl and R₂ is unsubstituted phenyl, X and Y, alone or in combination, do not form -O-CH=CH-C(O)-NH-CH₂-; and
- (d) when E is absent and R₂ is pyridinyl, X and Y, alone or in combination, do not form -CH₂-NH-CH₂-CH(Me)-CH₂-NH-, -CH₂-NH-CH₂-CH(OH)-CH₂-NH-, -CH₂-NH-CH₂-C(Me)₂-CH₂-NH- or -CH₂-NH-CH₂-CH₂-C(O)-NH-.

[0013] In some embodiments, E is optionally substituted with -O-aryl, heterocycloalkyl, -OH, halogen or -NH-CH₂-heteroaryl, where the aryl, heterocycloalkyl and heteroaryl are optionally substituted with heteroaryl, halogen, or (C1-6)alkyloxy.


[0014] In some embodiments, the compound of formula (II) has the structure of formula (IIa):



(IIa)

or a pharmaceutically acceptable salt thereof.

[0015] In some embodiments, the compound of formula (II) has the structure of formula (IIb):




(IIb)

or a pharmaceutically acceptable salt thereof,

wherein A and B are in the 1,4-positions.


[0016] In some embodiments, the compound of formula (II) has the structure of formula (IIc):



(IIc)

or a pharmaceutically acceptable salt thereof.

[0017] In some embodiments, the compound of formula (II) has the structure of formula (IIId):




(IIId)

or a pharmaceutically acceptable salt thereof,

wherein A and B are in the 1,4-positions.

[0018] In some embodiments, the compound of formula (II) has the structure of formula (IIe):



(IIe)

or a pharmaceutically acceptable salt thereof.

[0019] In some embodiments, A and B are independently -N- or -CH-.

[0020] In some embodiments, R₁ is aryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl (optionally substituted by halogen, hydroxy and amino), (C3-7)cycloalkyl and C(1-6)alkoxy.

[0021] In some embodiments, R₁ is phenyl substituted with from 1 to 3 substituents independently selected from halogen and C(1-6)alkoxy. For example, R₁ may be phenyl substituted with 2 substituents independently selected from halogen and C(1-6)alkoxy.

[0022] In some embodiments, R₁ is phenyl substituted with two chloro groups.

[0023] In some embodiments, R₂ is a 5 or 6-membered aryl or heteroaryl ring which is optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy.

[0024] In other embodiments, R₂ is aryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy. For example, R₂ may be phenyl optionally substituted with from 1 to 3 substituents independently selected from halogen, (C1-6)alkyl, perfluoro(C1-3)alkyl or amino.

[0025] In some embodiments, R₂ is unsubstituted phenyl. In other embodiments, R₂ is phenyl substituted with two substituents independently selected from halogen, (C1-6)alkyl and perfluoro(C1-3)alkyl. For example, R₂ may be phenyl substituted with one halogen. In some examples, the halogen is fluoro.

[0026] In some embodiments, R₂ is heteroaryl optionally substituted with from 1 to 3 substituents independently selected from halogen, cyano, hydroxy, (C1-6)alkyl, perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino or carboxy. For example, R₂ may be pyridyl optionally substituted with from 1 to 3 substituents independently selected from halogen, (C1-6)alkyl, perfluoro(C1-3)alkyl or amino.

[0027] In some embodiments, R₂ is unsubstituted pyridyl. In other embodiments, R₂ is pyridyl substituted with two substituents independently selected from halogen, (C1-6)alkyl and perfluoro(C1-3)alkyl. For example, R₂ may be pyridyl substituted with one halogen. In some embodiments, the halogen is fluoro.

[0028] In some embodiments, X is (C1-6)alkyl, -N(R₈)-, -(C1-6)alkyl-N(R₈)-, (C1-6)alkyl-N(R₈)-(C1-6)alkyl, -O-, -(C1-6)alkyl-O-, (C1-6)alkyl-O-(C1-6)alkyl, -(C1-6)alkenyl-O-, (C1-6)alkenyl-O-(C1-6)alkenyl, -S-, -(C1-6)alkyl-S-, (C1-6)alkyl-S-(C1-6)alkyl, -C(O)N(R₈)-, -C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-C(O)N(R₈)-, -(C1-6)alkyl-C(O)N(R₈)-(C1-6)alkyl-, -C(O)-, -(C1-6)alkyl-C(O)-, -(C1-6)alkyl-C(O) -(C1-6)alkyl-, -C(O)O-, -(C1-6)alkyl-C(O)O-, -C(O)O-(C1-6)alkyl-, -(C1-6)alkyl-C(O)O-(C1-6)alkyl-,

-OC(O)N(R₈)-, -OC(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-OC(O)N(R₈)-, -(C1-6)alkyl-OC(O)N(R₈)-(C1-6)alkyl-, -N(R₈)C(O)N(R₈)-, -N(R₈)C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-N(R₈)C(O)N(R₈)-(C1-6)alkyl-,

wherein R₈ is hydrogen, (C1-6)alkyl, -C(O)-(C1-6)alkyl, -C(O)O-(C1-6)alkyl, and

wherein each (C1-6)alkyl is optionally substituted with (C1-6)alkyl, -N(R₈)₂, -OH or -O-(C1-6)alkyl.

[0029] In other embodiments, X is -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂-N(R₈)-, -CH₂-N(R₈)-CH₂-, -CH₂CH₂-N(R₈)-, -CH₂CH₂-N(R₈)-CH₂CH₂-, -CH(CH₃)CH₂-N(R₈)-, -CH(OH)CH₂-N(R₈)-, -CH₂-O-, -CH₂-O-CH₂-, -CH₂CH₂-O-, -CH₂CH₂-O-CH₂CH₂-, -CH₂-C(O)-, -CH₂-C(O)-CH₂-, -CH₂CH₂-C(O)-, -CH₂CH₂-C(O)-CH₂CH₂-, -CH₂-C(O)N(R₈)-, -CH₂-C(O)N(R₈)-CH₂-, -CH₂CH₂-C(O)N(R₈)-, -CH₂CH₂-C(O)N(R₈)-CH₂CH₂-, -CH₂-C(O)O-, -CH₂-C(O)O-CH₂-, -CH₂CH₂-C(O)O-, -CH₂CH₂-C(O)O-CH₂CH₂-,

wherein R₈ is hydrogen or -C(O)CH₃.

[0030] In some embodiments, Y is (C1-6)alkyl, -N(R₈)-, -(C1-6)alkyl-N(R₈)-, (C1-6)alkyl-N(R₈)-(C1-6)alkyl, -O-, -(C1-6)alkyl-O-, (C1-6)alkyl-O-(C1-6)alkyl, -(C1-6)alkenyl-O-, (C1-6)alkenyl-O-(C1-6)alkenyl, -S-, -(C1-6)alkyl-S-, (C1-6)alkyl-S-(C1-6)alkyl, -C(O)N(R₈)-, -C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-C(O)N(R₈)-, -(C1-6)alkyl-C(O)N(R₈)-(C1-6)alkyl-, -C(O)-, -(C1-6)alkyl-C(O)-, -(C1-6)alkyl-C(O)-(C1-6)alkyl-, -C(O)O-, -(C1-6)alkyl-C(O)O-, -C(O)O-(C1-6)alkyl-, -(C1-6)alkyl-C(O)O-(C1-6)alkyl-, -OC(O)N(R₈)-, -OC(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-OC(O)N(R₈)-, -(C1-6)alkyl-OC(O)N(R₈)-(C1-6)alkyl-, -N(R₈)C(O)N(R₈)-, -N(R₈)C(O)N(R₈)-(C1-6)alkyl-, -(C1-6)alkyl-N(R₈)C(O)N(R₈)-(C1-6)alkyl-,

wherein R₈ is hydrogen, (C1-6)alkyl, -C(O)-(C1-6)alkyl, -C(O)O-(C1-6)alkyl, and

wherein each (C1-6)alkyl is optionally substituted with (C1-6)alkyl, -N(R₈)₂, -OH or -O-(C1-6)alkyl.

[0031] In other embodiments, Y is -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂-N(R₈)-, -CH₂-N(R₈)-CH₂-, -CH₂CH₂-N(R₈)-, -CH₂CH₂-N(R₈)-CH₂CH₂-, -CH(CH₃)CH₂-N(R₈)-, -CH(OH)CH₂-N(R₈)-, -CH₂-O-, -CH₂-O-CH₂-, -CH₂CH₂-O-, -CH₂CH₂-O-CH₂CH₂-, -CH₂-C(O)-, -CH₂-C(O)-CH₂-, -CH₂CH₂-C(O)-, -CH₂CH₂-C(O)-CH₂CH₂-, -CH₂-C(O)N(R₈)-, -CH₂-C(O)N(R₈)-CH₂-, -CH₂CH₂-C(O)N(R₈)-, -CH₂CH₂-C(O)N(R₈)-CH₂CH₂-, -CH₂-C(O)O-, -CH₂-C(O)O-CH₂-, -CH₂CH₂-C(O)O-, -CH₂CH₂-C(O)O-CH₂CH₂-,

wherein R₈ is hydrogen or -C(O)CH₃.

[0032] In some embodiments, the compound of formula (II) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):

No.	Chemical Name
1627	2-[(3-[(3,5-dichlorophenyl)methyl]amino)propyl]amino]-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile
1671	N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2,4-dichlorophenoxy)acetamide
1674	2-(2,4-dichlorophenoxy)-N-(1H-indol-2-ylmethyl)acetamide
1675	N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-2-(2,4-dichlorophenoxy)acetamide
1699	benzyl N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl}carbamate
1701	2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)carbamate
1702	3-(1H-1,3-benzodiazol-2-ylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]urea
1703	(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(4-fluorophenyl)butanamide
1706	2-(2,4-dichlorophenyl)ethyl N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl}carbamate
1707	2-(2,4-dichlorophenyl)ethyl N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)carbamate
1708	[(3,5-dichlorophenyl)methyl][2,2-difluoro-3-({3H-imidazo[4,5-b]pyridin-2-yl}amino)propyl]amine
1716	N-(3-[[1-(3,5-dichlorophenyl)cyclopropyl]amino]propyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine
1720	(3R)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide
1726	(3S)-3-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)butanamide
1728	2-(2,4-dichlorophenyl)ethyl N-(1H-1,3-benzodiazol-2-ylmethyl)-N-methylcarbamate
1731	1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(2,4-dichlorophenyl)ethan-1-one
1732	1-[3-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1733	1-[3-(4-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1734	1-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1735	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2-chlorophenyl)methyl]piperazin-2-one
1736	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3-chlorophenyl)methyl]piperazin-2-one
1737	(3E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2,4-dichlorophenyl)but-3-enamide
1738	N-[1-(1H-1,3-benzodiazol-2-yl)cyclopropyl]-3-(2,4-dichlorophenoxy)propanamide
1739	1H-1,3-benzodiazol-2-ylmethyl N-[2-(2,4-dichlorophenyl)ethyl]carbamate
1740	3-(2,4-dichlorophenoxy)-N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]propanamide
1741	2-(2,4-dichlorophenyl)ethyl N-[(6-fluoro-1H-1,3-benzodiazol-2-yl)methyl]carbamate
1744	2-(3,5-dichlorophenyl)-1-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]ethan-1-one
1745	1-[3-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-

	dichlorophenyl)ethan-1-one
1746	1-[3-(5-chloro-6-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1747	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]piperazin-2-one
1748	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(3,5-dichlorophenyl)methyl]piperazin-2-one
1752	2-({1-[(2,4-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl} methyl)-1H-1,3-benzodiazole
1753	2-({1-[(3,5-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl} methyl)-1H-1,3-benzodiazole
1754	(5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-dione
1755	methyl (2S)-2-[(1H-1,3-benzodiazol-2-ylmethyl)carbamoyl]amino)-3-(2,4-dichlorophenyl)propanoate
1756	N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1-benzofuran-2-yl)acetamide
1757	1-[(3R)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1758	1-[(3S)-3-(5-chloro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1759	3-(5-chloro-1H-1,3-benzodiazol-2-yl)-N-(3,5-dichlorophenyl)piperidine-1-carboxamide
1760	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-(naphthalene-2-carbonyl)piperazin-2-one
1761	2-(3,5-dichlorophenyl)-1-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl)ethan-1-one
1762	1-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl)-2-(3,5-dichlorophenyl)ethan-1-one
1763	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-[(2,4-dichlorophenyl)amino]propanamide
1764	N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(5,7-dichloro-1H-1,3-benzodiazol-2-yl)acetamide
1765	(2E)-N'-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enehydrazide
1766	(2E)-N-(1H-1,3-benzodiazol-2-yl)-3-(2,4-dichlorophenoxy)prop-2-enehydrazide
1767	[2-(6-chloro-1H-1,3-benzodiazol-2-yl)ethyl][(3,5-dichlorophenyl)methyl]amine
1768	(2E)-3-(2,4-dichlorophenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)prop-2-enamide
1769	3-[(1H-1,3-benzodiazol-2-ylmethyl)amino]-4-[(2,4-dichlorophenyl)methyl]amino}cyclobut-3-ene-1,2-dione
1779	(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-{2,4-dichloro-6-[(methylamino)methyl]phenoxy}prop-2-enamide
1780	(2-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
1785	3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidine-1-carboxamide
1786	N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-2-(3,5-dichlorophenyl)acetamide

1787	2-amino-1-[(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl]-2-(3,5-dichlorophenyl)ethan-1-one
1788	3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1789	N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1790	1-(2-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}morpholin-4-yl)-2-(3,5-dichlorophenyl)ethan-1-one
1791	N-(2-amino-6-chloropyridin-3-yl)-4-[2-(3,5-dichlorophenyl)acetyl]piperazine-2-carboxamide
1792	(4S)-1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]imidazolidin-2-one
1793	3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dichlorophenyl)methyl]urea
1794	[1-(5-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1795	2-amino-3-(1H-1,3-benzodiazol-2-yl)-N-[2-(2,4-dichlorophenyl)ethyl]propanamide
1796	2-chloro-6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)pyrimidin-4-amine
1797	6-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-[4-(pyrazin-2-yl)piperazin-1-yl]pyrimidin-4-amine
1798	1-[2-(3,5-dichlorophenyl)ethyl]-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidine
1799	(2S)-2-amino-1-[(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-1-yl]-3-(2,4-dichlorophenyl)propan-1-one
1800	N-[(3,5-dichlorophenyl)methyl]-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexan-1-amine
1801	N-[(3,5-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
1802	N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-[(2,4-dichlorophenyl)methyl]ethanediamide
1803	N-(1H-1,3-benzodiazol-2-ylmethyl)-N'-(2,4-dichlorophenyl)propanediamide
1804	2-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1805	[(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1806	[(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1807	(2S)-2-amino-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
1808	(2S)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenyl)-2-(methylamino)propanamide
1809	3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]cyclohexan-1-amine
1810	N-(3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(2,4-dichlorophenyl)methyl]acetamide
1811	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine

1812	3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[2-(3,5-dichlorophenyl)ethyl]piperidine
1813	5-chloro-2-[(3S)-1-[(3,5-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole
1814	3-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-[(3,5-dichlorophenyl)methyl]piperidine
1815	3-(1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1816	N-[3-(1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1817	N-[(3,5-dichlorophenyl)methyl]-3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexan-1-amine
1818	N-[(3,5-dichlorophenyl)methyl]-N-(3-{1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
1819	[1-(1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1820	[(3,5-dichlorophenyl)methyl][1-(6-methyl-1H-1,3-benzodiazol-2-yl)propan-2-yl]amine
1821	[1-(6-bromo-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1822	[1-(5,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1823	[1-(4,6-dichloro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1824	[1-(6-chloro-5-fluoro-1H-1,3-benzodiazol-2-yl)propan-2-yl][(3,5-dichlorophenyl)methyl]amine
1825	[(3,5-dichlorophenyl)methyl]({1-[6-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]propan-2-yl})amine
1826	[(3,5-dichlorophenyl)methyl](1-{1H-naphtho[2,3-d]imidazol-2-yl}propan-2-yl)amine
1827	[(2S)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)butan-2-yl][(3,5-dichlorophenyl)methyl]amine
1828	[(2R)-1-(6-chloro-1H-1,3-benzodiazol-2-yl)-3-methylbutan-2-yl][(3,5-dichlorophenyl)methyl]amine
1829	{2-[(6-chloro-1H-1,3-benzodiazol-2-yl)amino]ethyl}[(3,5-dichlorophenyl)methyl]amine
1830	N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-{{(3,5-dichlorophenyl)methyl}amino}acetamide
1831	(2S)-N-(6-chloro-1H-1,3-benzodiazol-2-yl)-2-{{(3,5-dichlorophenyl)methyl}amino}propanamide
1832	[3-(6-chloro-1H-1,3-benzodiazol-2-yl)propyl][(3,5-dichlorophenyl)methyl]amine
1833	N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)piperidin-1-yl]acetamide
1835	N-[(3,5-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}propyl)acetamide
1836	N-[(2,4-dichlorophenyl)methyl]-N-(3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)acetamide
1837	5-chloro-2-[(3S)-1-[(2,4-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole

1838	5-chloro-2-[(3R)-1-[(3,5-dichlorophenyl)methyl]piperidin-3-yl]-1H-1,3-benzodiazole
1839	N-[(3,5-dichlorophenyl)methyl]-3-(5-fluoro-1H-1,3-benzodiazol-2-yl)cyclohexan-1-amine
1840	3-(5-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1841	3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1842	N-(3-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1844	(2-{6-chloro-3H-imidazo[4,5-b]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
1845	(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine
1846	(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine
1847	(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine
1848	(3R)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine
1849	[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}amino)ethyl][(3,5-dichlorophenyl)methyl]amine
1850	[2-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}amino)ethyl][(3,5-dichlorophenyl)methyl]amine
1851	N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide
1852	N-[(6-chloro-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide
1853	[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine
1854	(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]cyclohexan-1-amine
1855	(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine
1856	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-3-amine
1857	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,4-dichlorophenyl)methyl]piperidin-3-amine
1858	[(3,5-dichlorophenyl)methyl](3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}propyl)amine
1859	N-[(1R,3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1860	N-[(3,5-dichlorophenyl)methyl]-N-[3-(5-fluoro-1H-1,3-benzodiazol-2-yl)cyclohexyl]acetamide
1861	N-[3-(5-chloro-1H-1,3-benzodiazol-2-yl)cyclohexyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1862	3,5-dichloro-N-[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]aniline
1863	N-[(1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)methyl]-3,5-dichloroaniline

1864	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
1865	1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azetidin-3-amine
1866	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-4-[(3,5-dichlorophenyl)methyl]piperazine
1867	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]piperidin-4-amine
1868	(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dichlorophenyl)methyl]piperidine
1869	(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(2,4-dichlorophenyl)methyl]piperidine
1870	(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,4-dichlorophenyl)methyl]piperidine
1871	(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dibromophenyl)methyl]piperidine
1872	(3S)-3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-1-[(3,5-dimethoxyphenyl)methyl]piperidine
1873	N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(3,5-dichlorophenyl)acetamide
1874	N-[(6-bromo-1H-1,3-benzodiazol-2-yl)methyl]-2-(2,4-dichlorophenyl)acetamide
1875	N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1876	N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
1877	N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1878	N-({6-chloro-1H-imidazo[4,5-b]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
1879	N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(3,5-dichlorophenyl)acetamide
1880	N-({6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}methyl)-2-(2,4-dichlorophenyl)acetamide
1881	(3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}propyl)[(3,5-dichlorophenyl)methyl]amine
1882	(2-{6-chloro-1H-imidazo[4,5-c]pyridin-2-yl}ethyl)[(3,5-dichlorophenyl)methyl]amine
1883	6-(2-chloro-4-methoxyphenoxy)-2-N,4-N-bis({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazine-2,4-diamine
1884	4,6-bis(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,3,5-triazin-2-amine
1885	4-(2-chloro-4-methoxyphenoxy)-6-[(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]-1,3,5-triazin-2-ol
1886	N-[(3,5-dichlorophenyl)methyl]-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine
1887	N-[(3,5-dichlorophenyl)methyl]-N-(1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl)acetamide
1888	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-(3,5-


	dichlorophenyl)piperidine-3-carboxamide
1889	3,5-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]benzamide
1890	3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-(3,5-dichlorophenyl)urea
1891	3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)-1-(2,4-dichlorophenyl)urea
1892	({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}methyl)[2-(2,4-dichlorophenyl)ethyl]amine
1893	5-chloro-N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1894	6-bromo-5-chloro-N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1895	N-(3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}propyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1896	[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}sulfanyl)ethyl][(3,5-dichlorophenyl)methyl]amine
1897	N-[(3,5-dichlorophenyl)methyl]-N-[2-({5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}amino)ethyl]acetamide
1898	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-3-[(3,5-dichlorophenyl)methoxy]piperidine
1899	6,8-dichloro-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]-1,2,3,4-tetrahydroquinolin-4-amine
1900	(3S)-N-[(3,5-dichlorophenyl)methyl]-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine
1901	N-[(3,5-dichlorophenyl)methyl]-N-[(3S)-1-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]acetamide
1902	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine
1903	1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]azepan-3-amine
1904	(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-3-[(3,5-dichlorophenyl)methoxy]piperidine
1905	(3S)-1-{6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(2,3,5-trichlorophenyl)methyl]piperidin-3-amine
1906	(5S)-3-(1H-1,3-benzodiazol-2-ylmethyl)-5-[(2,4-dichlorophenyl)methyl]imidazolidine-2,4-diol
1907	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one
1908	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromophenyl)methyl]piperidin-3-amine
1909	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-methoxyphenyl)methyl]piperidin-3-amine
1910	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dibromo-2-ethoxyphenyl)methyl]piperidin-3-amine
1911	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-methoxyphenyl)methyl]piperidin-3-amine
1912	(3S)-N-[(3-bromo-5-chlorophenyl)methyl]-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-amine

1913	N-(2-({(3,5-dichlorophenyl)methyl}amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1914	N-[(3,5-dichlorophenyl)methyl]-N-[2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)(methylamino)ethyl]acetamide
1915	[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}azetidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine
1916	[(1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}pyrrolidin-2-yl)methyl][(3,5-dichlorophenyl)methyl]amine
1917	5-chloro-N-(2-({(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1918	N-[2-(1H-1,3-benzodiazol-2-yl)ethyl]-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
1919	N-(2-({(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl}amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1920	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-ethoxyphenyl)methyl]piperidin-3-amine
1921	2,4-dichloro-6-({[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]amino)methyl}phenol
1922	3,5-dichloro-N-({[(3R)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]methyl}aniline
1923	3,5-dichloro-N-({[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}piperidin-3-yl]methyl}aniline
1924	N-(1H-1,3-benzodiazol-2-ylmethyl)-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
1925	5-chloro-N-(2-({(3,5-dichloro-2-ethoxyphenyl)methyl}amino)ethyl)-N-methyl-3H-imidazo[4,5-b]pyridin-2-amine
1926	N-[2-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)(methylamino)ethyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1927	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-propoxyphenyl)methyl]piperidin-3-amine
1928	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-({[3,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]methyl}piperidin-3-amine
1929	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-({[3,5-dichloro-2-(cyclopropylmethoxy)phenyl]methyl}piperidin-3-amine
1930	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichloro-2-cyclopropoxyphenyl)methyl]piperidin-3-amine
1931	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-({[3,5-dichloro-2-(propan-2-yloxy)phenyl]methyl}piperidin-3-amine
1932	N-[(3,5-dichlorophenyl)methyl]-N-[(1R,3S)-3-{5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl}cyclohexyl]acetamide
1933	N-(1H-1,3-benzodiazol-2-ylmethyl)-4-(2-chloro-4-methoxyphenoxy)pyridin-2-amine
1934	(4S)-1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-5-hydroxyimidazolidin-2-one
1935	3-(1H-1,3-benzodiazol-2-ylmethyl)-1-[(2S)-1-(2,4-dichlorophenyl)-3-hydroxypropan-2-yl]urea
1936	1-(1H-1,3-benzodiazol-2-ylmethyl)-4-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-1H-imidazol-2-ol
1937	(3S)-N-[(3-bromo-5-chloro-2-ethoxyphenyl)methyl]-1-{5-chloro-1H-

	imidazo[4,5-b]pyridin-2-yl] piperidin-3-amine
1938	N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]acetamide
1939	N-(2-([(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl][2-({5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]amino)ethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine
1940	(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-{[3,5-dichloro-2-(ethylamino)phenyl]methyl} piperidin-3-amine
1941	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2-chloro-4-methoxyphenoxy)aniline
1942	N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]propanamide
1943	N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]-N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)acetamide
1944	3-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
1945	N-(1-acetyl-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-[(3S)-1-{5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]acetamide
1949	5-chloro-N-(2-([(3,5-dichlorophenyl)methyl]amino)ethyl)-N-ethyl-3H-imidazo[4,5-b]pyridin-2-amine
1950	N-(1H-1,3-benzodiazol-2-ylmethyl)-2-(2-chloro-4-methoxyphenoxy)pyridin-4-amine
1951	2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} sulfanyl)-N-[(3,5-dichlorophenyl)methyl]acetamide
1952	3-(6-chloro-1H-1,3-benzodiazol-2-yl)-N-[(3,5-dichlorophenyl)methyl]aniline
1953	3,5-dichloro-N-[3-(6-chloro-1H-1,3-benzodiazol-2-yl)phenyl]benzamide
1954	3,5-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
1955	(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]-N-ethylpiperidin-3-amine
1956	2,4-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
1957	2-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]acetamide
1958	3-amino-N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]propanamide
1959	N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]acetamide
1960	4-(2-chloro-4-methoxyphenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)pyridin-2-amine
1962	4-[(2,4-dichlorophenyl)methyl]-1-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2,3-dihydro-1H-imidazol-2-one
1963	methyl N-[2-({5-chloro-1H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]carbamate
1964	methyl N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]carbamate
1965	methyl 2-[(3-[(3,5-dichlorophenyl)methyl](methoxycarbonyl)amino)propyl]amino]-5-fluoro-3H-imidazo[4,5-b]pyridine-3-carboxylate
1966	3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-

	dichlorophenyl)methyl]aniline
1967	3,5-dichloro-N-[3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]aniline
1968	3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]-3-propanamidopropanamide
1969	3-amino-3-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl}-N-[(3,5-dichlorophenyl)methyl]propanamide
1970	2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-N-[(3,5-dichlorophenyl)methyl]acetamide
1971	N-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-N-[(3,5-dichlorophenyl)methyl]-2-hydroxyacetamide
1972	1-[2-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} (methyl)amino)ethyl]-1-[(3,5-dichlorophenyl)methyl]urea
1973	N-[(3,5-dichlorophenyl)methyl]-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-2-hydroxyacetamide
1974	1-[(3,5-dichlorophenyl)methyl]-1-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]urea
1990	N-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-2-[(3,5-dichlorophenyl)amino]acetamide
1991	3-({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)-1-[(3,5-dichlorophenyl)methyl]urea
1992	3-chloro-5-({[(3S)-1-{5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} piperidin-3-yl]amino} methyl)benzonitrile
1994	({5-chloro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)({2-[(3,5-dichlorophenyl)amino]ethyl})amine
1996	5-chloro-N-[3-(4,6-dichloro-1H-indol-1-yl)propyl]-3H-imidazo[4,5-b]pyridin-2-amine

[0033] In another embodiment, the compound has the structure of formula (III):




(III)

or a pharmaceutically acceptable salt thereof, wherein

R is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁸, -SR⁸, -N(R⁸)₂, -C(O)R⁸, -C(O)OR⁸, -C(O)N(R⁸)₂, -S(O)₂R⁸, -OC(

O)R⁸, -OC(O)OR⁸, -OC(O)N(R⁸)₂, -N(R⁸)C(O)R⁸, -N(R⁸)C(O)OR⁸,
or -N(R⁸)C(O)N(R⁸)₂, wherein each R⁸ is independently hydrogen or C₁₋₆ alkyl.

[0034] In another embodiment, the compound has the structure of formula (IV):




or a pharmaceutically acceptable salt thereof, wherein

R³ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl,

-OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl; and

R⁴ is hydrogen, halogen, C₁₋₆ alkyl, or -OR¹⁰, where R¹⁰ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -OR⁹, -SR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)OR⁹, -C(O)N(R⁹)₂, -S(O)₂R⁹, -OC(O)R⁹, -OC(O)OR⁹, -OC(O)N(R⁹)₂, -N(R⁹)C(O)R⁹, -N(R⁹)C(O)OR⁹, or -N(R⁹)C(O)N(R⁹)₂, wherein each R⁹ is independently hydrogen or C₁₋₆ alkyl.

[0035] In another embodiment, the compound has the structure of formula (V):



or a pharmaceutically acceptable salt thereof, wherein

R⁵ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, C₃₋₁₂ cycloalkyl, heterocyclyl, aryl, arylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆ alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, C₁₋₆ alkyl, C₁₋₆

haloalkyl, $-OR^9$, $-SR^9$, $-N(R^9)_2$, $-C(O)R^9$, $-C(O)OR^9$, $-C(O)N(R^9)_2$, $-S(O)_2R^9$, $-OC(O)R^9$, $-OC(O)OR^9$, $-OC(O)N(R^9)_2$, $-N(R^9)C(O)R^9$, $-N(R^9)C(O)OR^9$, or $-N(R^9)C(O)N(R^9)_2$, wherein each R^9 is independently hydrogen or C_{1-6} alkyl.

[0036] In some embodiments, the compound of formulae (III) or (IV) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):

No.	Chemical Name
1575	N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
1576	3-([(3,5-dichlorophenyl)methyl]amino)-N-{1H-imidazo[4,5-b]pyridin-2-yl}propanamide
1599	N1-(3,5-dichlorobenzyl)-N3-(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
1614	[(3,5-dichlorophenyl)methyl][3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propylamine
1634	1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
1641	N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine
1655	(S)-N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine
1673	[(3,5-dichlorophenyl)methyl][(2S)-3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]-2-methylpropylamine
1683	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
1704	3-(2,4-dichlorophenoxy)-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)propanamide
1705	3-(2,4-dichlorophenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylmethyl)propanamide
1709	(4R)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
1710	(R)-N1-(6,8-dichlorochroman-4-yl)-N3-(3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
1711	(4S)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
1717	(4R)-6,8-dichloro-N-[3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino]propyl]-1,2,3,4-tetrahydroquinolin-4-amine
1727	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)-N-methylpropanamide
1729	(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
1730	(2Z)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide

[0037] In some embodiments, the compound of formulae (III) or (IV) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):

No.	Chemical Name
1614	[(3,5-dichlorophenyl)methyl][3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]amine
1634	1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
1641	N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine
1673	[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-2-methylpropyl]amine
1705	3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide
1709	(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
1711	(4S)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-3,4-dihydro-2H-1-benzopyran-4-amine
1717	(4R)-6,8-dichloro-N-[3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)propyl]-1,2,3,4-tetrahydroquinolin-4-amine

[0038] In some embodiments, the compound of formulae (III) or (IV) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):


No.	Chemical Name
1576	3- {[(3,5-dichlorophenyl)methyl]amino} -N- {1H-imidazo[4,5-b]pyridin-2-yl} propanamide
1634	1-((1H-imidazo[4,5-b]pyridin-2-yl)amino)-3-((3,5-dichlorobenzyl)amino)propan-2-ol
1641	N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2,2-dimethylpropane-1,3-diamine
1655	(S)-N1-(3,5-dichlorobenzyl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine
1673	[(3,5-dichlorophenyl)methyl][(2S)-3-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} amino)-2-methylpropyl]amine
1683	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
1704	3-(2,4-dichlorophenoxy)-N-{3H-imidazo[4,5-b]pyridin-2-ylmethyl}propanamide
1705	3-(2,4-dichlorophenoxy)-N-({5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl} methyl)propanamide
1727	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)-N-methylpropanamide
1729	(2E)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide

1730	(2Z)-N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)prop-2-enamide
------	--

[0039] In some embodiments, the compound of formulae (III) or (IV) is one of the following compounds (or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof):

No.	Chemical Name
1673	[(3,5-dichlorophenyl)methyl][(2S)-3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino)-2-methylpropyl]amine
1683	N-(1H-1,3-benzodiazol-2-ylmethyl)-3-(2,4-dichlorophenoxy)propanamide
1705	3-(2,4-dichlorophenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)propanamide

[0040] In a third aspect, also disclosed are compounds used in the synthesis a compound of formulae (I) - (V). For example, the compound may have the structure of compound A or compound B:



[0041] In an embodiment of the third aspect, a method for the synthesis of a compound of formulae (I) - (V), wherein compound A or B is an intermediate. For example, Scheme 71 shows the use of compounds A and B in the synthesis of 6-fluoropyridine-2,3-diamine, which is used in the synthesis of compound 1614 in Scheme 72.

[0042] In a fourth aspect, the compounds of the disclosure are capable of inhibiting the activity of MetRS. Inhibition of MetRS may be either *in vivo* and/or *in vitro*. Accordingly, in a third aspect the disclosure provides methods for treating diseases that are ameliorated by the inhibition of MetRS providing to a patient in need of such treatment a therapeutically effective amount of either a compound of the disclosure (e.g., compounds formulae (I)-(V) or any preceding embodiment), or a pharmaceutical composition comprising one or more of compounds of the disclosure.

[0043] Examples of diseases that are ameliorated by the inhibition of MetRS by the compounds of the present disclosure include Staphylococcus infections (including MRSA infections), Enterococcus infections (including VRE infections), Streptococcus infections, and Clostridium infections. Further examples of diseases that are ameliorated by the

inhibition of MetRS by the compounds of the present disclosure include Mycobacterial infections, including infections from *Mycobacterium tuberculosis*, *Mycobacterium avium* complex, *Mycobacterium fortuitum*, and others. Further examples of diseases that are ameliorated by the inhibition of MetRS by the compounds of the present disclosure include protozoan infections, including infections caused by *Trypanosoma*, *Leishmania*, *Giardia*, *Trichomonas*, and others.

[0044] For example, the present disclosure provides methods for treating diseases that are ameliorated by the inhibition of MetRS, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of formulae (I) - (V) or a pharmaceutical composition thereof. In such methods, the disease may be selected from the group consisting of Protozoan, Mycobacterial, Staphylococcus, Enterococcus, Streptococcus, and Clostridium infections.

[0045] In other embodiments, the disease is a bacterial infection, such as, for example, a Gram positive bacterial infection. In some embodiments, the Gram positive bacterial infection is selected from one of Staphylococcus, Enterococcus, Streptococcus, Clostridium, Bacillus, Helicobacter pylori, and Listeria. In other embodiments, the bacteria is a Gram negative bacteria, such as, for example, Brucella.

[0046] In other embodiments, the disease is a Mycobacterium tuberculosis infection.

[0047] In other embodiments, the disease is a Trypanosomatid protozoa infection. For example, the Trypanosomatid protozoa may be one of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania species.

[0048] In a fifth aspect, the present disclosure also provides a pharmaceutical composition comprising one or more of compounds according to any of formulae (I) - (V) and a pharmaceutically acceptable carrier, diluent, or excipient.

[0049] The development of the compositions of the present application is highly significant as it solves the problem of poor oral bioavailability of MetRS inhibitors. Their development makes possible their use as orally administered antibiotics for treating systemic infections. Importantly, the compounds are active against Gram positive bacteria such as *Staphylococcus aureus* and *Enterococcus faecalis* that are becoming increasingly resistant to existing antibiotics. There is a very large market, particularly in modern hospitals, for antibiotics to treat drug-resistant bacteria. The compounds under study also have potential for development as oral drugs against pathogenic protozoa, such as trypanosomes, that affect millions of people worldwide.

[0050] As used herein, the term “subject”, “individual,” or “patient,” used interchangeably, refers to any animal, including mammals, such as mice, rats, other rodents, rabbits, dogs, cats, birds, swine, horses, livestock (e.g., pigs, sheep, goats, cattle), primates or humans. In one embodiment, the patient is a human.

[0051] As used here, a subject “in need thereof” refers to a subject that has the disorder or disease to be treated or is predisposed to or otherwise at risk of developing the disease or disorder.

[0052] As used here, the terms “treatment” and “treating” means:

inhibiting the progression the disease;

prophylactic use, for example, preventing or limiting development of a disease, condition or disorder in an individual who may be predisposed or otherwise at risk to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;

inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder;

ameliorating the referenced disease state, for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, reversing or improving the pathology and/or symptomatology) such as decreasing the severity of disease; or

eliciting the referenced biological effect.

[0053] As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following: (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder; and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

[0054] The pharmaceutical compositions described herein generally comprise a combination of one or more of compounds described herein and a pharmaceutically acceptable carrier, diluent, or excipient. Such compositions are substantially free of non-pharmaceutically acceptable components, *i.e.*, contain amounts of non-pharmaceutically acceptable components lower than permitted by US regulatory requirements at the time of filing this application. In some embodiments of this aspect, if the compound is dissolved or suspended in water, the composition further optionally comprises an additional pharmaceutically acceptable carrier, diluent, or excipient. In one embodiment, the pharmaceutical compositions described herein are solid pharmaceutical compositions (*e.g.*, tablet, capsules, *etc.*).

[0055] These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (*e.g.*, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, *e.g.*, intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

[0056] Also, pharmaceutical compositions can contain, as the active ingredient, one or more of the compounds described herein above in combination with one or more pharmaceutically acceptable carriers. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions,

solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0057] In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, *e.g.* about 40 mesh.

[0058] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

[0059] The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[0060] The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0061] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into

equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of a compound described herein.

[0062] The tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0063] The liquid forms in which the compounds and compositions can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0064] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described *supra*. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

[0065] The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

[0066] The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

[0067] The therapeutic dosage of the compounds can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound described herein in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (*e.g.*, hydrophobicity), and the route of administration. For example, the compounds described herein can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 µg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0068] The compounds described herein can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.

Definitions

[0069] Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”. Words using the singular or plural number also include the plural or singular number, respectively. Additionally, the words “herein,” “above” and

"below" and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application.

[0070] Terms used herein may be preceded and/or followed by a single dash, "-", or a double dash, "=", to indicate the bond order of the bond between the named substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double bond. In the absence of a single or double dash it is understood that a single bond is formed between the substituent and its parent moiety; further, substituents are intended to be read "left to right" unless a dash indicates otherwise. For example, C₁-C₆alkoxycarbonyloxy and -OC(O)C₁-C₆alkyl indicate the same functionality; similarly arylalkyl and -alkylaryl indicate the same functionality.

[0071] The term "alkenyl" as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons, unless otherwise specified, and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and 3,7-dimethylocta-2,6-dienyl.

[0072] The term "alkyl" as used herein, means a straight or branched chain hydrocarbon containing from 1 to 12 carbon atoms, unless otherwise specified. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When an "alkyl" group is a linking group between two other moieties, then it may also be a straight or branched chain; examples include, but are not limited to -CH₂-, -CH₂CH₂-, -CH₂CH₂CHC(CH₃)-, -CH₂CH(CH₂CH₃)CH₂-.

[0073] The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 12 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butyne, 2-pentyne, and 1-butyne.

[0074] The term "aryl," as used herein, means a phenyl (*i.e.*, monocyclic aryl), a bicyclic ring system containing at least one phenyl ring or an aromatic bicyclic ring containing only carbon atoms in the aromatic bicyclic ring system or a multicyclic aryl ring system, provided that the bicyclic or multicyclic aryl ring system does not contain a heteroaryl ring when fully aromatic. The bicyclic aryl can be azulenyl, naphthyl, or a phenyl fused to a monocyclic cycloalkyl, a monocyclic cycloalkenyl, or a monocyclic heterocyclyl. The bicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the phenyl

portion of the bicyclic system, or any carbon atom with the naphthyl or azulenyl ring. The fused monocyclic cycloalkyl or monocyclic heterocyclyl portions of the bicyclic aryl are optionally substituted with one or two oxo and/or thia groups. Representative examples of the bicyclic aryls include, but are not limited to, azulenyl, naphthyl, dihydroinden-1-yl, dihydroinden-2-yl, dihydroinden-3-yl, dihydroinden-4-yl, 2,3-dihydroindol-4-yl, 2,3-dihydroindol-5-yl, 2,3-dihydroindol-6-yl, 2,3-dihydroindol-7-yl, inden-1-yl, inden-2-yl, inden-3-yl, inden-4-yl, dihydronaphthalen-2-yl, dihydronaphthalen-3-yl, dihydronaphthalen-4-yl, dihydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 2,3-dihydrobenzofuran-7-yl, benzo[d][1,3]dioxol-4-yl, benzo[d][1,3]dioxol-5-yl, 2H-chromen-2-on-5-yl, 2H-chromen-2-on-6-yl, 2H-chromen-2-on-7-yl, 2H-chromen-2-on-8-yl, isoindoline-1,3-dion-4-yl, isoindoline-1,3-dion-5-yl, inden-1-on-4-yl, inden-1-on-5-yl, inden-1-on-6-yl, inden-1-on-7-yl, 2,3-dihydrobenzo[b][1,4]dioxan-5-yl, 2,3-dihydrobenzo[b][1,4]dioxan-6-yl, 2H-benzo[b][1,4]oxazin-3(4H)-on-5-yl, 2H-benzo[b][1,4]oxazin-3(4H)-on-6-yl, 2H-benzo[b][1,4]oxazin-3(4H)-on-7-yl, 2H-benzo[b][1,4]oxazin-3(4H)-on-8-yl, benzo[d]oxazin-2(3H)-on-5-yl, benzo[d]oxazin-2(3H)-on-6-yl, benzo[d]oxazin-2(3H)-on-7-yl, benzo[d]oxazin-2(3H)-on-8-yl, quinazolin-4(3H)-on-5-yl, quinazolin-4(3H)-on-6-yl, quinazolin-4(3H)-on-7-yl, quinazolin-4(3H)-on-8-yl, quinoxalin-2(1H)-on-5-yl, quinoxalin-2(1H)-on-6-yl, quinoxalin-2(1H)-on-7-yl, quinoxalin-2(1H)-on-8-yl, benzo[d]thiazol-2(3H)-on-4-yl, benzo[d]thiazol-2(3H)-on-5-yl, benzo[d]thiazol-2(3H)-on-6-yl, and, benzo[d]thiazol-2(3H)-on-7-yl. In certain embodiments, the bicyclic aryl is (i) naphthyl or (ii) a phenyl ring fused to either a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, or a 5 or 6 membered monocyclic heterocyclyl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. Multicyclic aryl groups are a phenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl, provided that when the base ring is fused to a bicyclic cycloalkyl, bicyclic cycloalkenyl, or bicyclic heterocyclyl, then the base ring is fused to the base ring of the a bicyclic cycloalkyl, bicyclic cycloalkenyl, or bicyclic heterocyclyl. The multicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the base ring. In certain

embodiments, multicyclic aryl groups are a phenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl, provided that when the base ring is fused to a bicyclic cycloalkyl, bicyclic cycloalkenyl, or bicyclic heterocyclyl, then the base ring is fused to the base ring of the a bicyclic cycloalkyl, bicyclic cycloalkenyl, or bicyclic heterocyclyl. Examples of multicyclic aryl groups include but are not limited to anthracen-9-yl and phenanthren-9-yl.

[0075] The term “arylalkyl” and “-alkylaryl” as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

[0076] The terms “cyano” and “nitrile” as used herein, mean a -CN group.

[0077] The term “cycloalkyl” as used herein, means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. Monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In certain embodiments, cycloalkyl groups are fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form $-(CH_2)_w-$, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl,

a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted by one or two groups which are independently oxo or thia. Multicyclic cycloalkyl ring systems are a monocyclic cycloalkyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other rings systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. The multicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the base ring. In certain embodiments, multicyclic cycloalkyl ring systems are a monocyclic cycloalkyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other rings systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl. Examples of multicyclic cycloalkyl groups include, but are not limited to tetradecahydrophenanthrenyl, perhydrophenothiazin-1-yl, and perhydrophenoxazin-1-yl.

[0078] "Cycloalkenyl" as used herein refers to a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system. Monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups are unsaturated (*i.e.*, containing at least one annular carbon-carbon double bond), but not aromatic. Examples of monocyclic ring systems include cyclopentenyl and cyclohexenyl. Bicyclic cycloalkenyl rings are bridged monocyclic rings or a fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkenyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form $-(CH_2)_w-$, where w is 1, 2, or 3). Representative examples of bicyclic cycloalkenyls include, but are not limited to, norbornenyl and bicyclo[2.2.2]oct-2-enyl. Fused bicyclic cycloalkenyl ring systems contain a monocyclic cycloalkenyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkenyl ring. Cycloalkenyl groups are optionally substituted with one or two groups which are independently oxo or thia. Multicyclic cycloalkenyl rings contain a

monocyclic cycloalkenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two rings systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. The multicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained within the base ring. IN certain embodiments, multicyclic cycloalkenyl rings contain a monocyclic cycloalkenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two rings systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl.

[0079] The term “halo” or “halogen” as used herein, means -Cl, -Br, -I or -F.

[0080] The term “haloalkyl” as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.

[0081] The term “heteroaryl,” as used herein, means a monocyclic, bicyclic, or a multicyclic heteroaryl ring system. The monocyclic heteroaryl can be a 5 or 6 membered ring. The 5 membered ring consists of two double bonds and one, two, three or four nitrogen atoms and optionally one oxygen or sulfur atom. The 6 membered ring consists of three double bonds and one, two, three or four nitrogen atoms. The 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heteroaryl. Representative examples of monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The fused cycloalkyl or heterocyclyl portion of the bicyclic heteroaryl group is optionally substituted with one or two groups which are independently oxo or thia. When the bicyclic heteroaryl contains a fused cycloalkyl, cycloalkenyl, or heterocyclyl ring, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon or nitrogen atom contained within the

monocyclic heteroaryl portion of the bicyclic ring system. When the bicyclic heteroaryl is a monocyclic heteroaryl fused to a phenyl ring or a monocyclic heteroaryl, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon atom or nitrogen atom within the bicyclic ring system. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzoxathiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl, and 6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-onyl. In certain embodiments, the fused bicyclic heteroaryl is a 5 or 6 membered monocyclic heteroaryl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. The multicyclic heteroaryl group is a monocyclic heteroaryl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic heterocyclyl, a bicyclic cycloalkenyl, and a bicyclic cycloalkyl; or (ii) two ring systems selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic heterocyclyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic cycloalkyl. The multicyclic heteroaryl group is connected to the parent molecular moiety through any carbon atom or nitrogen atom contained within the base ring. In certain embodiments, multicyclic heteroaryl groups are a monocyclic heteroaryl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic heterocyclyl, a bicyclic cycloalkenyl, and a bicyclic cycloalkyl; or (ii) two ring systems selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic heterocyclyl, a monocyclic cycloalkenyl, and a monocyclic cycloalkyl. Examples of multicyclic heteroaryls include, but are not limited to 5H-[1,2,4]triazino[5,6-b]indol-5-yl, 2,3,4,9-tetrahydro-1H-carbazol-9-yl, 9H-pyrido[3,4-b]indol-9-yl, 9H-carbazol-9-yl, and acridin-9-yl.

[0082] The term “heteroarylalkyl” and “-alkylheteroaryl” as used herein, means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heteroarylalkyl include, but are not

limited to, fur-3-ylmethyl, 1H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl, 1-(pyridin-4-yl)ethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, pyrimidin-5-ylmethyl, 2-(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.

[0083] The term “heterocyclyl” as used herein, means a monocyclic, bicyclic, or multicyclic heterocycle. The monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic. The 3 or 4 membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring can contain zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidiny, azepanyl, aziridiny, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidiny, isothiazoliny, isothiazolidiny, isoxazoliny, isoxazolidiny, morpholiny, oxadiazoliny, oxadiazolidiny, oxazoliny, oxazolidiny, piperaziny, piperidiny, pyranyl, pyrazoliny, pyrazolidiny, pyrroliny, pyrrolidiny, tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny, thiadiazolidiny, thiazoliny, thiazolidiny, thiomorpholiny, 1,1-dioxidothiomorpholiny (thiomorpholine sulfone), thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocycle, or a monocyclic heteroaryl. The bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle portion of the bicyclic ring system. Representative examples of bicyclic heterocyclyls include, but are not limited to, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothien-2-yl, decahydroquinoliny, decahydroisoquinoliny, octahydro-1H-indolyl, and octahydrobenzofuranyl. Heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain embodiments, the bicyclic heterocyclyl is a 5 or 6 membered monocyclic heterocyclyl ring fused to phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the bicyclic heterocyclyl is optionally substituted by one or two groups which are independently oxo or thia. Multicyclic heterocyclyl ring

systems are a monocyclic heterocyclyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other rings systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. The multicyclic heterocyclyl is attached to the parent molecular moiety through any carbon atom or nitrogen atom contained within the base ring. In certain embodiments, multicyclic heterocyclyl ring systems are a monocyclic heterocyclyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other rings systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl. Examples of multicyclic heterocyclyl groups include, but are not limited to 10H-phenothiazin-10-yl, 9,10-dihydroacridin-9-yl, 9,10-dihydroacridin-10-yl, 10H-phenoxazin-10-yl, 10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl, 1,2,3,4-tetrahydropyrido[4,3-g]isoquinolin-2-yl, 12H-benzo[b]phenoxazin-12-yl, and dodecahydro-1H-carbazol-9-yl. As used herein, heterocyclyl groups may be optionally substituted with one or more oxo group.

[0084] The term “nitro” as used herein means a -NO₂ group.

[0085] The term “oxo” as used herein means a =O group.

[0086] The term “saturated” as used herein means the referenced chemical structure does not contain any multiple carbon-carbon bonds. For example, a saturated cycloalkyl group as defined herein includes cyclohexyl, cyclopropyl, and the like.

[0087] The term “thia” as used herein means a =S group.

[0088] The term “unsaturated” as used herein means the referenced chemical structure contains at least one multiple carbon-carbon bond, but is not aromatic. For example, an unsaturated cycloalkyl group as defined herein includes cyclohexenyl, cyclopentenyl, cyclohexadienyl, and the like.


[0089] As used herein, the phrase “pharmaceutically acceptable salt” refers to both pharmaceutically acceptable acid and base addition salts and solvates. Such pharmaceutically acceptable salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC-(CH₂)_n-COOH where n is 0-4, and the like. Non-toxic pharmaceutical base addition salts include salts of bases such as sodium,

potassium, calcium, ammonium, and the like. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts.

EXAMPLES

[0090] Unless otherwise stated, all chemicals were purchased from commercial suppliers and used without further purification. Inhibitors were synthesized through several different routes. The microwave irradiation was performed in CEM Discover System. The final purity of all compounds was determined by analytical LCMS with Phenomenex Onyx Monolithic C18 column (4.6 mm x 100 mm). The products were detected by UV at the detection frequency of 220 nm. All compounds were determined to be > 95% pure by this method. The purification by preparative HPLC was performed on Waters Xterra Prep RP18 OBD 5 μ M (19 mm x 50 mm) with CH₃CN/H₂O and 0.1% TFA as eluent. The mass spectra were recorded with the Agilent Liquid Chromatograph - Ion Trap Mass Spectrometer. NMR spectra were recorded with either a Bruker 500 MHz spectrometer or Bruker 300 MHz spectrometer at ambient temperature. Inhibitors were synthesized through several different routes, as represented in Schemes 1-85. All other syntheses and compound characterization data are presented below.

[0091] A general procedure of synthesis of compound 1614, 1673, 1709 and 1717




[0092] **Synthesis of 6-fluoropyridine-2,3-diamine.** Trifluoroacetic anhydride (8.8 ml) was slowly added to a solution of 5-amino-2-fluoropyridine (1.0 g) dissolved in trifluoroacetic acid (15.2 ml) at 0 °C. After stirring for 5 min, to the clear solution was added ammonium nitrate (1.43g) in several portions. The mixture was stirred at 0 °C for 3h, then room temperature for 1h. After the solvent was removed, the residue was dissolved in EtOAc, washed with brine, dried over Na₂SO₄. The orange residue was purified via silica gel column with EtOAc/hexane elution to obtain 1.4 g of 2,2,2-trifluoro-N-(6-fluoro-2-nitropyridin-3-yl)acetamide as a yellow oil. ¹H NMR (500 MHz, MeOD) δ 8.60 (t, J = 10.5 Hz, 1H), 7.61 (d, J = 3.4 Hz, 1H).

[0093] 2,2,2-trifluoro-N-(6-fluoro-2-nitropyridin-3-yl)acetamide (1.4 g) was added into a solution of K₂CO₃ (1.0 g) in 10 ml of MeOH and 5 ml of water. After stirring at room temperature for 3h, the mixture was cooled down at 4 °C overnight. The yellow solid was collected and washed with cooled MeOH to obtain 6-fluoro-2-nitropyridin-3-amine (0.92 g). m/z: 159.2 ([M+H]⁺)

[0094] 6-fluoro-2-nitropyridin-3-amine (250 mg) was dissolved in 40 ml of MeOH and reduced with H₂ (in a balloon) in the presence of 86 mg of 10% Pd/carbon for 2h at room temperature. The solution was filtered through a celite pad. After the solvent was removed, the residue was purified via


silica gel column with MeOH/DCM elution to obtain 128 mg of 6-fluoropyridine-2,3-diamine as a light pink solid. ^1H NMR (500 MHz, MeOD) δ 7.00 (dd, $J = 7.9, 7.2$ Hz, 1H), 6.07 (dd, $J = 8.0, 2.2$ Hz, 1H). m/z : 128.8 ($[\text{M}+\text{H}]^+$)



[0095] Synthesis of 1614. The synthetic procedure was based on the reference¹. (3-amino-propyl)-(3,5-dichloro-benzyl)-carbamic acid tert-butyl ester (1.0 mmol)² in 10 ml of acetonitrile was dropwise added into the solution of 1,1'-thiocarbonyldiimidazole (1.5 mmol), imidazole (0.3 mmol) in 50 ml of acetonitrile at 0 °C with stirring. After 10 min of stirring at 0 °C, the mixture was allowed to warm to room temperature and stirred for 3 h. 6-fluoropyridine-2,3-diamine (1.2 mmol) in 10 ml of acetonitrile was added and the mixture was refluxed overnight. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with MeOH/DCM, to give tert-butyl 3,5-dichlorobenzyl 3-(3-(2-amino-6-fluoropyridin-3-yl)thioureido)propylcarbamate as a yellow oil. m/z : 502.8 ($[\text{M}+\text{H}]^+$)

[0096] A mixture of tert-butyl 3,5-dichlorobenzyl 3-(3-(2-amino-6-fluoropyridin-3-yl)thioureido)propylcarbamate (0.2 mmol), HgO (0.4 mmol), sulfur (0.04 mmol) and EtOH (10 ml) was combined and refluxed for 2 hours. The reaction mixture was cooled and filtered through a celite pad. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with MeOH/DCM to give tert-butyl 3,5-dichlorobenzyl 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate as an off-white solid. m/z : 468.9 ($[\text{M}+\text{H}]^+$)

[0097] tert-butyl 3,5-dichlorobenzyl 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate (0.15 mmol) was dissolved in a mixture of dioxane (20 ml) and 4 M HCl in dioxane (60 μl). The precipitate was formed in 5 min. The mixture was stirred in 30 min. The solid was collected and washed with cooled dioxane to obtain a white solid of **1614** as HCl salt. m/z : 368.8 ($[\text{M}+\text{H}]^+$)




[0098] **Synthesis of 1673.** A mixture of 3,5-dichlorobenzylamine (1.5 mmol) and (R)-(-)-3-bromo-2-methyl-1-propanol (0.5 mmol), DIPEA (0.5 mmol) and trace amount of KI in ethanol (1.0 ml) was microwave irradiated at 90 °C for 30 min. To the solution were added (Boc)₂O (1.25 mmol) and DIPEA (1.5 mmol) in 2 ml of acetonitrile. The mixture was stirred at room temperature overnight. After the solvents were removed, the residue were dissolved in ethyl acetate, washed with water, brine and dried over Na₂SO₄. The organic extract was purified via silica gel chromatography to obtain compound **A** in 50% yield. m/z: 371.0 ([M+Na]⁺

[0099] To a solution of compound **A** (0.25 mmol) in 20 ml of dry DCM at -10 °C was added DIPEA (0.45 mmol) and methanesulfonyl chloride (0.38 mmol). The mixture was stirred at -10 °C for 30 min. After the solvent was removed, the residue was dissolved in 5 ml of DMF and NaN₃ (0.50 mmol) was added. The mixture was stirred at 40-45 °C overnight. The solvent was removed and the residue was dissolved with ethyl acetate. The organic solution was washed with water, brine and dried over Na₂SO₄. The residue was purified via silica gel chromatography to obtain compound **B**. ¹H NMR (500 MHz, CDCl₃) δ 7.28 (m, 1H), 7.10 (s, 2H), 4.37 (s, 2H), 3.24 (m, 4H), 2.04 (br, 1H), 1.48 (m, 9H), 0.97 (d, *J* = 6.7 Hz, 3H). m/z: 395.8 ([M+Na]⁺


[0100] A mixture of compound **B** (0.083 mmol), PPh₃ (0.25 mmol) in 1 ml of THF and 15 μl of water was stirred at room temperature overnight. Purification was performed via silica gel chromatography to obtain compound **C**. m/z: 347.8 ([M+H]⁺

[0101] Following the synthetic procedure of **1614**, compound **1673** was synthesized using compound C. ^1H NMR (500 MHz, MeOD) δ 7.93 – 7.83 (m, 1H), 7.64 (s, 2H), 7.56 (s, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.30 (q, J = 13.3 Hz, 2H), 3.58 – 3.38 (m, 2H), 3.28 (m, 1H), 3.10 – 2.96 (m, 1H), 2.42 (s, 1H), 1.20 (d, J = 6.7 Hz, 3H). m/z : 383.0 ($[\text{M}+\text{H}]^+$)



[0102] A solution of 2,4-dichlorophenol (10 mmol) and NaOH (10 mmol) in 20 mL of water was heated at 100°C for 20 min. A solution of 3-bromopropionic acid (20 mmol) and NaOH (20 mmol) in 10 mL of water was added slowly to the above hot solution. The mixture was heated at 100°C overnight and then cooled to room temperature. The reaction mixture was made acidic with concentrated HCl. The mixture was extracted into ether (3 times), and the combined organic layer was extracted with saturated NaHCO_3 . The water layer was made acidic and extracted with ether (3 times). The combined organic layer was washed with brine and dried over Na_2SO_4 . After solvent was removed, the residue was purified via silica gel chromatography, eluted with MeOH/DCM to give 3-(2,4-dichlorophenoxy)propanoic acid as a white solid.

[0103] Oxalyl chloride (5.2 mmol) was added to the solution of 3-(2,4-dichlorophenoxy)propanoic acid (2.6 mmol) in 20 mL of anhydrous DCM followed by a drop of DMF³. After 1.5 hours, the solution was cooled in an ice-water bath. AlCl_3 (2.86 mmol) was added and the dark red solution was allowed to slowly reach room temperature and stirred overnight. The mixture was poured into ice and the organic layer was separated. The aqueous layer was extracted with ethyl acetate twice. The combined organic layers were washed with 1 N NaOH, brine, dried over Na_2SO_4 and concentrated. Purification via silica gel chromatography of this residue eluted with hexane and EtOAc provided 6,8-dichloro-2,3-dihydrochromen-4-one as a white solid. m/z : 218,2 ($[\text{M}+\text{H}]^+$)




[0104] A mixture of 2,4-dichloroaniline (1.2 mmol), methyl acrylate (4.8 mmol), cuprous chloride (0.12 mmol) in 2 mL of AcOH was microwave irradiated at 135 °C for 1 h⁴.

[0105] Solvents were removed by evaporation and the residue partitioned between EtOAc (30 ml) and water (30 ml). The organic layer was washed with brine and dried over Na₂SO₄. After solvent was removed, the residue was purified via silica gel chromatography, eluted with EtOAc/hexane to give methyl 3-(2,4-dichlorophenylamino)propanoate. *m/z*: 249.5 ([M+H]⁺)

[0106] Methyl 3-(2,4-dichlorophenylamino)propanoate (0.8 mmol) was hydrolyzed in 1 ml of MeOH and 1 ml of 1M NaOH with microwave irradiation at 80 °C for 10 min. The mixture was made acidic and extracted with ethyl acetate. The organic layer was washed with brine and dried over Na₂SO₄. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with MeOH/DCM to give 3-(2,4-dichlorophenylamino)propanoic acid. *m/z*: 235.2 ([M+H]⁺)

[0107] A mixture of 3-(2,4-dichlorophenylamino)propanoic acid (0.6 mmol) in 2 ml of phosphorus pentoxide - methanesulfonic acid (Eaton's reagent) was microwave irradiated at 70 °C for 20 min⁵. Ice-cold water was added to the reaction mixture. The mixture was made basic (pH 12) with 50 wt % NaOH, and extracted with EtOAc several times. The combined organic extracts were dried over Na₂SO₄. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with EtOAc/hexane to give 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one as a yellow solid. *m/z*: 217.4 ([M+H]⁺)




[0108] To a solution of (R)-(+)-tert-butylsulfinamide (0.60 mmol) in tetrahydrofuran (4 ml) was added subsequently 6,8-dichloro-2,3-dihydrochromen-4-one (0.30 mmol) and tetraethyl orthotitanate (0.75 mmol) and the solution was microwave irradiated at 80 °C for 1h⁶. The mixture was cooled to room temperature, treated with brine (400 ml), the suspension was filtered through the celite pad. The layers were separated; the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, dried and concentrated in vacuo. The residue was purified via silica gel chromatography using ethyl acetate/hexane as the eluent to give compound **D**.

[0109] Compound **D** (0.2 mmol) was dissolved in 98:2 THF/H₂O (2 ml) and cooled to -50 °C. To the mixture was then added NaBH₄ (0.6 mmol), and the resulting solution was warmed to room

temperature over a 3 h period⁷. The solvent was then removed in vacuo, and the resulting residue was extracted with ethyl acetate. The organic layer was washed with water, brine, dried and concentrated in vacuo. The residue was purified via silica gel chromatography using ethyl acetate/hexane as the eluent to give compound **E**. ¹H NMR(500 MHz, CDCl₃) δ 7.32 (m, 1H), 4.57 (br, 1H), 4.42-4.46 (m, 1H), 4.30-4.35 (m, 1H), 3.34 (s, 1H), 2.13-2.17 (m, 2H), 1.26 (s, 9H). m/z: 323.0 ([M+H]⁺)



[0110] Hydrogen chloride (3.0 equiv, 4M solution in 1,4-dioxane) was added to a solution of compound **E** (0.15 mmol) in MeOH (1.5 ml) at room temperature and the reaction was proceeded for 1.5 h. Most of the solvent was removed in vacuum and diethyl ether was added, resulting in the appearance of a solid. The supernatant was removed and the solid was washed several times with diethyl ether and dried in vacuum to give (R)-6,8-dichloro-3,4-dihydro-2H-chromen-4-amine.

[0111] (R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine was synthesized via the same procedure as (R)-6,8-dichloro-3,4-dihydro-2H-chromen-4-amine by using 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one. m/z: 219.5 ([M+H]⁺)



[0112] N-(3,3-diethoxypropyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine was synthesized using 3-Aminopropionaldehyde diethyl acetal by following the synthetic procedure described for the synthesis of **1614**. ¹H NMR (500 MHz, MeOD) δ 7.55 – 7.47 (m, 1H), 6.55 (d, *J* = 8.2 Hz, 1H), 4.67 (t, *J* = 5.5 Hz, 1H), 3.73 – 3.64 (m, 2H), 3.54 (m, 2H), 3.48 (m, 2H), 1.96 (dd, *J* = 12.4, 6.8 Hz, 2H), 1.19 (t, *J* = 7.1 Hz, 6H). m/z: 283.3 ([M+H]⁺)


[0113] 2N of HCl (3.0 equiv) was added to a solution of N-(3,3-diethoxypropyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine (0.15 mmol) in dioxane (1.5 ml) at room temperature and the mixture was stirred for 1.5h. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with EtOAc/hexane to give 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propanal. m/z: 209.5 ([M+H]⁺)



[0114] Synthesis of 1709 and 1717. To a solution of (R)-6,8-dichloro-3,4-dihydro-2H-chromen-4-amine HCl salt (0.1 mmol) in 5 ml of methanol was added DIPEA (0.1 mmol), 0.15 ml of HOAc and 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propanal (0.12 mmol). The mixture was stirred at room temperature for 30 min, and then NaBH₃CN (0.2 mmol) was added. The reaction mixture was stirred at 50 °C for 2 days. After the solvent was removed, the residue was purified via silica gel chromatography, eluted with MeOH/DCM and further purified by using preparative HPLC to give compound **1709** as TFA salt. Conversion of TFA salt to HCl was performed via adding HCl in methanol and removing solvent to give a white solid. m/z: 411.1 ([M+H]⁺)

[0115] Following the synthetic procedure of compound **1709**, compound **1717** was synthesized using (R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine. m/z: 410.2 ([M+H]⁺)


Scheme 1



Reagents and conditions (a) EDC, DIPEA, DMAP; (b) TFA, DCM


General Procedure 1 (1720, 1726):

[0116] The solution of Boc-(R)-3-amino-4-(2,4-dichlorophenyl)butyric acid (30 mg, 0.086 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10 min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography. The above purified compound was dissolved in 3 mL of DCM. To the solution, 1 mL of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was evaporated under vacuum, neutralized with aq NaHCO₃ and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated to give **1720**. LC/MS: (ESI) (M + H)⁺ = 378.3.



[0117] **1726** was synthesized using Boc-(S)-3-amino-4-(2,4-dichlorophenyl)butyric acid following General Procedure 1. LC/MS: (ESI) (M + H)⁺ = 378.3

Scheme 2




Reagents and conditions (a) EDC, DIPEA, HOBT, CH₂Cl₂; (b) AcOH, 60 °C, 4h; (c) TFA, CH₂Cl₂; (d) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN


General Procedure 2 (1767, 1794, 1805-1806, 1819-1828):

[0118] To a 10 mL DCM solution of Boc-β-alanine (50 mg, 0.265 mmol) were added N,N-diisopropylethylamine (0.80 mmol), EDC HCl (0.40 mmol), HOBT (0.265 mmol), and 4-chlorobenzene-1,2-diamine (0.265 mmol). The reaction mixture was stirred at room temperature for 6 hr. The solution was diluted with 50 mL DCM, washed with water, sat. ammonium chloride, sat. sodium bicarbonate and brine, dried over anhydrous Na₂SO₄, filtered and concentrated. To the residue, 3 mL of acetic acid was added and this mixture was heated for 4 hrs at 60 °C. After evaporation, the obtained mixture was purified by flash


column chromatography (DCM/MeOH) to give tert-butyl 2-(5-chloro-1H-benzo[d]imidazol-2-yl)ethylcarbamate. TFA (1 ml) was added to tert-butyl 2-(5-chloro-1H-benzo[d]imidazol-2-yl)ethylcarbamate (20mg, 0.068mmol) in methylene chloride (3 ml) and the reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated off completely, under vacuum, and the residue was co-distilled 2× with methylene chloride. The residue was dissolved in 3 ml MeOH, neutralized with DIPEA, 0.15 ml AcOH and 3,5-Dichlorobenzaldehyde (1.1 equiv) were added. After the mixture was stirred for 30 min, NaBH₃CN (2 equiv) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding [2-(6-Chloro-1H-benzimidazol-2-yl)-ethyl]-(3,5-dichloro-benzyl)-amine (**1716**) in colorless oil. The oily product was dissolved in 1 ml of 4 N HCl in MeOH. The solvent was evaporated under vacuum to give solid **1716** in HCl salt form. LC/MS: (ESI) (M + H)⁺ = 355.6

**1794**


[0119] **1794** was synthesized using 3-tert-butoxycarbonylamino-butyric acid in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 369.7.

**1805**

[0120] **1805** was synthesized using (S)-3-tert-butoxycarbonylamino-butyric acid in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 369.7.


**1806**

1806 was synthesized using (R)- 3-tert-butoxycarbonylamino-butyrlic acid in General Procedure 2. LC/MS: (ESI) (M +H)⁺ = 369.7.




1819

[0121] **1819** was synthesized using benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M +H)⁺ = 335.3




1820

1820 was synthesized using 4-methyl-benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M +H)⁺ = 339.5




1821

[0122] **1821** was synthesized using 4-bromobenzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M +H)⁺ = 414.1.




1822


[0123] **1822** was synthesized using 4,5-dichloro-benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M +H)⁺ = 404.3.

**1823**


[0124] **1823** was synthesized using 3,5-dichloro-benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 404.3.

**1824**

[0125] **1824** was synthesized using 4-chloro-5-fluoro-benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 387.7.


**1825**

[0126] **1825** was synthesized using 4-trifluoromethyl-benzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 403.4.


**1826**

[0127] **1826** was synthesized using Naphthalene-2,3-diamine in General Procedure 2.


[0128] LC/MS: (ESI) (M + H)⁺ = 385.2.

**1827**


[0129] **1827** was synthesized using (S)-3-tert-Butoxycarbonylamino-pentanoic acid in General Procedure 2. LC/MS: (ESI) (M + H)⁺ = 383.2.

**1828**

[0130] **1828** was synthesized using (R)-3-tert-Butoxycarbonylamino-4-methyl-pentanoic acid in General Procedure 2. LC/MS: (ESI) (M+H)⁺= 397.8.


**1832**

[0131] **1832** was synthesized using 4-tert-Butoxycarbonylamino-butyric acid and 4-chlorobenzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M+H)⁺= 369.6.

**1853**

[0132] **1853** was synthesized using Boc-glycine and 4-bromobenzene-1,2-diamine in General Procedure 2. LC/MS: (ESI) (M+H)⁺= 385.7.

Scheme 3



[0133] Reagents and conditions: (a) NaBH₃CN, AcOH, CH₃OH, r.t. overnight; (b) (Boc)₂O, DIPEA, DCM, r.t., 3h; (c) LiOH, CH₃OH/H₂O, r.t. overnight; (d) EDC, pyridine, r.t. overnight; (e) AcOH, POCl₃, Microwave 150 °C, 1h.

[0134] (a) 3,5-dichlorobenzaldehyde (88 mg, 0.5 mM) and methyl 4-aminobutanoate (77 mg, 0.5 mM) were dissolved in CH₃OH, AcOH (60 mg, 1 mM) and NaBH₃CN (63mg, 1 mM) were added to the solution. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was

dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was used for the next step without purification.

[0135] (b) Intermediate methyl 4-((3,5-dichlorobenzyl)amino) butanoate obtained from above step was dissolved in DCM, DIPEA (1.5 eq) was added to the solution. (Boc)₂O was then added in portions at 0 °C, the mixture was stirred at r.t. for 3 hours. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with EA-hexane to give intermediate methyl 4-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)butanoate.

[0136] (c) LiOH·H₂O (3 eq) was added to the solution of methyl 4-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)butanoate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was extracted with EA/1N HCl solution. The organic layer was dried over sodium sulfate, concentrated in vacuum to give the intermediate 4-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)butanoic acid which was used for the next step without further purification.


[0137] (d) 4-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)butanoic acid obtained from above step was dissolved in pyridine (2 mL), EDC (1.5 eq) was added and the mixture was stirred at r.t. overnight. Pyridine was removed under reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave tert-butyl (4-((2-amino-6-fluoropyridin-3-yl)amino)-4-oxobutyl)(3,5-dichlorobenzyl)carbamate.

[0138] (d) Intermediate tert-butyl (4-((2-amino-6-fluoropyridin-3-yl)amino)-4-oxobutyl)(3,5-dichlorobenzyl)carbamate obtained from above step was dissolved in 3 mL glacial acetic acid, POCl₃ (3 eq) was added, the mixture was microwave irradiated at 150 °C for 1 hour. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give compounds **1858** N-(3,5-dichlorobenzyl)-3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-

yl)propan-1-amine. MS (ESI) (M+H)⁺ = 354.3; and **1835** N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)propyl)acetamide. MS (ESI) (M+H)⁺ = 396.8.

[0139] **1895**: N-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)propyl)-N-(3,5-dichlorobenzyl)acetamide. MS (ESI) (M+H)⁺ = 412.6.

Scheme 4




Reagents and conditions: (a) Dioxane, 80 °C, 30 min; (b) EDC, pyridine, r.t. overnight; (c) AcOH, POCl₃, Microwave 150 °C, 1h.

[0140] (a) Succinic anhydride (1 eq) and (3,5-dichlorophenyl)methanamine (1 eq) in dioxane was heated to 80 °C for 30 min. The solvent was evaporated off and residue was purified via flash column chromatography directly eluting with 20% MeOH in DCM to yield 4-((3,5-dichlorobenzyl)amino)-4-oxobutanoic acid.

[0141] (b,c) Steps b and c were conducted following steps d and e in Scheme 3 to produce compound **1944**. LC/MS: (ESI) (M + H)⁺ = 384.8.

Scheme




Reagents and conditions (a) NaHSO₃, DMF, 100 °C; (b) TFA, CH₂Cl₂; (c) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN

General Procedure 3 (1780, 1844, 1881, 1882):


[0142] DMF (1.0 mL) solution of aldehyde (1.0 mmol) was added dropwise to a mixture of 6-chloropyridine-2,3-diamine (1.0 mmol), and sodium bisulfite (1.0 mmol) in DMF (1.0 mL) over a 10-min period at 100 °C. After 2 h, the reaction mixture was concentrated, and the residue was purified by flash column chromatography (DCM/MeOH) to give tert-butyl 2-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)ethylcarbamate¹. Following the general procedure A to remove Boc with TFA/DCM and perform the reductive amination with 3,5-

dichlorobenzaldehyde yields [2-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-ethyl]-(3,5-dichloro-benzyl)-amine (**1780**). LC/MS: (ESI) (M + H)⁺ = 356.6.

**1844**


[0143] **1844** was synthesized using 5-chloro-pyridine-2,3-diamine in General Procedure 3.

[0144] LC/MS: (ESI) (M + H)⁺ = 356.6.

**1882**

[0145] **1882** was synthesized using 2,3-diamine-5-chloropyridine in General Procedure 3.


[0146] LC/MS: (ESI) (M + H)⁺ = 356.6.

**1881**

[0147] **1881** was synthesized using (4-oxo-butyl)-carbamic acid tert-butyl ester in General Procedure 3.

[0148] LC/MS: (ESI) (M + H)⁺ = 370.7.

Scheme 6




Reagents and conditions (a) MeOH/H₂O, 2h; (b) C-(1H-benzoimidazol-2-yl)-methylamine, saturated NaHCO₃

[0149] 2,4-Dichloro-benzylamine (47.3mg 0.269mmol) and 3,4-dimethoxy-3-cyclobutene-1,2-dione (38.2mg, 0.269mmol) were combined in MeOH (2 ml) and water

(2ml) and stirred for 2h. C-(1H-benzoimidazol-2-yl)-methylaniline HCl (59.4 mg, 0.269mmol) and sat. NaHCO₃ (1ml) was added *in situ*. The mixture was stirred at room temperature overnight. After the mixture was extracted with ethyl acetate, washed with brine, concentrated under vacuum and purified via flash column chromatography to yield 3-[(1H-Benzimidazol-2-ylmethyl)-amino]-4-(2,4-dichloro-benzylamino)-cyclobut-3-ene-1,2-dione(**1769**). LC/MS: (ESI) (M + H)⁺ = 402.5.

Scheme 7




Reagents and conditions (a) EDC, DIPEA, DMAP, DCM; (b) TFA, CH₂Cl₂; (c) LAH, THF, μ W 80 °C, 30 min; (d) triphosgene, DCM.

[0150] The solution of (S)-Boc-2-amino-3-(2,4-dichlorophenyl)propionic acid (203 mg, 0.608 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous sodium sulphate and evaporated under vacuum to afford tert-butyl (S)-1-((1H-benzo[d]imidazol-2-yl)methylcarbamoyl)-2-(2,4-dichlorophenyl)ethylcarbamate. The above compound was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was evaporated under vacuum, neutralized with aq NaHCO₃ and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulphate and concentrated give (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-2-amino-3-(2,4-dichlorophenyl)propanamide. To the solution of (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-2-amino-3-(2,4-dichlorophenyl)propanamide (95 mg, 0.262 mmol) in 3 ml of anhydrous THF, lithium aluminium hydride (40mg, 4.0 equiv) was added in portion-wise at 0 °C. The reaction mixture was then microwave irradiated at 80 °C for 30min. Thereafter it was cooled and

slowly quenched with water, aq NaOH and extracted with ethyl acetate. The organic layer was washed with water, brine, and dried over anhydrous sodium sulphate. It was evaporated under vacuum to afford (S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-3-(2,4-dichlorophenyl)propane-1,2-diamine³. To a stirred solution of (S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-3-(2,4-dichlorophenyl)propane-1,2-diamine (74mg, 0.213 mmol) in DCM (10 mL) was added DIPEA (5 equiv) and cooled to 0 °C. A solution of triphosgene (0.33 equiv) in DCM (2 mL) was added dropwise to the reaction mixture and stirred at room temperature for 4 h. The reaction mixture was washed with brine, dried over anhydrous sodium sulphate and evaporated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH) to give 1-(1H-Benzoimidazol-2-ylmethyl)-4-(2,4-dichloro-benzyl)-imidazolidin-2-one (**1792**). LC/MS: (ESI) (M +H)⁺ = 376.7.

Scheme 8




Reagents and conditions (a) CH₃I, NaHCO₃, DMF; (b) TFA, CH₂Cl₂ ; (c) triphosgene, DCM; (d) pyridine, μ W 120 °C, 15 min.

[0151] To a solution of (S)-Boc-2-amino-3-(2,4-dichlorophenyl)propionic acid (150 mg , 0.4488 mmol, 1.0 equiv) in 10 ml of DMF was added NaHCO₃ (4 equiv) and CH₃I (10 equiv). The mixture was stirred at room temperature for 2 days. The solvent was removed and the residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The solid was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was evaporated under vacuum, neutralized with aq NaHCO₃ and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated give (S)-methyl 2-amino-3-(2,4-dichlorophenyl)propanoate. To a stirred solution of (S)-methyl 2-amino-3-(2,4-dichlorophenyl)propanoate (103 mg, 0.415 mmol) in DCM (10 mL) was added DIPEA (1.5 equiv) and cooled to 0 °C. A solution of triphosgene (0.33 equiv) in DCM (2 mL) was added dropwise to the reaction mixture and stirred at room temperature for 2 h. The solution was

back to 0 °C and (1H-benzo[d]imidazol-2-yl)methanamine (1.5 equiv) in DCM (2 ml) was added. The reaction mixture was stirred at 0 °C for 30min. The solution washed with brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (S)-methyl 2-(3-((1H-benzo[d]imidazol-2-yl)methyl)ureido)-3-(2,4-dichlorophenyl)propanoate. The solution of (S)-methyl 2-(3-((1H-benzo[d]imidazol-2-yl)methyl)ureido)-3-(2,4-dichlorophenyl)propanoate (40 mg) in pyridine (2ml) was microwave irradiated at 120 °C for 15 min. After the solvent was removed under vacuum, residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (S)-3-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorobenzyl)imidazolidine-2,4-dione (**1754**). LC/MS: (ESI) (M + H)⁺ = 390.8.

Scheme 9




Reagents and conditions (a) NaOH, H₂O, refluxing; (b) HBTU, DIPEA, DMF, (5-fluoro-1H-benzo[d]imidazol-2-yl)methanamine


General Procedure 4 (1740, 1683, 1704, 1705, 1671, 1675, 1674, 1727):

[0152] A solution of 2,4-dichlorophenol (10 mmol) and NaOH (10 mmol) in 20 mL of water was heated at 100°C for 20min. A solution of 3-bromopropionic acid (20 mmol) and NaOH (20 mmol) in 10 ml of water was added slowly to the above hot solution. The mixture was heated at 100°C overnight, cooling to room temperature. The reaction mixture was made acidic with concentrated HCl. The mixture was extracted into ether (3 times), and the combined organic layer was extracted with saturated NaHCO₃. The water layer was made acidic and extracted with ether (3 times). The combined organic layer was washed with brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 3-(2,4-dichlorophenoxy)propanoic acid in white solid. The solution of 3-(2,4-dichlorophenoxy)propanoic acid (20 mg, 0.085 mmol), DIPEA (0.25mmol), EDC HCl (0.12mmol) and DMAP (0.085mmol) in DMF (20 mL) was stirred for 10min. To this reaction mixture (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (0.085mmol) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous


sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford 3-(2,4-dichlorophenoxy)-N-((6-fluoro-1H-benzo[d]imidazol-2-yl)methyl)propanamide (**1740**). LC/MS: (ESI) (M + H)⁺ = 383.3.

**1683**


[0153] **1683** was synthesized using (1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 385.6.

**1704**


[0154] **1704** was synthesized using (3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 366.5.

**1705**


[0155] **1705** was synthesized using (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 384.7.

**1671**


[0156] **1671** was synthesized using 2-bromoacetyl bromide and (1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 351.4.

**1675**

[0157] **1675** was synthesized using 2-bromoacetyl bromide and 2-(1H-benzo[d]imidazol-2-yl)ethanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 365.4.


**1674**

[0158] **1674** was synthesized using 2-bromoacetyl bromide and (1H-indol-2-yl)methanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 350.7.

**1727**

[0159] **1727** was synthesized using (1H-benzo[d]imidazol-2-yl)-N-methylmethanamine in General Procedure 4. LC/MS: (ESI) (M + H)⁺ = 379.3.

Scheme 10




[0160] Reagents and conditions (a) CH₃CN, NMM; (b) NaOH. Ethanol; (c) EDC, DIPEA, DCM, (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine

[0161] A solution of 2,4-dichloro-phenol (1 mmol), ethyl propiolate (1.2 mmol) and N-methylmorpholine (0.06 mmol) in CH₂Cl₂ (10 mL) was stirred at room temperature overnight. The solution was then washed with water and brine, and dried over anhydrous sodium sulfate. After removal of the solvent, the crude product was purified by column chromatography to give (E)- 3-(2,4-Dichloro-phenoxy)-acrylic acid ethyl ester. To a solution of (E)- 3-(2,4-Dichloro-phenoxy)-acrylic acid ethyl ester (30 mg, 0.115 mmol) in ethanol (2 mL) was added and 1 N NaOH (1ml). The resultant mixture was microwave irradiated for 15min at 80 °C. After being cooled to room temperature, it was poured into ethyl acetate (50 mL), washed with 0.1 N HCl, water, brine dried over magnesium sulfate, and evaporated to dry to yield 3-(2,4-Dichloro-phenoxy)-acrylic acid. The solution of 3-(2,4-Dichloro-phenoxy)-acrylic acid (20 mg , 0.086 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10min. To this reaction

mixture (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO_3 and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford 3-(2,4-Dichloro-phenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylmethyl)-acrylamide (**1768**). LC/MS: (ESI) $(\text{M} + \text{H})^+ = 382.2$.


Scheme 11




Reagents and conditions (a) DCM, pyridine; (b) 5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine

General Procedure 5(**1741**, **1701**, **1706**, **1707**, **1699**, **1728**):


[0162] To a solution of 2-(2,4-dichloro-phenyl)-ethanol (200 mg, 1.04 mmol) in 5 ml of DCM was added 4-nitrophenol chloroformate (200mg, 0.99 mmol) in 3 ml of DCM and pyridine (84.8 μl , 1.05 mmol) at 0 °C. The mixture was at 0 °C for 3h. The solvent was removed and the residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give carbonic acid 2-(2,4-dichloro-phenyl)-ethyl ester 4-nitro-phenyl ester. 5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (0.06mmol) was added into the solution of carbonic acid 2-(2,4-dichloro-phenyl)-ethyl ester 4-nitro-phenyl ester (0.06mmol) in DCM (10ml) at 0 °C with stirring. The mixture was stirred at room temperature overnight. The solution was diluted with 50 ml of DCM and washed with 0.1 N NaOH (50ml), brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (6-Fluoro-1H-benzoimidazol-2-ylmethyl)-carbamic acid 2-(2,4-dichloro-phenyl)-ethyl ester (**1741**). LC/MS: (ESI) $(\text{M} + \text{H})^+ = 383.1$.

**1701**


[0163] **1701** was synthesized using (1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 5. LC/MS: (ESI) (M + H)⁺ = 365.7.

**1728**


[0164] **1728** was synthesized using (1H-benzo[d]imidazol-2-yl)-N-methylmethanamine in General Procedure 5. LC/MS: (ESI) (M + H)⁺ = 379.5.

**1706**

[0165] **1706** was synthesized using (3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 5. LC/MS: (ESI) (M + H)⁺ = 366.6.


**1707**

[0166] **1707** was synthesized using (3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 5. LC/MS: (ESI) (M + H)⁺ = 384.5.

**1699**

[0167] **1699** was synthesized using phenylmethanol and (3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 5. LC/MS: (ESI) (M + H)⁺ = 283.4.


Scheme 12



Reagents and conditions (a) CH₃CN, NMM; (b) NaOH, Ethanol; (c) EDC, DIPEA, DMAP, DCM, (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine


General Procedure 6 (1768, 1729, 1779, 1765, 1766):

[0168] A solution of 2,4-dichloro-phenol (1 mmol), ethyl propiolate (1.2 mmol) and N-methylmorpholine (0.06 mmol) in CH₂Cl₂ (10 mL) was stirred at room temperature overnight. The solution was then washed with water and brine, and dried over anhydrous sodium sulfate. After removal of the solvent, the crude product was purified by column chromatography to give (E)-3-(2,4-Dichloro-phenoxy)-acrylic acid ethyl ester. To a solution of (E)-3-(2,4-Dichloro-phenoxy)-acrylic acid ethyl ester (30 mg, 0.115 mmol) in ethanol (2 mL) was added and 1 N NaOH (1ml). The resultant mixture was microwave irradiated for 15min at 80 °C. After being cooled to room temperature, it was poured into ethyl acetate (50 mL), washed with 0.1 N HCl, water, brine dried over magnesium sulfate, and evaporated to dry to yield 3-(2,4-Dichloro-phenoxy)-acrylic acid. The solution of 3-(2,4-Dichloro-phenoxy)-acrylic acid (20 mg, 0.086 mmol), DIPEA (0.26mmol), EDC HCl (0.13mmol) and DMAP (0.086mmol) in DCM (20 mL) was stirred for 10min. To this reaction mixture (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (0.086mmol) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford 3-(2,4-Dichloro-phenoxy)-N-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl-acrylamide (**1768**). LC/MS: (ESI) (M + H)⁺ = 382.2.



1729


[0169] **1729** was synthesized using (1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 6. LC/MS: (ESI) (M + H)⁺ = 363.4.



1779

[0170] 1779 was synthesized using 2,4-dichloro-6-((methylamino)methyl)phenol and (1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 6. LC/MS: (ESI) (M + H)⁺ = 406.6.

Scheme 13




1739

Reagents and conditions (a) Boc₂O, CH₃CN/MeOH, DIPEA, μ W, 50 °C, 10min; (b) DCM, pyridine, 4-nitrophenol chloroformate; (c) 2-(2,4-dichloro-phenyl)-ethylamine; (d) TFA, CH₂Cl₂

[0171] The mixture of (1H-Benzimidazol-2-yl)-methanol (71mg, 0.48mmol), DIPEA (0.17 ml) and Boc₂O (105mg, 0.48mmol) in CH₃CN (1ml) and MeOH(0.5ml) was microwave irradiated for 10 min at 50 °C. After the solvents were removed, the residue was dissolved in 3 ml of DCM. 4-nitrophenol chloroformate (0.48 mmol) in 2 ml of DCM and pyridine (20 μ l) was added at 0 °C and stirred for 2 h. The solvent was removed and the residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give 2-(4-Nitro-phenoxy-carbonyloxymethyl)-benzimidazole-1-carboxylic acid tert-butyl ester. 2-(2,4-Dichloro-phenyl)-ethylamine (0.06mmol) was added into the solution of 2-(4-Nitro-phenoxy-carbonyloxymethyl)-benzimidazole-1-carboxylic acid tert-butyl ester (0.06mmol) in DCM (10ml) at 0 °C with stirring. The mixture was stirred at room temperature overnight. The solution was diluted with 50 ml of DCM and washed with 0.1 N NaOH (50ml), brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography and further de-protected with TFA/DCM to give [2-(2,4-Dichloro-phenyl)-ethyl]-carbamic acid 1H-benzimidazol-2-ylmethyl ester (1739). LC/MS: (ESI) (M + H)⁺ = 365.7.


Scheme 14



Reagents and conditions (a) NMM, μ W 80 °C, 15min; (b) EDC, DIPEA, DCM, (1H-benzo[d]imidazol-2-yl)methanamine

[0172] (2,4-Dichloro-phenyl)-acetaldehyde (38mg, 0.2mmol) and malonic acid (23mg, 1.1 equiv) in 70 μ l of NMM were mixed thoroughly and subjected to microwave irradiation at 80 C for 15min. The mixture was diluted with ethyl acetate (50ml) and washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (E)-4-(4-Chloro-2-hydroxy-phenyl)-but-3-enoic acid. The solution of (E)-4-(4-Chloro-2-hydroxy-phenyl)-but-3-enoic acid (20 mg , 0.094 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO_3 and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford 4-(4-Chloro-2-hydroxy-phenyl)-but-3-enoic acid (1H-benzoimidazol-2-ylmethyl)-amide (**1737**). LC/MS: (ESI) $(\text{M} + \text{H})^+ = 342.3$.

Scheme 15




Reagents and conditions (a) 100 °C 2h; (b) EDC, DIPEA, DCM, (1H-benzo[d]imidazol-2-yl)methanamine

[0173] A mixture of 2,4-dichloroaniline(1.032g), acrylic acid (2ml) was heated at 100 °C for 2h with stirring to give brownish solution. The hot solution was added dropwise into 500 ml of water with vigorously stirring. The precipitate was collected by filtration and washed with water. The solid was dissolved in ethyl acetate and washed with water, brine and dried over anhydrous sodium sulfate and evaporated under vacuum. The solid was directly used without further purification. The solution of (3-(2,4-dichlorophenylamino)propanoic acid (20 mg , 0.089 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10min. To this reaction mixture (1H-

benzo[d]imidazol-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford N-(1H-Benzoimidazol-2-ylmethyl)-3-(2,4-dichloro-phenylamino)-propionamide (**1763**). LC/MS: (ESI) (M+H)⁺= 364.3.

Scheme 16




Reagents and conditions (a) NaN₃, water; (b) ethyl but-3-ynoate, CuSO₄, sodium ascorbate; (c) EDC, DIPEA, DCM, (1H-benzo[d]imidazol-2-yl)methanamine; (d) AcOH, 60 °C, 4h.

General Procedure 7 (1752, 1753):


[0174] A solution of 2,4-dichlorobenzyl bromide (100mg) in acetone was treated with excess NaN₃ and refluxed for 5 hours. The reaction was concentrated by 20% and diluted with saturated sodium chloride solution. The reaction was then extracted with ether, washed with brine, dried (Na₂SO₄) and concentrated to give 1-(azidomethyl)-2,4-dichlorobenzene. To the solution of 3-butyric acid (0.4 mmol) in 2 ml MeOH and 2ml water was added 1-(azidomethyl)-2,4-dichlorobenzene (0.4 mmol), CuSO₄ (10 mol %), and sodium ascorbate (20 mol %). The resulting mixture was stirred at room temperature overnight. The mixture was extracted with ethyl acetate. The organic layers were washed once with brine, dried over Na₂SO₄, and evaporated under vacuum. The residue was purified by flash chromatography on silica gel with CH₂Cl₂/MeOH to give 2-(1-(2,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl)acetic acid. To a 10 mL DCM solution of 2-(1-(2,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl)acetic acid (50 mg, 0.175 mmol) were added N,N-diisopropylethylamine (3 equiv), EDC HCl (1.5 equiv), HOBT (1 equiv), 4-chlorobenzene-1,2-diamine (1 equiv). The reaction mixture was stirred at room temperature for 6 hr. The solution was diluted with 50ml DCM, washed with water, sat. ammonium chloride, sat. sodium bicarbonate and brine, dried over anhydrous Na₂SO₄, filtered and concentrated. To

the residue, 3 ml of acetic acid was added and this mixture was heated for 4 hrs at 60°C. After evaporation, the obtained mixture was purified by flash column chromatography (DCM/MeOH) to give 2-((1-(2,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-benzo[d]imidazole(**1752**). LC/MS: (ESI) (M + H)⁺ = 359.8.

**1753**

[0175] **1753** was synthesized using 3,5-dichlorobenzyl bromide in General Procedure 7. LC/MS: (ESI) (M + H)⁺ = 359.8.

Scheme 17




Reagents and conditions (a) DIPEA, DCM; (b) NaOH, Ethanol; (c) EDC, DIPEA, HOBT, 4-chlorobenzene-1,2-diamine; (d) AcOH, 60 °C, 4h.

[0176] To a solution of 3,5-dichlorobenzylamine (133 mg, 0.756 mmol) and DIPEA (0.756 mmol) in 10 ml of DCM was added ethyl malonyl chloride (0.756 mmol) in 3 ml of DCM at 0 °C with stirring. The reaction was performed at 0 °C for 2h. The solvent was removed and the residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give ethyl 2-(3,5-dichlorobenzylcarbamoyl)acetate. To a solution of ethyl 2-(3,5-dichlorobenzylcarbamoyl)acetate (30 mg, 0.103 mmol) in ethanol (2 mL) was added 1 N NaOH (1ml). The resultant mixture was microwave irradiated for 15min at 80 °C. After being cooled to room temperature, it was poured into ethyl acetate (50 mL), washed with 0.1 N HCl, water, brine dried over magnesium sulfate, and evaporated to dry to yield 2-(3,5-dichlorobenzylcarbamoyl)acetic acid. The solution of 2-(3,5-dichlorobenzylcarbamoyl)acetic acid (20 mg, 0.076 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and HOBT (1.0 equiv) in DCM (20 mL) was stirred for 10min. To this reaction mixture 4-chlorobenzene-1,2-diamine (1.0 equiv) was added. The reaction mixture was stirred at room

temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. To the residue, 3 ml of acetic acid was added and this mixture was heated for 4 hrs at 60°C. After evaporation, the obtained mixture was purified by flash column chromatography (DCM/MeOH) to give N-(3,5-dichlorobenzyl)-2-(6-chloro-1H-benzo[d]imidazol-2-yl)acetamide (1804). LC/MS: (ESI) (M + H)⁺ = 369.5.

Scheme 18



1968


Reagents and conditions: (a) EDC, pyridine, r.t. overnight; (b) Propionic acid, Microwave 160 °C, 1h; (c) LiOH, MeOH/H₂O, r.t. 2h; (d) (3,5-dichlorophenyl)methanamine, EDC, HOBt, DIPEA, DMF, r.t.

[0177] 6-chloropyridine-2,3-diamine (1 eq) and Boc-Asp(OMe) (1 eq) in pyridine (2 mL) was added EDC (1.5 eq). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave intermediate methyl 4-((3-amino-6-chloropyridin-2-yl)amino)-3-((tert-butoxycarbonyl)amino)-4-oxobutanoate.

[0178] Intermediate methyl 4-((3-amino-6-chloropyridin-2-yl)amino)-3-((tert-butoxycarbonyl)amino)-4-oxobutanoate was microwave irradiated in 3 mL propionic acid at 160 °C for 1 hours. The reaction was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave methyl 4-((3-amino-6-chloropyridin-2-yl) amino)-4-oxo-3-propionamidobutanoate.


[0179] The ethyl ester group of intermediate methyl 4-((3-amino-6-chloropyridin-2-yl)amino)-4-oxo-3-propionamidobutanoate was hydrolyzed using LiOH to get the free acid and used for the next step without purification.

[0180] 3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-3-propionamidopropanoic acid (1eq), DIPEA (3 eq), (3,5-dichlorophenyl)methanamine (2 eq) were dissolved in DMF, then EDC (1.5 eq) and HOBt (1.5 eq) were added, the resulting mixture was stirred at r.t. for 3h. The solvent was removed under vacuum and the residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding compound **1968**. LC/MS: (ESI) (M + H)⁺ = 455.5.

**1969**

[0181] **1969** 3-amino-3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)propanamide was synthesized using 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid in General Procedure with minor modifications. LC/MS: (ESI) (M + H)⁺ = 372.1.

Scheme 19

**1970**

Reagents and conditions: (a) CH₃CN, r.t.- reflux; (b) DIC, reflux, overnight; (c) LiOH, CH₃OH/H₂O, r.t., overnight; (d) (3,5-dichlorophenyl)methanamine, EDC, HOBt, DIPEA, DMF, r.t.

[0182] 6-chloropyridine-2,3-diamine (1 eq) was dissolved in CH₃CN, then ethyl 2-thiocyanatoacetate was added dropwise at r.t. After refluxed for 1h, the solvent was removed under vacuum and the residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding compound ethyl 2-(3-(2-amino-6-chloropyridin-3-yl)thioureido)acetate.


[0183] Ethyl 2-(3-(2-amino-6-chloropyridin-3-yl)thioureido)acetate in anhydrous acetonitrile, was added DIC (2eq). The solution was refluxed overnight. The solvent was removed under vacuum and residue was purified by flash column chromatography (DCM/MeOH), yielding compound ethyl 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetate.

[0184] LiOH·H₂O (3 eq) was added to the solution of ethyl 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was removed under vacuum and residue was purified by flash column chromatography (DCM/MeOH), yielding 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetic acid.

[0185] A solution of 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetic acid (1eq), (3,5-dichlorophenyl)methanamine (1eq), EDC (1.5 eq), HOBT (1.5 eq) and DIPEA (2eq) in DMF was stirred at room temperature overnight. The solvent was then removed under vacuum. The residue was dissolved in DCM. The organic layer was washed with brine, dried and concentrated under vacuum. Purification by chromatography afforded **1970**: 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)-N-(3,5-dichlorobenzyl)acetamide.

LC/MS: (ESI) (M + H)⁺ = 385.5.

Scheme 20




Reagents and conditions (a) PPh₃, DIAD, THF; (b) NaOH, methanol; (c) EDC, DIPEA, DMAP, C-(1H-benzoimidazol-2-yl)-methanamine; (d) TFA, DCM, 4h.

[0186] To a solution of N-trityl-L-serine methyl ester (110mg, 0.303 mmol), 2,4-dichlorophenol (49.4mg, 0.303 mmol), and triphenylphosphine (0.303 mmol) in anhydrous THF (5 mL) was added DIAD (0.303mmol) dropwise at room temperature. The solution was microwave irradiated at 90 °C for 1h. The crude product was purified with flash column chromatography to give (S)-methyl 3-(2,4-dichlorophenoxy)-2-(tritylamino)propanoate. To a solution of (S)-methyl 3-(2,4-dichlorophenoxy)-2-(tritylamino)propanoate (80 mg, 0.158 mmol) in ethanol (2 mL) was added and 1 N NaOH (1ml). The resultant mixture was microwave irradiated for 10 min at 80 °C. After being cooled to room temperature, it was poured into ethyl acetate (50 mL), washed with 0.1 N HCl, water, brine dried over

magnesium sulfate, and evaporated. The crude product was purified with flash column chromatography. The solution of (S)-3-(2,4-dichlorophenoxy)-2-(tritylamino)propanoic acid (60 mg, 0.12 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10 min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with aq NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was treated with TFA (1 mL) and DCM (3 mL) for 4 h. After the solvents were removed, the residue was dissolved in methanol and purified by preparative HPLC to give (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-3-(2,4-dichlorophenoxy)-2-aminopropanamide (**1807**). LC/MS: (ESI) (M + H)⁺ = 380.3.


Scheme 21



Reagents and conditions (a) EDC, DIPEA, DMAP, DCM


General Procedure 8 (**1851**, **1852**, **1873-1880**):

[0187] The solution of 2-(3,5-dichlorophenyl)acetic acid (30 mg, 0.146 mmol, 1.0 equiv), DIPEA (3 equiv), EDC HCl (1.5 equiv) and DMAP (1.0 equiv) in DCM (20 mL) was stirred for 10 min. To this reaction mixture (6-chloro-1H-benzo[d]imidazol-2-yl)methanamine was added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford N-((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)-2-(3,5-dichlorophenyl)acetamide (**1851**). LC/MS: (ESI) (M + H)⁺ = 369.5.




1852


[0188] **1852** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 369.5.

**1873**


[0189] **1873** was synthesized using 2-(3,5-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 414.1.

**1874**


[0190] **1874** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 414.1.

**1875**


[0191] **1875** was synthesized using 2-(3,5-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 370.5.

**1876**


[0192] **1876** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 370.5.

**1877**


[0193] **1877** was synthesized using 2-(3,5-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M + H)⁺ = 370.5.

**1878**

[0194] **1878** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M+H)⁺ = 370.5.


**1879**

[0195] **1879** was synthesized using 2-(3,5-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M+H)⁺ = 370.5.

**1880**

[0196] **1880** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 8. LC/MS: (ESI) (M+H)⁺ = 370.5.

Scheme 22



Reagents and conditions: (a) EDC, pyridine, r.t. overnight; (b) 4a: AcOH, 60 °C, 3h; (c) TFA, DCM, r.t., overnight; (d) 6a: EDC, HOBT, DIPEA, THF, r.t. 3h; 6b: NaBH₃CN, AcOH, CH₃OH, r.t., overnight.

General Procedure 9:

[0197] (a) Benzene-1,2-diamine (0.5 mM) and 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (0.5 mM) in pyridine (2 mL) was added EDC (144 mg, 0.75 mM). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure.


After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with EA. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave intermediate tert-butyl 3-((2-aminophenyl)carbamoyl)piperidine-1-carboxylate.

[0198] (b) tert-butyl 3-((2-aminophenyl)carbamoyl)piperidine-1-carboxylate was heated in 5 mL glacial acetic acid at 60 °C for 3 hours. The reaction was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave intermediate tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate.


[0199] (c) tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate was dissolved in DCM, the solution was cooled to 0 °C, then TFA (5 eq) was added dropwise. The mixture was stirred at r.t. overnight, the solvent was removed in vacuum. HCl in Methanol was added to the residue, and the solvent was removed to give intermediate 2-(piperidin-3-yl)-1H-benzo[d]imidazole as HCl salt.

[0200] (d) a: Intermediate 2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.2 mM) and substituted phenylacetic acid (0.2 mM) were dissolved in THF, EDC (mM), HOBt (mM) and DIPEA (0.24 mM) were added to the reaction solution. The mixture was stirred at r.t. for 3 hours. The solvent was removed under reduced pressure and the residue was extracted with DCM. The organic layer was dried over sodium sulfate, concentrated in vacuum, and the residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compound a.


[0201] b: Intermediate 2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.2 mM) and substituted benzaldehyde (0.2 mM) were dissolved in CH₃OH, AcOH (0.3 mM) and NaBH₃CN (0.4 mM) were added. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by DCM. The organic was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compound b.

**1731**


1731: 1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(2,4-dichlorophenyl) ethanone was synthesized using 2,4-dichlorophenyl)acetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and benzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 389.1$

**1732**


1732: 1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone was synthesized using 3,5-dichlorophenyl)acetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and benzene-1,2-diamine following the general procedure 9. ^1H NMR (500 MHz, MeOD) δ 7.85 – 7.71 (m, 2H), 7.67-7.54 (m, 2H), 7.34-7.28 (m, 1H), 7.27-7.21 (m, 2H), 4.74 (d, $J = 12.0$ Hz, 0.81H), 4.55 (dd, $J = 35.4, 12.3$ Hz, 0.53H), 4.03 (d, $J = 13.7$ Hz, 0.72H), 3.96 – 3.78 (m, 1.98H), 3.53 (dd, $J = 24.9, 12.4$ Hz, 0.54H), 3.39 (dt, $J = 10.2, 6.8$ Hz, 2.29H), 2.86 (t, $J = 11.6$ Hz, 0.23H), 2.39 (d, $J = 9.4$ Hz, 0.97H), 2.12 (dt, $J = 13.7, 7.0$ Hz, 0.72H), 2.01 (dd, $J = 40.9, 12.5$ Hz, 0.52H), 1.88 (d, $J = 13.6$ Hz, 0.72H), 1.76 – 1.58 (m, 0.98H). MS (ESI) $(M+H)^+ = 389.1$

**1733**


1733: 1-(3-(4-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone was synthesized using 3,5-dichlorophenyl)acetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 3-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 423.6$

**1734**


[0202] **1734:** **1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone** was synthesized using 3,5-dichlorophenyl)acetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. ^1H NMR (500 MHz, CDCl_3) δ 7.52 (s, 1H), 7.44 (d, $J = 7.3$ Hz, 1H), 7.19-7.11 (m, 2H), 7.00 (s, 2H), 4.35 (d, $J = 11.2$ Hz, 1H), 3.77-3.70 (m, 1H), 3.68 (d, $J = 6.9$ Hz, 2H), 3.65 – 3.56 (m, 1H), 3.44 (t, $J = 11.2$ Hz, 1H), 3.27 (s, 1H), 2.65-2.54 (m, 1H), 2.12 (dd, $J = 16.0, 7.0$ Hz, 1H), 1.62-1.49 (m, 1H), 1.44 – 1.34 (m, 1H). MS (ESI) $(\text{M}+\text{H})^+ = 423.6$

**1757**


[0203] **1757:** **(R)-1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone** was synthesized using 3,5-dichlorophenyl)acetic acid, (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(\text{M}+\text{H})^+ = 423.6$

**1758**


[0204] **1758:** **(S)-1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone** was synthesized using 3,5-dichlorophenyl)acetic acid, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(\text{M}+\text{H})^+ = 423.5$

**1744**

[0205] 1744: 2-(3,5-dichlorophenyl)-1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethanone was synthesized using 3,5-dichlorophenylacetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-fluorobenzene-1,2-diamine following the general procedure 9. MS (ESI) (M+H)⁺ = 407.8


**1745**

[0206] 1745: 1-(3-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone was synthesized using 3,5-dichlorophenylacetic acid, 1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4,5-dichlorobenzene-1,2-diamine following the general procedure 9. ¹H NMR (500 MHz, CDCl₃) δ 8.02 (s, 0.29H), 7.66 (s, 2.00H), 7.16 (s, 0.79H), 7.01 (s, 1.87H), 4.36 (dd, J = 13.3, 3.8 Hz, 1H), 3.76-3.70 (m, 1H), 3.70-3.67 (m, 1H), 3.64 (d, J = 13.6 Hz, 1H), 3.46 (t, J = 10.2 Hz, 1H), 3.38-3.27 (m, 1H), 2.64 (dd, J = 13.4, 4.7 Hz, 1H), 2.15 (dd, J = 13.5, 9.9 Hz, 1H), 1.66-1.54 (m, 1H), 1.43-1.31 (m, 1H). MS (ESI) (M+H)⁺ = 457.4

**1746**


[0207] 1746: 1-(3-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone was synthesized using 3,5-dichlorophenylacetic acid, 1-(tert-

butoxycarbonyl)piperidine-3-carboxylic acid and 4-chloro-5-fluorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 441.6$




1787

[0208] 1787: 2-amino-1-((S)-3-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone was synthesized using 2-((tert-butoxycarbonyl)amino)-2-(3,5-dichlorophenyl)acetic acid, (S)-methyl piperidine-3-carboxy(S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid late and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 439.8$; HPLC analysis: 97.2% purity




1799

[0209] 1799: (S)-2-amino-1-((S)-3-(5-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(2,4-dichlorophenyl)propan-1-one was synthesized using (S)-2-((tert-butoxycarbonyl)amino)-3-(2,4-dichlorophenyl)propanoic acid, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 453.8$; HPLC analysis: 100% purity




1813


[0210] 1813: (S)-5-chloro-2-(1-(3,5-dichlorobenzyl)piperidin-3-yl)-1H-benzo[d]imidazole was synthesized using 3,5-dichlorobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 395.5$; HPLC analysis: 94.3% purity

**1837**


[0211] 1837: (S)-5-chloro-2-(1-(2,4-dichlorobenzyl)piperidin-3-yl)-1H-benzo[d]imidazole was synthesized using 2,4-dichlorobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 395.6$; HPLC analysis: 99.0% purity

**1838**


[0212] 1838: (R)-5-chloro-2-(1-(3,5-dichlorobenzyl)piperidin-3-yl)-1H-benzo[d]imidazole was synthesized using 3,5-dichlorobenzaldehyde, (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 4-chlorobenzene-1,2-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 395.6$; HPLC analysis: 100% purity.

**1868**


[0213] 1868: (S)-5-chloro-2-(1-(3,5-dichlorobenzyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 3,5-dichlorobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 6-chloropyridine-2,3-diamine following the general procedure 9. MS (ESI) $(M+H)^+ = 396.5$; HPLC analysis: 95.4% purity

**1869**


[0214] **1869:** (S)-5-chloro-2-(1-(2,4-dichlorobenzyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 2,4-dichlorobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 6-chloropyridine-2,3-diamine following the general procedure 9. MS (ESI) (M+H)⁺ = 396.5; HPLC analysis: 98.8% purity

**1870**

[0215] **1870:** (S)-5-chloro-2-(1-(3,4-dichlorobenzyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 3,4-dichlorobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 6-chloropyridine-2,3-diamine following the general procedure 9. MS (ESI) (M+H)⁺ = 396.5; HPLC analysis: 100% purity


**1871**

[0216] **1871:** (S)-5-chloro-2-(1-(3,4-dibromobenzyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 3,4-dibromobenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 6-chloropyridine-2,3-diamine following the general procedure 9. MS (ESI) (M+H)⁺ = 485.3; HPLC analysis: 93.7% purity



[0217] **1872:** (S)-5-chloro-2-(1-(3,5-dimethoxybenzyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 3,5-dimethoxybenzaldehyde, (S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid and 6-chloropyridine-2,3-diamine following the general procedure 9. MS (ESI) (M+H)⁺ = 387.7; HPLC analysis: 100% purity

Scheme 23



Reagents and conditions: (a) triphosgen, DIPEA, DCM, 0 °C (b) EDC, HOBT, DIPEA, DMF, r.t. 3h; (c) LiOH, CH₃OH/H₂O, r.t. overnight; (d) BH₃, THF, 0 °C-r.t., overnight (e) 6-fluoropyridine-2,3-diamine, EDC, pyridine, r.t. overnight; (f) AcOH, POCl₃, Microwave 150 °C, 1h.

General Procedure 10:

[0218] (a) To a stirred solution of methyl piperidine-3-carboxylate (72 mg, 0.5 mmol) in DCM (10 mL) was added DIPEA (2 eq) and cooled to 0 °C. A solution of triphosgene (59 mg, 0.2 mmol) in DCM (2 mL) was added dropwise to the reaction mixture and stirred at room temperature for 2 h. The solution was cooled to 0 °C and 3,5-dichloroaniline (81 mg, 0.5 mmol) in DCM (2 mL) was added. The reaction mixture was stirred at 0 °C for 30min. The solution was washed with brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give methyl 1-((3,5-dichlorophenyl)carbamoyl)piperidine-3-carboxylate.

[0219] (b): 2-(3,5-dichlorophenyl)acetic acid (1 mM) and methyl piperidine-3-carboxylate (1 mM) were dissolved in DMF, EDC (1.2 mM), HOBT (1.2 mM) and DIPEA (1.5 mM) were added to the mixture. The reaction mixture was stirred at r.t. for 3 hours. The

solvent was removed under reduced pressure and the residue was extracted with DCM. The organic layer was dried over sodium sulfate, concentrated in vacuum, and the residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give intermediate methyl 1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxylate.


[0220] (c) LiOH·H₂O (3 eq) was added to the solution of methyl 1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxylate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was extracted with EA/1N HCl solution. The organic layer was dried over sodium sulfate, concentrated in vacuum to give 1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxylic acid without further purification.

[0221] (d) Methyl 1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxylate in anhydrous THF was added BH₃ (5 eq) in THF at 0 °C. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure, saturated NaHCO₃ was added and extracted with DCM. The organic layer was dried over sodium sulfate, concentrated in vacuum, and the residue was purified through flash chromatography on silica gel to give methyl 1-(3,5-dichlorophenethyl)piperidine-3-carboxylate.


[0222] (e) 1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxylic acid (0.2 mM) and 6-fluoropyridine-2,3-diamine (0.2 mM) in pyridine (2 mL) was added EDC (0.3 mM). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with EA. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave N-(2-amino-6-fluoropyridin-3-yl)-1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxamide.

[0223] (f) N-(2-amino-6-fluoropyridin-3-yl)-1-(2-(3,5-dichlorophenyl)acetyl)piperidine-3-carboxamide was dissolved in 3 mL glacial acetic acid, POCl₃ (3 eq) was added, the mixture was microwave irradiated at 150 °C for 1 hour. The reaction was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compound 1761: 2-(3,5-dichlorophenyl)-1-(3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)ethanone MS (ESI) (M+H)⁺= 408.6


[0224]

**1762**


[0225] **1762:** 1-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone was synthesized using 3,5-dichlorophenyl)acetic acid, methyl piperidine-3-carboxylate and 6-chloropyridine-2,3-diamine following the general procedure 10. MS (ESI) (M+H)⁺= 424.5

**1786**


[0226] **1786:** N-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-2-(3,5-dichlorophenyl)acetamide was synthesized using 3,5-dichlorophenyl)acetic acid, methyl 3-aminocyclohexanecarboxylate and 6-fluoropyridine-2,3-diamine following the general procedure 10. MS (ESI) (M+H)⁺= 438.8; HPLC analysis: 91.0% purity

**1790**


[0227] **1790:** 1-(2-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)morpholino)-2-(3,5-dichlorophenyl)ethanone was synthesized using 3,5-dichlorophenyl)acetic acid, methyl morpholine-2-carboxylate and 6-chloropyridine-2,3-diamine following the general procedure 10. MS (ESI) (M+H)⁺= 427.4

**1791**


[0228] 1791: N-(2-amino-6-chloropyridin-3-yl)-4-(2-(3,5-dichlorophenyl)acetyl)piperazine-2-carboxamide was synthesized using 3,5-dichlorophenyl)acetic acid, 1-tert-butyl 2-methyl piperazine-1,2-dicarboxylate and 6-chloropyridine-2,3-diamine following the general procedure 10 with minor modifications. MS (ESI) (M+H)⁺ = 443.4

**1759**

[0229] 1759: 3-(5-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorophenyl)piperidine-1-carboxamide was synthesized following the general procedure 10. MS (ESI) (M+H)⁺ = 424.8


**1785**

[0230] 1785: 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidine-1-carboxamide was synthesized using (3,5-dichlorophenyl)methanamine and 6-chloropyridine-2,3-diamine following the general procedure 10. MS (ESI) (M+H)⁺ = 435.6

**1812**


[0231] **1812: 5-chloro-2-(1-(3,5-dichlorophenethyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine** was synthesized using (3,5-dichlorophenyl)methanamine and 6-chloropyridine-2,3-diamine following the general procedure 10. ^1H NMR (500 MHz, MeOD) δ 8.08 (d, J = 8.3 Hz, 0.65H), 8.00 (d, J = 8.2 Hz, 0.34H), 7.47 (d, J = 8.3 Hz, 0.62H), 7.44-7.35 (m, 3.38H), 4.21 (d, J = 11.7 Hz, 0.33H), 4.10 (d, J = 11.4 Hz, 0.60H), 3.86 – 3.71 (m, 1.64H), 3.61 (d, J = 10.9 Hz, 0.42H), 3.56-3.47 (m, 2.29H), 3.43 (dd, J = 20.3, 12.7 Hz, 0.98H), 3.26 – 3.14 (m, 2.60H), 2.42 (d, J = 11.4 Hz, 0.61H), 2.29-2.18 (m, 1.30H), 2.13 (dd, J = 26.5, 14.8 Hz, 1H), 2.04 – 1.90 (m, 1.00H), 1.89-1.75 (m, 0.35H). MS (ESI) $(\text{M}+\text{H})^+ = 410.5$

[0232]

**1798**

[0233] **1798: 5-fluoro-2-(1-(3,5-dichlorophenethyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine** was synthesized using (3,5-dichlorophenyl)methanamine and 6-fluoropyridine-2,3-diamine following the general procedure 10. MS (ESI) $(\text{M}+\text{H})^+ = 394.3$

Scheme 24



Reagents and conditions: (a) NaBH_3CN , AcOH, CH_3OH , r.t., overnight; (b) $(\text{Boc})_2\text{O}$, DIPEA, DCM, r.t., 3h; (c) LiOH, $\text{CH}_3\text{OH}/\text{H}_2\text{O}$, r.t. overnight; (d) 6-chloropyridine-2,3-

diamine, EDC, pyridine, r.t. overnight; (e) (I) AcOH, 60 °C, 3h, (II) AcOH, POCl₃, Microwave 150 °C, 1h; (f) TFA, DCM, r.t., overnight, following condition (e) (I); (g) Ac₂O, DIPEA, DCM, r.t. 2h, following conditions (e) (I) and f; (f) TFA, DCM, r.t. overnight; (g) Ac₂O, DIPEA, DCM, r.t. 3h.

General Procedure 11:

[0234] (a) 3,5-dichlorobenzaldehyde (0.2 mM) and methyl 3-aminocyclohexanecarboxylate (0.2 mM) were dissolved in CH₃OH, AcOH (0.3 mM) and NaBH₃CN (0.4 mM) were added. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give methyl 3-((3,5-dichlorobenzyl)amino)cyclohexanecarboxylate which was used for next step without further purification.

[0235] (b) methyl 3-((3,5-dichlorobenzyl)amino)cyclohexanecarboxylate was dissolved in DCM, DIPEA (1.5 eq) was added to the solution. (Boc)₂O was then added in portions at 0 °C, and the mixture stirred at r.t. for 3 hours. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with EA-hexane to give methyl 3-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)cyclohexanecarboxylate.

[0236] (c) LiOH·H₂O (3 eq) was added to the solution of methyl 3-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)cyclohexanecarboxylate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was extracted with EA/1N HCl solution. The organic layer was dried over sodium sulfate, concentrated in vacuum to give 3-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)cyclohexanecarboxylic acid which was used for the next step without further purification.

[0237] (d) 3-((tert-butoxycarbonyl)(3,5-dichlorobenzyl)amino)cyclohexanecarboxylic acid (0.2 mM) and 6-chloropyridine-2,3-diamine (0.2 mM) in pyridine (2 mL) was added EDC (0.3 mM). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with EA. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on

silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave tert-butyl (3-((2-amino-6-chloropyridin-3-yl)carbamoyl)cyclohexyl)(3,5-dichlorobenzyl)carbamate.

[0238] (e I) tert-butyl (3-((2-amino-6-chloropyridin-3-yl)carbamoyl)cyclohexyl)(3,5-dichlorobenzyl)carbamate was heated in 5 mL glacial acetic acid at 60 °C for 3 hours. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave tert-butyl (3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)(3,5-dichlorobenzyl)carbamate.


[0239]

[0240] (e II) tert-butyl (3-((2-amino-6-chloropyridin-3-yl)carbamoyl)cyclohexyl)(3,5-dichlorobenzyl)carbamate was dissolved in 3 mL glacial acetic acid, POCl₃ (3 eq) was added, the mixture was microwave irradiated at 150 °C for 1 hour. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compounds **1788** 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine. ¹H NMR (500 MHz, MeOD) δ 8.21 (t, *J* = 8.6 Hz, 1H), 7.67-7.60 (m, 3H), 7.60-7.54 (m, 1H), 4.34 (s, 2H), 3.59-3.52 (m, 1H), 3.51-3.41 (m, 1H), 2.83-2.73 (m, 1H), 2.35 (d, *J* = 10.5 Hz, 1H), 2.27 (d, *J* = 11.7 Hz, 1H), 2.16 (d, *J* = 11.5 Hz, 1H), 2.07 – 1.93 (m, 1H), 1.71 (m, 3H). MS (ESI) (M+H)⁺ = 410.5; HPLC analysis: 88.2% purity; and **1789** N-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide. MS (ESI) (M+H)⁺ = 452.5; HPLC analysis: 98.0% purity.


[0241] (f) tert-butyl (3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)(3,5-dichlorobenzyl)carbamate was dissolved in DCM, the solution was cooled to 0 °C, then TFA (5 eq) was added dropwise. The mixture was stirred at r.t. overnight, the solvent was removed in vacuum. The residue was partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compound **1788** 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine.

[0242] (g) **1788** 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine was dissolved in DCM, DIPEA (1.5 eq) and Ac₂O (1.5 eq)


were added, the mixture was stirred at r.t. for 3 hours. H₂O was added and extracted with DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give target compound **1789** N-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide.




[0243] **1800:** N-(3,5-dichlorobenzyl)-3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 6-fluoropyridine-2,3-diamine following the general procedure 11. MS (ESI) (M+H)⁺ = 394.1; HPLC analysis: 95.5% purity




[0244] **1801:** N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)acetamide was obtained during the synthesis of ChemID:1800. MS (ESI) (M+H)⁺ = 436.2; HPLC analysis: 91.5% purity




[0245] **1809:** 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(2,4-dichlorobenzyl)cyclohexanamine was synthesized using 2,4-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 6-chloropyridine-2,3-diamine following the general procedure 11. MS (ESI) (M+H)⁺ = 411.3; HPLC analysis: 91.2% purity




[0246] 1810: N-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(2,4-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1809. MS (ESI) $(M+H)^+ = 452.7$; HPLC analysis: 95.0% purity




[0247] 1815: 3-(1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and benzene-1,2-diamine following the general procedure 11. MS (ESI) $(M+H)^+ = 374.9$; HPLC analysis: 96.1% purity




[0248] 1816: N-(3-(1H-benzo[d]imidazol-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1815. MS (ESI) $(M+H)^+ = 417.0$; HPLC analysis: 100% purity




[0249] 1817: N-(3,5-dichlorobenzyl)-3-(1H-imidazo[4,5-b]pyridin-2-yl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and pyridine-2,3-diamine following the general procedure 11. MS (ESI) $(M+H)^+ = 376.1$; HPLC analysis: 100% purity




[0250] 1818: N-(3-(1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1817. MS (ESI) $(M+H)^+ = 418.4$; HPLC analysis: 98.2% purity




[0251] 1836: N-(2,4-dichlorobenzyl)-N-(3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)acetamide was synthesized using 2,4-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 6-fluoropyridine-2,3-diamine following the general procedure. MS (ESI) $(M+H)^+ = 436.3$; HPLC analysis: 96.5% purity




[0252] 1839: N-(3,5-dichlorobenzyl)-3-(5-fluoro-1H-benzo[d]imidazol-2-yl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 4-fluorobenzene-1,2-diamine following the general procedure 11. MS (ESI) $(M+H)^+ = 392.9$; HPLC analysis: 100% purity




[0253] 1860: N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)cyclohexyl)acetamide was obtained during the synthesis of ChemID:1839. MS (ESI) $(M+H)^+ = 435.1$




[0254] 1932: N-(3,5-dichlorobenzyl)-N-((1R,3S)-3-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)acetamide was synthesized using 3,5-dichlorobenzaldehyde, (1S,3R)-methyl 3-aminocyclohexanecarboxylate and 4-fluorobenzene-1,2-diamine following the general procedure 11. MS (ESI) $(M+H)^+ = 436.0$




[0255] 1840: 3-(5-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 4-chlorobenzene-1,2-diamine following the general procedure 11. ^1H NMR (500 MHz, CDCl_3) δ 7.50-7.43 (br, 1H), 7.38 (d, $J = 6.3$ Hz, 1H), 7.42-7.35 (m, 3H), 7.16 (dd, $J = 8.5, 1.7$ Hz, 1H), 3.85 (s, 2H), 3.10 (s, 1H), 2.85 (s, 1H), 2.33 (d, $J = 12.4$ Hz, 2H), 2.01 (s, 2H), 2.00-1.90 (m, 1H), 1.87-1.78 (m, 1H), 1.74 (dd, $J = 21.6, 9.0$ Hz, 1H), 1.63 (dd, $J = 21.6, 9.0$ Hz, 1H), 1.51-1.37 (m, 2H). MS (ESI) $(M+H)^+ = 409.5$




[0256] 1861: N-(3-(5-chloro-1H-benzo[d]imidazol-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1839. MS (ESI) $(M+H)^+ = 452.9$




[0257] 1841: 3-(6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, methyl 3-aminocyclohexanecarboxylate and 5-chloropyridine-2,3-diamine following the general procedure 11. MS (ESI) $(M+H)^+ = 410.4$; HPLC analysis: 85.0% purity.



[0258] 1842: N-(3-(6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1841. MS (ESI) $(M+H)^+ = 452.6$; HPLC analysis: 100% purity.




[0259] 1854: (1R,3S)-3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine was synthesized using 3,5-dichlorobenzaldehyde, (1S,3R)-methyl 3-aminocyclohexanecarboxylate and 6-chloropyridine-2,3-diamine following the general procedure 11. ^1H NMR (500 MHz, CDCl_3) δ 8.05-7.88 (br, 1H), 7.26 (s, 1H), 7.25-7.23 (m, 2H), 7.22 (s, 1H), 3.83 (dd, $J = 33.3, 13.8$ Hz, 2H), 3.20 (t, $J = 10.4$, 1H), 2.74 (t, $J = 10.4$, 1H), 2.42 (d, $J = 12.5$ Hz, 1H), 2.18-2.10 (m, 1H), 2.09-1.97 (m, 1H), 1.96-1.87 (m, 1H), 1.74 – 1.62 (m, 2H), 1.49 (td, $J = 12.0, 3.4$ Hz, 1H), 1.27 (dd, $J = 16.4, 9.3$ Hz, 1H). MS (ESI) $(M+H)^+ = 410.5$; HPLC analysis: 100% purity.



[0260] 1859: N-((1R,3S)-3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)cyclohexyl)-N-(3,5-dichlorobenzyl)acetamide was obtained during the synthesis of ChemID:1854. MS (ESI) (M+H)⁺ = 453.2; HPLC analysis: 95.3% purity.

Scheme 25



Reagents and conditions: (a) CS₂, EtOH/Pyridine, 40 °C, overnight; (b) Br₂, HBr, AcOH, r.t. overnight; (c) Pyridine, 100 °C, 30 min; (d) TFA, DCM, r.t., overnight; (e) 3,5-dichlorobenzaldehyde, DIPEA, NaBH₃CN, AcOH, CH₃OH, r.t., overnight.

General Procedure 12:

[0261] (a) To a solution of 6-chloropyridine-2,3-diamine (144 mg, 1 mM) in a mixture of EtOH (5 mL) and pyridine (2 mL) was added carbon disulfide (0.5 mL) at r.t.. The mixture was stirred at 40 °C overnight. The mixture was cooled to r.t., the resulting solid was filtered and washed with ether to give light yellow solid 5-chloro-1H-imidazo[4,5-b]pyridine-2(3H)-thione.


[0262] (b) 5-chloro-1H-imidazo[4,5-b]pyridine-2(3H)-thione (92.5 mg, 0.5 mM) was dissolved in acetic acid (2 mL), 48% HBr (aq) (0.084 mL) was added and the mixture cooled under ice. Br₂ (0.1 mL) was added to the mixture under vigorous shaking. The mixture was vigorously stirred at r.t. over night. H₂O (2 mL) was added, and the resulting solution was cooled in an ice bath. The pH was adjusted to 4 with solid NaOH, and the precipitate was collected by filtration and washed by ether to get 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine.

[0263] (c) 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine (60 mg, 0.258 mM) was dissolved in pyridine (2 mL), tert-butyl azetidin-3-ylcarbamate (155 mg, 0.77 mM) was

added and the reaction mixture was microwave irradiated at 100 °C for 30 min. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give tert-butyl (1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)azetidin-3-yl)carbamate.


[0264] (d) tert-butyl (1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)azetidin-3-yl)carbamate was dissolved in DCM, the solution was cooled to 0 °C, then TFA (5 eq) was added dropwise. The mixture was stirred at r.t. overnight, the solvent was removed in vacuum. HCl in Methanol was added to the residue, and the solvent was removed to give 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)azetidin-3-amine as HCl salt.

[0265] (e) 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)azetidin-3-amine was dissolved in CH₃OH, DIPEA (1.2 eq) was added and the solution stirred at r.t. for 10 min. Substituted benzaldehyde 8 (1.2 eq) was added, following by adding AcOH (2 eq) and NaBH₃CN (2eq). The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by DCM. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give **1864**. ¹H NMR (500 MHz, CDCl₃) δ 7.80-7.43 (br, 1H), 7.35 – 7.21 (m, 3H), 7.13-6.76 (br, 1H), 4.37-3.97 (m, 2H), 3.81 (s, 2H), 3.29-3.06 (br, 2H), 2.78 (s, 1H), 2.00-1.92 (br, 2H), 1.53-1.40 (br, 2H). MS (ESI) (M+H)⁺ = 383.6; HPLC analysis: 100% purity.


**1865**

[0266] **1865** was synthesized using 3,5-dichlorobenzaldehyde, tert-butyl azetidin-3-ylcarbamate and 2,6-dibromo-5-chloro-1H-imidazo[4,5-b]pyridine following the general procedures 12. LC/MS: (ESI) (M + H)⁺ = 462.4.

[0267]

**1845**


[0268] 1845 was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl (S)-pyrrolidin-3-ylcarbamate following the general Procedure 12. LC/MS: (ESI) (M + H)⁺ = 397.7.



1846


[0269] 1846 was synthesized using 2,4-dichlorobenzaldehyde following the general Procedure 12.

[0270] LC/MS: (ESI) (M + H)⁺ = 397.7.




1847

[0271] 1847 was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl (R)-pyrrolidin-3-ylcarbamate following the general Procedure 12. LC/MS: (ESI) (M + H)⁺ = 397.7.



1848


[0272] 1848 was synthesized using 2,4-dichlorobenzaldehyde and tert-butyl (R)-pyrrolidin-3-ylcarbamate following the general Procedure 12. LC/MS: (ESI) (M + H)⁺ = 397.7.



1811


[0273] 1811: 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine was synthesized using 3,5-dichlorobenzaldehyde and

tert-butyl piperidin-3-ylcarbamate following the general procedure 12. ^1H NMR (500 MHz, CDCl_3) δ 7.65-7.37 (br, 1H), 7.19 (s, 1H), 7.12 (s, 2H), 7.08-6.84 (br, 1H), 4.20-3.95 (br, 1H), 3.91-3.77 (br, 1H), 3.71 (s, 2H), 3.34-2.87 (m, 1H), 2.77 (s, 1H), 2.02-1.91 (m, 1H), 1.90-1.77 (m, 1H), 1.68-1.50 (m, 1H), 1.50-1.33 (m, 2H). MS (ESI) $(\text{M}+\text{H})^+ = 411.7$; HPLC analysis: 99.6% purity.




1857

[0274] 1857: 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(2,4-dichlorobenzyl)piperidin-3-amine was synthesized using 2,4-dichlorobenzaldehyde and tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(\text{M}+\text{H})^+ = 411.6$; HPLC analysis: 96.7% purity.



1855


[0275] 1855: (R)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine was synthesized using 3,5-dichlorobenzaldehyde and (R)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS(ESI) $(\text{M}+\text{H})^+ = 412.0$; HPLC analysis: 100% purity




1856

[0276] 1856: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine was synthesized using 3,5-dichlorobenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. ^1H NMR (500


MHz, CDCl₃) δ 7.64-7.43 (br, 1H), 7.22-7.18 (m, 1H), 7.18-7.11 (m, 1H), 7.08-6.91 (br, 1H), 4.19 – 3.95 (br, 1H), 3.93-3.77 (br, 1H), 3.75 (s, 2H), 3.33-2.97 (m, 2H), 2.85-2.71 (br, 1H), 2.03-1.92 (m, 1H), 1.91-1.79 (m, 1H), 1.69-1.55 (m, 1H), 1.55-1.40 (m, 1H). MS (ESI) (M+H)⁺ = 411.4; HPLC analysis: 95.6% purity.




[0277] 1912: (S)-N-(3-bromo-5-chlorobenzyl)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 3-bromo-5-chlorobenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺ = 455.9




[0278] 1992: (S)-3-chloro-5-(((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)amino)methyl)benzonitrile was synthesized using 3-chloro-5-formylbenzonitrile and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺ = 402.2




[0279] 1940: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-(ethylamino)benzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-(ethylamino)benzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺ = 454.6




[0280] 1921: (S)-N-(3-bromo-5-chloro-2-ethoxybenzyl)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 3,5-dichloro-2-hydroxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=427.6




[0281] 1937: (S)-N-(3-bromo-5-chloro-2-ethoxybenzyl)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 3-bromo-5-chloro-2-ethoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=500.2




[0282] 1911: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-methoxybenzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-methoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=441.8




[0283] 1920: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-ethoxybenzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-ethoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 455.7$




[0284] 1927: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-propoxybenzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-propoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 469.8$




[0285] 1928: (S)-N-(2-(allyloxy)-3,5-dichlorobenzyl)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 2-(allyloxy)-3,5-dichlorobenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 467.7$




[0286] 1929: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-(cyclopropylmethoxy)benzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-(cyclopropylmethoxy)benzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=481.7




[0287] 1930: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-cyclopropoxybenzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-cyclopropoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=467.7




[0288] 1931: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichloro-2-isopropoxybenzyl)piperidin-3-amine was synthesized using 3,5-dichloro-2-isopropoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺=469.4




[0289] 1902: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(2,3,5-trichlorobenzyl)piperidin-3-amine was synthesized using 2,3,5-trichloro-2-benzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 445.8$



[0290] 1905: (S)-1-(6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(2,3,5-trichlorobenzyl)piperidin-3-amine was synthesized using 2,3,5-trichlorobenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate and 2,6-dibromo-5-chloro-1H-imidazo[4,5-b]pyridine following the general procedure 12. MS (ESI) $(M+H)^+ = 525.7$




[0291] 1908: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dibromobenzyl)piperidin-3-amine was synthesized using 3,5-dibromo-benzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 500.6$




1909

[0292] 1909: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dibromo-2-methoxybenzyl)piperidin-3-amine was synthesized using 3,5-dibromo-2-methoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 530.3$




1910

[0293] 1910: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dibromo-2-ethoxybenzyl)piperidin-3-amine was synthesized using 3,5-dibromo-2-ethoxybenzaldehyde and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 544.4$




1886


[0294] 1886: N-(3,5-dichlorobenzyl)-1-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) $(M+H)^+ = 395.0$; HPLC analysis: 96.7% purity.




[0295] **1900:** (S)-N-(3,5-dichlorobenzyl)-1-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-amine was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl piperidin-3-ylcarbamate and 2-bromo-5-fluoro-1H-imidazo[4,5-b]pyridine following the general procedure 12. MS (ESI) (M+H)⁺ = 395.0; HPLC analysis: 96.7% purity.



[0296] **1899:** 6,8-dichloro-N-((S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)-1,2,3,4-tetrahydroquinolin-4-amine. In the case of compound 1899, intermediate 21 (1eq) reacted with 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one (1eq) in EtOH under MW condition at 100 °C for 1h to get the target compound 1899. MS (ESI) (M+H)⁺ = 452.7




[0297] **1903** 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azepan-3-amine was synthesized using 3,5-dichlorobenzoic acid and tert-butyl azepan-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺ = 425.9




1889

[0298] 1889: (S)-3,5-dichloro-N-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzamide was synthesized using 3,5-dichlorobenzoic acid and (S)-tert-butyl piperidin-3-ylcarbamate following the general procedure 12. MS (ESI) (M+H)⁺= 425.5; HPLC analysis: 95.3% purity.



1915


[0299] 1915 1-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)azetidin-2-yl)-N-(3,5-dichlorobenzyl)methanamine was synthesized using 3,5-dichlorobenzoic acid and tert-butyl (azetidin-2-ylmethyl)carbamate following the general procedure 12. MS (ESI) (M+H)⁺= 397.5



1916

[0300] 1916 1-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)-N-(3,5-dichlorobenzyl)methanamine was synthesized using 3,5-dichlorobenzoic acid and tert-butyl (pyrrolidin-2-ylmethyl)carbamate following the general procedure 12. MS (ESI) (M+H)⁺= 411.9

Scheme 26




Reagents and conditions: (a) $\text{Ti}(\text{OEt})_4$, NaBH_3CN , DCE, MW, 100 °C, 30 min; (b) AcCl , K_2CO_3 , CH_3CN , 60 °C, 3h; (c) TFA, DCM, r.t., overnight; (d) NaBH_3CN , $\text{CH}_3\text{OH}/\text{AcOH}$, r.t., 3h.

[0301] 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one (1eq) and tert-butyl 3-aminopiperidine-1-carboxylate (1.5 eq) were dissolved in DCE, $\text{Ti}(\text{OEt})_4$ (3 eq) and NaBH_3CN (2 eq) were added, the mixture was then microwave irradiated at 100 °C for 30min. Saturated NaHCO_3 was added, extracted with DCM, washed with brine, concentrated under vacuum and purified via flash column chromatography to yield intermediate N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-((S)-piperidin-3-yl)acetamide.

[0302] N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-((S)-piperidin-3-yl)acetamide was dissolved in CH_3CN , K_2CO_3 (6 ea) and AcCl (6eq) were added. The mixture was stirred at 60 °C for 3 h. The solvent was evaporated off, extracted with DCM, washed with brine, concentrated under vacuum and purified via flash column chromatography to yield intermediates (3S)-tert-butyl 3-(N-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)acetamido)piperidine-1-carboxylate and N-(1-acetyl-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N-((S)-piperidin-3-yl)acetamide, then follow the procedures of (d) and (e) in Scheme 25 to produce the products **1943** and **1945**. **1943**: MS (ESI) $(\text{M}+\text{H})^+=494.5$; **1945**: MS (ESI) $(\text{M}+\text{H})^+=536.5$

Scheme 27




Reagents and conditions: (a) NaH , DMF, 0 °C- r.t., 2h; (b) TFA, DCM, r.t. overnight; (c) Pyridine, 100 °C, 30 min.

General Procedure 13


[0303] (S)-tert-butyl 3-hydroxypiperidine-1-carboxylate (1 eq) was dissolved in dry DMF, the solution was cooled to 0 °C, NaH (2 eq) was added, stirred for 10 min, then 1-(bromomethyl)-3,5-dichlorobenzene (1 eq) in DMF was added dropwise. The solution was stirred at r.t for 2h and the solvent was removed under vacuum. The residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was dissolved in DCM, and TFA (5 eq) was added, the mixture was stirred at r.t. over night. The solvent was removed under vacuum to get the deprotected intermediate which was used for next step without further purification.

[0304] Step C was conducted following the procedure of step (c) in Scheme 22 to get compound **1898**: ¹H NMR (500 MHz, MeOD) δ 7.69 (d, *J* = 8.3 Hz, 1H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.24-7.21 (m, 1H), 7.17-7.14 (m, 2H), 4.67 (d, *J* = 12.7 Hz, 1H), 4.55 (d, *J* = 12.7 Hz, 1H), 4.56 (s, 1H), 4.54 (s, 1H), 3.99 (dd, *J* = 14.0, 3.7 Hz, 1H), 3.95-3.86 (m, 2H), 3.78 (d, *J* = 13.8 Hz, 1H), 3.61 (ddd, *J* = 13.6, 10.5, 3.0 Hz, 1H), 2.15 – 2.04 (m, 2H), 2.01 – 1.93 (m, 1H), 1.82 – 1.73 (m, 1H). MS (ESI) (M+H)⁺=412.8



[0305] **1904**: (S)-6-bromo-5-chloro-2-(3-((3,5-dichlorobenzyl)oxy)piperidin-1-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 2,6-dibromo-5-chloro-1H-imidazo[4,5-b]pyridine following the general procedure 13. MS (ESI) (M+H)⁺=491.2



Scheme 28




Reagents and conditions: (a) X=H: NaBH₃CN, AcOH, CH₃OH, r.t., overnight; X=O: EDC, pyridine, r.t. overnight ; (b) BH₃ in THF, r.t., overnight; (c) 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine, Pyridine, 100 °C, 30 min.

General Procedure 14


[0306] Compound 3,5-dichloroaniline reacted with tert-butyl 3-formylpiperidine-1-carboxylate under reductive amination condition to get intermediate tert-butyl 3-(((3,5-dichlorophenyl)amino)methyl)piperidine-1-carboxylate, then Boc protective group was removed using TFA to get 3,5-dichloro-N-(piperidin-3-ylmethyl)aniline which reacted with 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine following procedure of **Scheme 22** to get target compound **1862** 3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline. ^1H NMR (500 MHz, MeOD) δ 7.70 (d, J = 7.8 Hz, 1H), 7.39-7.27 (m, 1H), 6.63-6.49 (m, 3H), 4.05 (d, J = 9.2 Hz, 1H), 3.96 – 3.89 (m, 1H), 3.49-3.41 (m, 1H), 3.12 (dd, J = 29.3, 15.1 Hz, 2H), 2.18 – 1.91 (m, 3H), 1.85-1.69 (m, 1H), 1.58-1.42 (m, 1H), 1.37-1.21 (s, 1H). MS (ESI) $(\text{M}+\text{H})^+ = 412.0$; HPLC analysis: 85.0% purity.

**1862****1863**

[0307] **1863** : N-((1-(6-bromo-5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)-3,5-dichloroaniline was synthesized using piperidine-3-carboxylic acid following the General Procedure 14. MS (ESI) $(\text{M}+\text{H})^+ = 489.7$


**1922**

[0308] 1922: (R)-3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline was synthesized using (S)-piperidine-3-carboxylic acid following the General Procedure 14. MS (ESI) (M+H)⁺ = 412.2



1923


[0309] 1923: (S)-3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline was synthesized using (R)-piperidine-3-carboxylic acid following the General Procedure 14. MS (ESI) (M+H)⁺ = 412.2



1888

[0310] 1888: (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorophenyl)piperidine-3-carboxamide was synthesized using 3,5-dichloroaniline reacted with (s)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid to get intermediate (s)-tert-butyl 3-((3,5-dichlorophenyl)carbamoyl)piperidine-1-carboxylate, then following the procedure of synthesizing ChemID:1862. MS (ESI) (M+H)⁺ = 426.0; HPLC analysis: 100% purity.

Scheme 29



Reagents and conditions: (a) CS₂, EtOH, 55 °C, overnight; (b) CH₃I, K₂CO₃, CH₃CN, r.t. overnight; (c) (S)-tert-butyl piperidin-3-ylcarbamate, pyridine, 150 °C, Microwave, overnight; (d) TFA, DCM, r.t. overnight; (e) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN, r.t., 3h.

[0311] (a) To a solution of 2-(aminomethyl)aniline (366 mg, 3 mM) in EtOH (5 mL) was added carbon disulfide (3 mL) at r.t.. The mixture was stirred at 55 °C overnight. The solvent


was evaporated off and the resulting solid was filtered and washed with ether to give light yellow solid 3,4-dihydroquinazoline-2(1H)-thione.

[0312] (b) 3,4-dihydroquinazoline-2(1H)-thione (1eq) was suspended in CH_3CN , K_2CO_3 (4eq) and CH_3I (3eq) were added. The resulting mixture stirred at r.t. over night. The reaction was concentrated in vacuum and the residue was extracted with DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to get (S)-tert-butyl (1-(1,4-dihydroquinazolin-2-yl)piperidin-3-yl)carbamate as brown solid.

[0313] (c) 2-(methylthio)-1,4-dihydroquinazoline was dissolved in pyridine, (S)-tert-butyl piperidin-3-ylcarbamate was added and the reaction mixture was microwave irradiated at 150 °C for 1h. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give intermediate (S)-tert-butyl (1-(1,4-dihydroquinazolin-2-yl)piperidin-3-yl).


[0314] (S)-tert-butyl (1-(1,4-dihydroquinazolin-2-yl)piperidin-3-yl) was deprotected the Boc protecting group under TFA/DCM condition, the resulting compound reacted with 3,5-dichlorobenzaldehyde under typical reductive amination conditions to yield target compound **1961** MS (ESI) $(\text{M}+\text{H})^+ = 390.1$.

Scheme 30




Reagents and conditions: (a) NaBH_3CN , MeOH/AcOH, 60 °C, overnight.

General Procedure 15 (1954, 1956 & 1967): 3-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)amino)propanal (1.2 eq) and 3,5-dichloroaniline (1eq) was dissolved in MeOH, AcOH (2 eq) and NaBH_3CN (2eq) were added. The mixture was heated to 60 °C overnight. The solvent was removed under vacuum and the residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding compound **1954**. MS (ESI) $(\text{M}+\text{H})^+ = 355.6$.


**1956**

[0315] 1956: N1-(2,4-dichlorophenyl)-N3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine was synthesized using 2,4-dichloroaniline following the General Procedure 15. MS (ESI) (M+H)⁺= 355.6.

**1957**

[0316] 1957: N1-(2,4-dichlorophenyl)-N3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine was synthesized using 2,4-dichloroaniline following the General Procedure 15. MS (ESI) (M+H)⁺=355.5.

Scheme 31

**1814**

Reagents and conditions: (a) **8**, NaBH₃CN, AcOH, CH₃OH, r.t., overnight; (b) LiOH, CH₃OH/H₂O, r.t. overnight; (c) **5**, EDC, pyridine, r.t. overnight; (d) AcOH, POCl₃, Microwave 150 °C, 1h.

[0317] (a) ethyl 2-(piperidin-3-yl)acetate (88 mg, 0.5 mM) and 3,5-dichlorobenzaldehyde (86 mg, 0.5 mM) were dissolved in CH₃OH, AcOH (60 mg, 1 mM) and NaBH₃CN (63mg, 1 mM) were added to the solution. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate and the solvent was removed under


reduced pressure. The residue was purified through flash chromatography on silica gel eluted with EA/ hexane to give ethyl 2-(1-(3,5-dichlorobenzyl)piperidin-3-yl)acetate.

[0318] (b) LiOH·H₂O (3 eq) was added to the solution of methyl 3-((3,5-dichlorobenzyl)amino)cyclohexanecarboxylate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was used for the next step without further purification.

[0319] (c) 2-(1-(3,5-dichlorobenzyl)piperidin-3-yl)acetic acid obtained from above step was dissolved in pyridine (2 mL), EDC (1.5 eq) was added and the mixture was stirred at r.t. overnight. Pyridine was removed under reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave N-(2-amino-6-chloropyridin-3-yl)-2-(1-(3-chloro-5-methylbenzyl)piperidin-3-yl)acetamide.

[0320] (d) N-(2-amino-6-chloropyridin-3-yl)-2-(1-(3-chloro-5-methylbenzyl)piperidin-3-yl)acetamide was dissolved in 3 mL glacial acetic acid, POCl₃ (3 eq) was added, the mixture was microwave irradiated at 150 °C for 1 hour. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give compound **1814**: 5-chloro-2-((1-(3,5-dichlorobenzyl)piperidin-3-yl)methyl)-1H-imidazo[4,5-b]pyridine, MS (ESI) (M+H)⁺ = 411.5.


Scheme 32



1866: 5-chloro-2-(4-(3,5-dichlorobenzyl)piperazin-1-yl)-1H-imidazo[4,5-b]pyridine was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl piperazine-1-carboxylate following the general procedure as Scheme 22. MS(ESI) (M+H)⁺ = 397.4; HPLC analysis: 98.1% purity

[0321] 1867: 1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-4-amine was synthesized using 3,5-dichlorobenzaldehyde and tert-butyl piperidin-4-ylcarbamate following the general procedure as Scheme 22. ^1H NMR (500 MHz, CDCl_3) δ 7.80-7.43 (br, 1H), 7.35 – 7.21 (m, 3H), 7.13-6.76 (br, 1H), 4.37-3.97 (m, 2H), 3.81 (s, 2H), 3.29-3.06 (br, 2H), 2.78 (s, 1H), 2.00-1.92 (br, 2H), 1.53-1.40 (br, 2H). MS(ESI) $(\text{M}+\text{H})^+ = 411.7$; HPLC analysis: 94.5% purity.


Scheme 33



[0322] Reagents and conditions (a) NaOH, water, acetone, 0 ° C; (b) C-(5-Fluoro-3H-imidazo[4,5-b]pyridin-2-yl)-methylamine, microwave irradiation, 80 ° C, 10min.

[0323] A mixture of 2-chloro-4-methoxyphenol (45mg, 0.285mmol) and 0.5N NaOH (0.516ml) was added slowly into cyanuric chloride (1 equiv) in 0.3ml acetone at 0 ° C. The mixture was stirred at 0 ° C for 1 hour. Then C-(5-Fluoro-3H-imidazo[4,5-b]pyridin-2-yl)-methylamine (1 equiv) was added and the mixture was microwave irradiated at 80 ° C for 20min. After most solvents were removed, methanol was added. The solution was acidified and subject to HPLC purification to collect **1883**, **1884** and **1885**. LC/MS: (ESI) $(\text{M}+\text{H})^+ = 566.2$ for **1883**; ESI) $(\text{M}+\text{H})^+ = 559.4$ for **1884**; ESI) $(\text{M}+\text{H})^+ = 418.5$ for **1885**.


Scheme 34




Reagents and conditions (a) EDC, DMAP, DIPEA, DMF; (b) TFA/DCM

General Procedure 16 (1720, 1703, 1808):

[0324] The solution of (R)-3-Boc-amino-4-(2,4-dichlorophenyl)butanoic acid (30 mg, 0.086 mmol), DIPEA (0.25mmol), EDC HCl (0.13mmol) and DMAP (0.086mmol) in DMF (20 mL) was stirred for 10min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (0.086mmol) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford (R)-N-((1H-benzo[d]imidazol-2-yl)methyl)-3-Boc-amino-4-(2,4-dichlorophenyl)butanamide. The above compound was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was completely evaporated under vacuum to afford (R)-N-((1H-benzo[d]imidazol-2-yl)methyl)-3-amino-4-(2,4-dichlorophenyl)butanamide (**1720**). LC/MS: (ESI) (M + H)⁺ = 378.5.


**1703**

[0325] **1703** was synthesized using (R)-3-Boc-4-(4-fluorophenyl)butanoic acid in General Procedure 16. LC/MS: (ESI) (M + H)⁺ = 327.5.

**1808**

[0326] **1808** was synthesized using (R)-3-Boc-amino-4-(4-fluorophenyl)butanoic acid in General Procedure 16. LC/MS: (ESI) (M + H)⁺ = 327.5.


Scheme 35

**1576**

Reagents and conditions (a) EDC, DIPEA, HOBt, DMF; (b) TFA, DCM; (c) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN


General Procedure 17(1576, 1830, 1831):

[0327] The solution of Boc-β-Ala (16 mg, 0.086 mmol), DIPEA (0.26mmol), EDC HCl (0.13mmol) and HOBt (0.086mmol) in DMF (20 mL) was stirred for 10min. To this reaction mixture 3H-imidazo[4,5-b]pyridin-2-amine (0.086mmol) was added. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was dissolved in ethyl acetate and washed with water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford 3-Boc-amino-N-(3H-imidazo[4,5-b]pyridin-2-yl)propanamide. The above compound was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The solvent was evaporated off completely under vacuum, and the residue was co-distilled 2× with methylene chloride. The residue was dissolved in 3 ml MeOH, neutralized with DIPEA and 0.15 ml AcOH was added. 3,5-Dichlorobenzaldehyde (1.1 equiv) was added. After the mixture was stirred for 30 min, NaBH₃CN (0.17mmol) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding 3-(3,5-dichlorobenzylamino)-N-(3H-imidazo[4,5-b]pyridin-2-yl)propanamide (**1576**). LC/MS: (ESI) (M + H)⁺ = 365.5.



1830


[0328] **1830** was synthesized using Boc-Gly and (6-chloro-1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 17. LC/MS: (ESI) (M + H)⁺ = 398.2.



1831

[0329] 1831 was synthesized using Boc-L-Ala and (6-chloro-1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 17. LC/MS: (ESI) (M + H)⁺ = 412.6.


Scheme 36



Reagents and conditions (a) μ w, 120 °C 2h; (b) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN


[0330] 2-chloro-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile (35mg, 0.2mmol) was dissolved in propane-1,3-diamine (1ml). The mixture was microwave irradiated at 120 °C for 2 h. After the solvent was removed in vacuum. The residue was dissolved in ethyl acetate and washed with water three time, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to 2-(3-aminopropylamino)-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile. 2-(3-aminopropylamino)-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile (15mg, 0.07mmol) was dissolved in 5 ml of MeOH, 0.15 ml of AcOH. 3,5-dichlorobenzaldehyde (0.07mmol) was added. After the mixture was stirred for 30 min, NaBH₃CN (0.14 mmol) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (25ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding 2-(3-(3,5-dichlorobenzylamino)propylamino)-1H-pyrrolo[3,2-b]pyridine-3-carbonitrile (**1627**). LC/MS: (ESI) (M + H)⁺ = 375.5.

Scheme 37



Reagents and conditions (a) DCM, pyridine; (b) (1H-benzo[d]imidazol-2-yl)methanamine


General Procedure 18 (1702, 1755): To a solution of 2-(2,4-dichlorophenyl)ethanamine (198 mg, 1.04 mmol) in 5 ml of DCM was added 4-nitrophenol chloroformate (200mg, 0.99 mmol) in 3 ml of DCM and pyridine (84.8μl, 1.05 mmol) at 0 °C. The mixture was at 0 °C for 3h. The solvent was removed and the residue was dissolved in ethyl acetate. The solution was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give 4-nitrophenyl 2,4-dichlorophenethylcarbamate. (1H-benzo[d]imidazol-2-yl)methanamine (0.06mmol) was added into the solution of 4-nitrophenyl 2,4-dichlorophenethylcarbamate (0.06mmol) in DCM (10ml) at 0 °C with stirring. The mixture was stirred at room temperature overnight. The solution was diluted with 50 ml of DCM and washed with 0.1 N NaOH (50ml), brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (1-((1H-benzo[d]imidazol-2-yl)methyl)-3-(2,4-dichlorophenethyl)urea (**1702**). LC/MS: (ESI) (M + H)⁺ = 364.8.



1755

[0331] **1755** was synthesized using (S)-methyl 2-amino-3-(2,4-dichlorophenyl)propanoate in General Procedure 18. LC/MS: (ESI) (M + H)⁺ = 422.5.

Scheme 38




Reagents and conditions (a) NaN₃, t-butanol; (b) NaOH, ethanol; (c) EDC, DIPEA, DCM, (1H-benzo[d]imidazol-2-yl)methanamine

[0332] To a stirred solution of 2,4-dichlorophenol (163mg, 1 mmol) and NaN₃ (0.1mmol) in 10ml of tert-butyl alcohol was added dropwise a mixture of ethyl propiolate (1 mmol) in 2ml of tert-butyl alcohol at room temperature over 10 min. The reaction mixture was microwave irradiated at 80 °C for 15min. After most of the solvent was removed, 50ml of

ethyl acetate was added. The organic was then washed with water and brine, and dried over anhydrous sodium sulfate. After removal of the solvent, the crude product was purified by column chromatography to give (Z)-3-(2,4-dichlorophenoxy)acrylic acid ethyl ester ⁶. To a solution of (Z)- 3-(2,4-Dichloro-phenoxy)-acrylic acid ethyl ester (30 mg, 0.115 mmol) in ethanol (2 mL) was added 1 N NaOH (1ml). The resultant mixture was microwave irradiated for 15min at 80 °C. After being cooled to room temperature, it was poured into ethyl acetate (50 mL), washed with 0.1 N HCl, water, brine dried over magnesium sulfate, and evaporated to dry to yield 3-(2,4-Dichloro-phenoxy)-acrylic acid. The solution of (Z)- 3-(2,4-Dichloro-phenoxy)-acrylic acid (20 mg , 0.086 mmol), DIPEA (0.26mmol), EDC HCl (0.13mmol) and DMAP (0.086mmol) in DCM (20 mL) was stirred for 10min. To this reaction mixture (1H-benzo[d]imidazol-2-yl)methanamine (0.086mmol) was added. The reaction mixture was stirred at room temperature overnight. The organic layer was washed with sat. NaHCO₃ and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford (Z)-N-((1H-benzo[d]imidazol-2-yl)methyl)-3-(2,4-dichlorophenoxy)acrylamide (**1730**). LC/MS: (ESI) (M +H)⁺ = 363.4.

Scheme 39




Reagents and conditions (a) HBTU, DIPEA, DMF; (b) HOAc, 60 °C, 4h; (c) TFA/DCM; (d) EDC, HOBt, DIPEA, DMF, 3-(2,4-dichlorophenoxy)propanoic acid.

[0333] To a 5 ml of DMF solution of 1-(Boc-amino)cyclopropanecarboxylic acid (100 mg, 0.50 mmol) were added N,N-diisopropylethylamine (1.5mmol), HBTU (0.55mmol), benzene-1,2-diamine (0.5mmol). The reaction mixture was stirred at room temperature for 6 hr. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. To the residue, 3 ml of acetic acid was added and this mixture was heated for 4 hr at 60°C. After evaporation, the obtained mixture was purified by flash column chromatography (DCM/MeOH) to give 1-(1H-benzo[d]imidazol-2-yl)-Boc-N-cyclopropanamine. 1-(1H-benzo[d]imidazol-2-yl)-Boc-N-cyclopropanamine (27mg, 0.1mmol) was dissolved in DCM (4ml) and TFA (2ml) was added. The mixture was stirred

at room temperature for 30min. and the solvent was removed completely in vacuum. The residue was dissolved in DMF and 3-(2,4-dichlorophenoxy)propanoic acid (0.1 mmol), N,N-diisopropylethylamine (0.5mmol), HBTU (0.15mmol). The reaction mixture was stirred at room temperature for 6 hr. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water, and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford N-(1-(1H-benzo[d]imidazol-2-yl)cyclopropyl)-3-(2,4-dichlorophenoxy)propanamide (**1738**). LC/MS: (ESI) (M +H)⁺= 391.5.

Scheme 40




1756

Reagents and conditions (a) NaOH, ethanol; (b) EDC, HOBt, DIPEA, DMF, (1H-benzo[d]imidazol-2-yl)methanamine

[0334] Ethyl 2-(5,7-dichlorobenzofuran-2-yl) acetate was prepared from 3,5-dichloro-2-hydroxybenzaldehyde and ethyl propiolate according to the literature procedure⁷. Ethyl 2-(5,7-dichlorobenzofuran-2-yl) acetate (0.5mmol) was dissolved in 1ml of 2N NaOH and 1ml of MeOH. The mixture was microwave irradiated at 80 °C for 8 min. After most of solvents were removed, the residue was neutralized with 1 N HCl and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was dissolved in DMF and EDC (0.5 mmol), HOBt (0.5 mmol), DIPEA (1.0 mmol), (1H-benzo[d]imidazol-2-yl)methanamine (0.5 mmol) were added. The solution was stirred at room temperature overnight and then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give N-((1H-benzo[d]imidazol-2-yl)methyl)-2-(5,7-dichlorobenzofuran-2-yl)acetamide (**1756**). LC/MS: (ESI) (M +H)⁺= 375.6.


Scheme 41



Reagents and conditions (a) HBTU, DIPEA, DMF; (b) AcOH, 60 °C, 4h; (c), NaOH/MeOH; (d) EDC, HOBT, DIPEA, DMF, (1H-benzo[d]imidazol-2-yl)methanamine.

[0335] To a 5 ml of DMF solution of 2-(methoxycarbonyl)acetic acid (59 mg, 0.50 mmol) were added N,N-diisopropylethylamine (1.5mmol), HBTU (0.55mmol), 3,5-dichlorobenzene-1,2-diamine (0.5mmol). The reaction mixture was stirred at room temperature for 6 hr. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. To the residue, 3 ml of acetic acid was added and this mixture was heated for 4 hrs at 60°C. After evaporation, the obtained mixture was purified by flash column chromatography (DCM/MeOH) to give methyl 2-(5,7-dichloro-1H-benzo[d]imidazol-2-yl)acetate. Methyl 2-(5,7-dichloro-1H-benzo[d]imidazol-2-yl)acetate (26mg, 0.1 mmol) was dissolved in 1ml of 2N NaOH and 1ml of MeOH. The mixture was microwave irradiated at 80 °C for 8 min. After most of solvents were removed, the residue was neutralized with 1 N HCl and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was dissolved in DMF and EDC (0.15 mmol), HOBT (0.1 mmol), DIPEA (0.25 mmol), (1H-benzo[d]imidazol-2-yl)methanamine (0.1 mmol) were added. The solution was stirred at room temperature overnight and then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give N-((1H-benzo[d]imidazol-2-yl)methyl)-2-(5,7-dichloro-1H-benzo[d]imidazol-2-yl)acetamide (**1764**). LC/MS: (ESI) (M + H)⁺ = 375.6.


Scheme 42



Reagents and conditions (a) 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, EtOH, HCl; (b) pyridine, 6-chloro-1H-benzo[d]imidazol-2-amine, μ W, 120 °C, 40 min.

[0336] A mixture of 4-chlorobenzene-1,2-diamine (71 mg, 0.5 mmol) and 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.5 mmol) in EtOH (3 mL) was refluxed overnight. After cooling, the solid was formed when diethyl ether was added. The solid was treated with 10ml of 1N HCl and heated for 2h. After cooling, the precipitate was formed with addition of NH₄OH. The collected solid was dissolved in 3 ml of pyridine and 6-chloro-1H-benzo[d]imidazol-2-amine (5 mmol) was added. The mixture was microwave irradiated at 120 °C for 40min. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give 1-(3,5-dichlorobenzyl)-3-(6-chloro-1H-benzo[d]imidazol-2-yl)urea (**1793**). LC/MS: (ESI) (M + H)⁺ = 370.3.


Scheme 43



Reagents and conditions (a) DCM; (b) NaOH/MeOH; (c) EDC, HOBt, DIPEA, DMF, (1H-benzo[d]imidazol-2-yl)methanamine

[0337] To a solution of (2,4-dichlorophenyl)methanamine (88 mg, 0.5 mmol) in DCM was added methyl (chlorocarbonyl)formate (0.5 mmol) at 0 °C. Then the solution was stirred at room temperature for 2h. After the solvent was removed, the residue was dissolved in 1ml of 2N NaOH and 1ml of MeOH. The mixture was microwave irradiated at 80 °C for 8 min. After most of solvents were removed, the residue was neutralized with 1 N HCl and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was dissolved in DMF and EDC (0.5 mmol), HOBt (0.5 mmol), DIPEA (1.0 mmol), (1H-benzo[d]imidazol-2-yl)methanamine (0.5 mmol) were added. The solution was stirred at room temperature overnight and then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give N1-((1H-benzo[d]imidazol-2-yl)methyl)-N2-(2,4-dichlorobenzyl)oxalamide (**1802**). LC/MS: (ESI) (M + H)⁺ = 378.6.


Scheme 44



Reagents and conditions (a) DCM; (b) NaOH/MeOH; (c) EDC, HOBt, DIPEA, DMF, (1H-benzo[d]imidazol-2-yl)methanamine

[0338] To a solution of 2,4-dichlorobenzeneamine (81 mg, 0.5 mmol) in DCM was added methyl 2-(chlorocarbonyl)acetate (0.5 mmol) at 0 °C. Then the solution was stirred at room temperature for 2h. After the solvent was removed, the residue was dissolved in 1ml of 2N NaOH and 1ml of MeOH. The mixture was microwave irradiated at 80 °C for 8 min. After most of solvents were removed, the residue was neutralized with 1 N HCl and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was dissolved in DMF and EDC (0.5 mmol), HOBt (0.5 mmol), DIPEA (1.0 mmol), (1H-benzo[d]imidazol-2-yl)methanamine (0.5 mmol) were added. The solution was stirred at room temperature overnight and then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give N1-((1H-benzo[d]imidazol-2-yl)methyl)-N3-(2,4-dichlorophenyl)malonamide (**1803**). LC/MS: (ESI) $(M+H)^+ = 378.6$.


Scheme 45




Reagents and conditions (a) EDC, DMAP, DIPEA, DMF

General Procedure 19 (1851, 1852, 1874, 1873, 1876, 1878, 1880, 1875, 1877, 1879): The solution 2-(3,5-dichlorophenyl)acetic acid (30 mg, 0.15 mmol), DIPEA (0.45 mmol), EDC HCl (0.20 mmol) and DMAP (0.15 mmol) in DMF (10 mL) was stirred for 10min. To this reaction mixture (6-chloro-1H-benzo[d]imidazol-2-yl)methanamine (0.15 mmol) was added. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The


residue was purified by flash column chromatography to give N-((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)-2-(3,5-dichlorophenyl)acetamide (**1851**). LC/MS: (ESI) (M + H)⁺ = 369.6.

**1852**


[0339] **1852** was synthesized using 2-(2,4-dichlorophenyl)acetic acid in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 369.6.

**1874**


[0340] **1874** was synthesized using 2-(2,4-dichlorophenyl)acetic acid and (5-bromo-1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 414.2.

**1873**


[0341] **1873** was synthesized using (5-bromo-1H-benzo[d]imidazol-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 414.1.

**1876**


[0342] **1876** was synthesized using 2-(2,4-dichlorophenyl)acetic acid and (5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.6.

**1878**


[0343] **1878** was synthesized using 2-(2,4-dichlorophenyl)acetic acid and (6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.6.

**1880**


[0344] **1880** was synthesized using 2-(2,4-dichlorophenyl)acetic acid and (6-chloro-3H-imidazo[4,5-c]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.6.

**1875**

[0345] **1875** was synthesized using (5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.5.

**1877**


[0346] **1877** was synthesized using (6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.5.



1879

[0347] 1879 was synthesized using (6-chloro-3H-imidazo[4,5-c]pyridin-2-yl)methanamine in General Procedure 19. LC/MS: (ESI) (M + H)⁺ = 370.5.


Scheme 46



1853


Reagents and conditions (a) MeOH, HOAc, NaBH₃CN

General Procedure 20 (1853, 1881, 1882, 1892): (6-bromo-1H-benzo[d]imidazol-2-yl)methanamine (30mg, 0.13mmol) was dissolved in 5 ml of MeOH, 0.15 ml of AcOH. 3,5-dichlorobenzaldehyde (0.15mmol) was added. After the mixture was stirred for 30 min, NaBH₃CN (0.30 mmol) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding N-(3,5-dichlorobenzyl)-(6-bromo-1H-benzo[d]imidazol-2-yl)methanamine (1853). LC/MS: (ESI) (M + H)⁺ = 385.9.




1881

[0348] 1881 was synthesized using 3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)propan-1-amine in General Procedure 20. LC/MS: (ESI) (M + H)⁺ = 370.5.



1882


[0349] 1882 was synthesized using 2-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine in General Procedure 20. LC/MS: (ESI) $(M+H)^+ = 356.6$.



1892

[0350] 1892 was synthesized using 2-(2,4-dichlorophenyl)acetaldehyde and 2-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine in General Procedure 20. LC/MS: (ESI) $(M+H)^+ = 356.6$.

Scheme 47




Reagents and conditions (a) EtMgBr, Ti(O-*i*-Pr)₄, BF₃·OEt₂; (b) MeOH, HOAc, NaBH₃CN.

[0351] To a solution of 3,5-dichlorobenzonitrile (86mg, 0.5 mmol) and Ti(O-*i*-Pr)₄ (0.6 mmol) in Et₂O (5 mL) was added ethylmagnesium bromide (1.1 mmol) in ether at -78 °C. The yellow solution was stirred for 10 min. After the solution was warmed to rt in 1h, BF₃·OEt₂ (0.13 mL, 1 mmol) was added. After the mixture was stirred for 1 h, 1 N HCl (2 mL) and ether (10 mL) were added. The ether layer was washed with 0.2 N NaOH, and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to give (3,5-dichlorophenyl)cyclopropanamine⁸. The above purified compound (30mg, 0.15mmol) was dissolved in 5 ml of MeOH, 0.15 ml of AcOH. 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propanal (0.15mmol) was added. After the mixture was stirred for 30 min, NaBH₃CN (0.30 mmol) was added. The mixture was stirred overnight and the solvent was

removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding N-(3-(1-(3,5-dichlorophenyl)cyclopropylamino)propyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-amine (1716). LC/MS: (ESI) (M +H)⁺= 395.6


Scheme 48



Reagents and conditions (a) EDC, DMAP, DIPEA, DMF; (b) TFA, DCM.

[0352] The solution 2-Boc-amino-3-(1H-benzo[d]imidazol-2-yl)propanoic acid (46 mg , 0.15 mmol), DIPEA (0.45 mmol), EDC HCl (0.20 mmol) and DMAP (0.15 mmol) in DMF (10 mL) was stirred for 10min. To this reaction mixture 2-(2,4-dichlorophenyl)ethanamine (0.15 mmol) was added. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography. The above purified compound was dissolved in 3 ml of DCM. To the solution, 1 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was evaporated under vacuum, neutralized with aq NaHCO₃ and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated give N-(2,4-dichlorophenethyl)-2-amino-3-(1H-benzo[d]imidazol-2-yl)propanamide (**1795**). LC/MS: (ESI) (M +H)⁺= 378.3.


Scheme 49




Reagents and conditions (a) DIPEA, acetonitrile, DMF

General Procedure 21(1890, 1891, 1991):

[0353] To a solution of 1,3-dichloro-5-isocyanatobenzene (18 mg, 0.1 mmol) in acetonitrile (5 mL) and DMF (0.1 mL) was slowly added (5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)methanamine 2HCl (0.11 mmol) and DIPEA (0.22 mmol) at 0 °C. The mixture was stirred at room temperature for 30 min and then diluted with 25 mL of DCM. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 1-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)methyl)-3-(3,5-dichlorophenyl)urea (**1890**), LC/MS: (ESI) (M + H)⁺ = 371.6.


**1891**

[0354] **1891** was synthesized using 2,4-dichloro-1-isocyanatobenzene in General Procedure 21. LC/MS: (ESI) (M + H)⁺ = 371.6.

**1991**

[0355] **1991** was synthesized using (3,5-dichlorophenyl)methanamine in General Procedure 21. LC/MS: (ESI) (M + H)⁺ = 385.1.

Scheme 50



Reagents and conditions (a) NaOAc, EtOH, reflux, overnight; (b) LiOH, CH₃OH/H₂O, r.t., overnight; (c) EDC, pyridine, r.t.; (d) BH₃ in THF, r.t.

[0356] 3,5-dichloroaniline (1 eq), ethyl 2-bromoacetate (3 eq) and NaOAc (3 eq) in EtOH was refluxed overnight. The solvent was removed under reduced pressure and the residue was extracted with DCM. The organic layer was dried over sodium sulfate, concentrated in


vacuum, and the residue was purified through flash chromatography on silica gel eluted with EA-Hexane to give ethyl 2-((3,5-dichlorophenyl)amino)acetate.

[0357] LiOH·H₂O (3 eq) was added to the solution of ethyl 2-((3,5-dichlorophenyl)amino)acetate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was used for next step without further purification.

[0358] 2-((3,5-dichlorophenyl)amino)acetic acid (1 eq) and (5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)methanamine 2HCl (1 eq) in pyridine (2 mL) was added EDC (1.5 eq). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave compound **1990**. LC/MS: (ESI) (M + H)⁺ = 385.5

[0359] Compound **1990** dissolved in anhydrous THF was added BH₃ (5 eq) in THF at r.t. The mixture was stirred at r.t. for 5h. The solvent was removed under reduced pressure, saturated NaHCO₃ was added and extracted with DCM. The organic layer was dried over sodium sulfate, concentrated in vacuum, and the residue was purified through flash chromatography on silica gel to give compound **1994**. LC/MS: (ESI) (M + H)⁺ = 371.9

Scheme 51




Reagents and conditions (a) pyridine, heating; (b) TFA, DCM; (c) MeOH, HOAc, NaBH₃CN


General Procedure 22(1893, 1894, 1925, 1949, 1757, 1599, 1634, 1641):

[0360] 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine (30 mg, 0.13 mmol) was dissolved in pyridine (2 mL), tert-butyl 2-(methylamino)ethylcarbamate (0.52mmol) was added and the reaction mixture was heated at 110 °C overnight or microwave irradiated at 120 °C for 1h . The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give


tert-butyl 2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethylcarbamate. Tert-butyl 2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethylcarbamate (32.5mg, 0.1mmol) was dissolved in DCM (4ml) and TFA (2ml) was added., The mixture was stirred at room temperature for 30min. and the solvent was removed completely in vacuum. The residue was dissolved in methanol (4ml) and neutralized with DIPEA (0.2mmol). The solution was added HOAc (0.12ml) and 3,5-dichlorobenzaldehyde (0.1mmol), following by adding NaBH₃CN (0.2 mmol). The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by DCM. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give N-(2-(3,5-dichlorobenzylamino)ethyl)-5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (**1893**). LC/MS: (ESI) (M + H)⁺ = 385.2.

**1894**


[0361] **1894** was synthesized using 2,6-dibromo-5-chloro-1H-imidazo[4,5-b]pyridine in General Procedure 22. LC/MS: (ESI) (M + H)⁺ = 464.6.

**1925**


[0362] **1925** was synthesized using 3,5-dichloro-2-ethoxybenzaldehyde in General Procedure 22. LC/MS: (ESI) (M + H)⁺ = 429.7.

**1949**


[0363] **1949** was synthesized using tert-butyl 2-(ethylamino)ethylcarbamate in General Procedure 22. LC/MS: (ESI) (M + H)⁺ = 399.5.




[0364] **1913** was synthesized using 2-bromo-5-fluoro-1H-imidazo[4,5-b]pyridine in General Procedure 22. LC/MS: (ESI) $(M+H)^+ = 369.3$.




[0365] **1575** was synthesized using 2-bromo-1H-imidazo[4,5-b]pyridine and tert-butyl 3-aminopropylcarbamate in General Procedure 22. ^1H NMR (500 MHz, MeOD) δ 7.98 (d, $J = 6.2$ Hz, 1H), 7.88 (d, $J = 7.7$ Hz, 1H), 7.61-7.45 (m, 3H), 7.26 (m, 1H), 4.25 (s, 2H), 3.65 (t, $J = 6.6$ Hz, 2H), 3.20 (m, 2H), 2.13 (m, 2H). LC/MS: (ESI) 351.6 $[M+H]^+$.



[0366] **1599** was synthesized using 2-bromo-5-methyl-1H-imidazo[4,5-b]pyridine and tert-butyl 3-aminopropylcarbamate in General Procedure 22. LC/MS: (ESI) 365.4 $[M+H]^+$.




[0367] **1634** was synthesized using 2-bromo-1H-imidazo[4,5-b]pyridine and tert-butyl 3-amino-2-hydroxypropylcarbamate in General Procedure 22. LC/MS: (ESI) 367.3 $[M+H]^+$.



[0368] **1641** was synthesized using 2-bromo-1H-imidazo[4,5-b]pyridine and tert-butyl 3-amino-2,2-dimethylpropylcarbamate in General Procedure 22. LC/MS: (ESI) 379.2 $[M+H]^+$.


Scheme 52




Reagents and conditions (a) pyridine, Microwave 100 °C, 1h; (b) HCl (2M), Acetone, reflux, 1h; (c) (R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine, MeOH, HOAc, NaBH₃CN

General Procedure 23 (1919, 1939, 1917):

[0369] 2-bromo-5-fluoro-1H-imidazo[4,5-b]pyridine (1 eq) was dissolved in pyridine (2 mL), 2,2-dimethoxy-N-methylethanamine (1.5 eq) was added and the reaction mixture was microwave irradiated at 100 °C for 1h. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. The residue was purified through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give N-(2,2-dimethoxyethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine. N-(2,2-dimethoxyethyl)-5-fluoro-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (32.5mg, 0.1mmol) was dissolved in Acetone (4ml) and HCl (2 M) was added, The mixture was refluxed for 1h and the solvent was removed completely in vacuum. The residue was dissolved in methanol (4ml) and neutralized with DIPEA (0.2mmol). The solution was added HOAc (0.12ml) and 3(R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine (0.1mmol), following by adding NaBH₃CN (0.2 mmol). The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by DCM. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give (R)-N1-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)-N2-methylethane-1,2-diamine (**1919**). LC/MS: (ESI) (M + H)⁺ = 410.3




[0370] **1939:** (R)-N1-(6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl)-N2-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)-N1-(2-((5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)(methyl)amino)ethyl)-N2-methylethane-1,2-diamine was synthesized using 0.5 eq of 3(R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine following the General Procedure 23. LC/MS: (ESI) (M + H)⁺ = 601.9

**1917**

[0371] **1917** was synthesized using 2-bromo-5-chloro-1H-imidazo[4,5-b]pyridine in General Procedure 23. LC/MS: (ESI) (M + H)⁺ = 426.5.


Scheme 44




Reagents and conditions (a) DCM, Ac₂O, DIPEA, 0°C

General Procedure 24 (1926, 1914, 1938):


[0372] To a solution of compound **1893** (17 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and acetic anhydride (0.045 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 mL of DCM. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give N-(3,5-dichlorobenzyl)-N-(2-((5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)acetamide (**1926**), LC/MS: (ESI) (M + H)⁺ = 427.4.

**1914**


[0373] 1914 was synthesized using 1913 in General Procedure 24. LC/MS: (ESI) (M+H)⁺ = 411.1



[0374] 1887: N-(3,5-dichlorobenzyl)-N-(1-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)acetamide was synthesized using 1886 in General Procedure 24. MS (ESI) (M+H)⁺ = 437.3; HPLC analysis: 100% purity.




[0375] 1901: (S)-N-(3,5-dichlorobenzyl)-N-(1-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)acetamide was synthesized following the procedure 24. MS (ESI) (M+H)⁺ = 437.3



[0376] 1938 was synthesized using 1917 in General Procedure 24. LC/MS: (ESI) (M+H)⁺ = 442.7.


Scheme 53



Reagents and conditions (a) DCM, propionic acid, EDC, DMAP, DIPEA


General Procedure 25 (1942, 1957, 1958):

[0377] The solution of propanoic acid (10 mg 0.135 mmol), DIPEA (0.4 mmol), EDC HCl (0.2 mmol) and DMAP (0.135 mmol) in DCM (20 mL) was stirred for 10 min. To this reaction mixture compound **1893** (0.135 mmol) was added. The reaction mixture was stirred at room temperature overnight and diluted with 20 mL of DCM. The organic layer was washed with water and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford N-(3,5-dichlorobenzyl)-N-(2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)propionamide (**1942**). LC/MS: (ESI) (M + H)⁺ = 441.3.



1957


[0378] **1957** was synthesized using Boc-Gly and following the Boc deprotection with TFA in DCM in General Procedure 25. LC/MS: (ESI) (M + H)⁺ = 442.7.



1958

[0379] **1958** was synthesized using Boc-β-Ala and following the Boc deprotection with TFA in DCM in General Procedure. LC/MS: (ESI) (M + H)⁺ = 456.7.

Scheme 54



1893


1963

Reagents and conditions (a) DCM, methyl chloroformate, DIPEA, 0°C

[0380] To a solution of compound **1893** (17 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and methyl chloroformate (0.045 mmol) in DCM at 0 °C.

The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give methyl 3,5-dichlorobenzyl-2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethylcarbamate (**1963**), LC/MS: (ESI) $(M+H)^+ = 443.5$.


Scheme 55



Reagents and conditions (a) DCM, trimethylsilylisocyanate, DIPEA, 0°C

[0381] To a solution of compound **1893** (17 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and trimethylsilylisocyanate (0.045 mmol) in DCM at 0°C . The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 1-(3,5-dichlorobenzyl)-N-(2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)urea (**1972**), LC/MS: (ESI) $(M+H)^+ = 428.4$.

Scheme 56




Reagents and conditions (a) DCM, acetoxyacetyl chloride, DIPEA, 0°C ; (b) K_2CO_3 , MeOH

[0382] To a solution of compound **1893** (17 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.05 mmol) and acetoxyacetyl chloride (0.045 mmol) in DCM at 0°C . The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give ((N-(3,5-dichlorobenzyl)-N-(2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)carbamoyl)methyl acetate. ((N-(3,5-dichlorobenzyl)-N-(2-(5-chloro-N-

methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)carbamoyl)methyl acetate (19mg, 0.04mmol) in MeOH was added K_2CO_3 (0.16 mmol), and stirred at room temperature for 1 hour. The mixture was concentrated, and water (10 mL) was added and extracted with CH_2Cl_2 (3x35 mL). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give N-(3,5-dichlorobenzyl)-N-(2-(5-chloro-N-methyl-1H-imidazo[4,5-b]pyridin-2-ylamino)ethyl)-2-hydroxyacetamide (**1971**), LC/MS: (ESI) $(M+H)^+ = 443.5$.


Scheme 57



Reagents and conditions (a) DCM, Ac_2O , DIPEA, 0 °C

[0383] To a solution of compound **1614** HCl salt (20 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and acetic anhydride (0.045 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propyl)acetamide (**1959**), LC/MS: (ESI) $(M+H)^+ = 411.5$.


Scheme 58



Reagents and conditions (a) DCM, methyl chloroformate, DIPEA, 0 °C

[0384] To a solution of compound **1614** HCl salt (20 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and methyl chloroformate (0.045 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give methyl 3,5-dichlorobenzyl 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate (**1964**), LC/MS: (ESI) $(M+H)^+ = 427.6$.


Scheme 59



Reagents and conditions (a) DCM, methyl chloroformate, DIPEA, 0 °C

[0385] To a solution of compound **1614** HCl salt (20 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.4 mmol) and methyl chloroformate (0.090 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give methyl 3,5-dichlorobenzyl-3-(3-(methoxycarbonyl)-5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate (**1965**), LC/MS: (ESI) (M + H)⁺ = 484.4.

Scheme 60




Reagents and conditions (a) DCM, acetoxyacetyl chloride, DIPEA, 0 °C ; (b) K₂CO₃, MeOH

[0386] To a solution of compound **1614** HCl salt (20 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and acetoxyacetyl chloride (0.045 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give (N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propyl)carbamoyl)methyl acetate. (N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propyl)carbamoyl)methyl acetate (18.8mg, 0.04mmol) in MeOH was added K₂CO₃ (0.16 mmol), and stirred at room temperature for 1 hour. The mixture was concentrated, and water (10 mL) was added and extracted with CH₂Cl₂ (3x35 mL). The combined organic extracts were dried (Na₂SO₄), filtered, and concentrated to give

N-(3,5-dichlorobenzyl)-N-(3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propyl)-2-hydroxyacetamide (**1973**), LC/MS: (ESI) (M + H)⁺ = 427.4.


Scheme 61



Reagents and conditions (a) DCM, trimethylsilylisocyanate, DIPEA, 0°C

[0387] To a solution of compound **1614** HCl salt (20 mg, 0.045 mmol) in DCM (5 mL) was slowly added DIPEA (0.2 mmol) and trimethylsilylisocyanate (0.045 mmol) in DCM at 0 °C. The mixture was stirred overnight and then diluted with 25 ml of DCM. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 1-(3,5-dichlorobenzyl)-1-(3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propyl)urea (**1974**), LC/MS: (ESI) (M + H)⁺ = 412.6.

Scheme 62




Reagents and conditions (a) DMF, Cs₂CO₃, μW, 90 °C, 10min; (b) 2-chloro-4-methoxyphenol, DMF, Cs₂CO₃, μW, 120C, 1h.

General Procedure 26 (1933, 1960):


[0388] A solution of 4-bromo-2-fluoropyridine (17.6 mg, 0.1 mmol), (1H-benzo[d]imidazol-2-yl)methanamine HCl salt (26.4 mg, 0.12 mmol), cesium carbonate (0.25 mmol) in DMF (1.0 mL) was microwave irradiated at 90 °C for 10min. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded the N-((1H-benzo[d]imidazol-2-yl)methyl)-4-bromopyridin-2-amine. The solution of N-((1H-benzo[d]imidazol-2-yl)methyl)-4-bromopyridin-2-amine (0.08mmol), 2-chloro-4-methoxyphenol (0.12 mmol) and cesium carbonate (0.16 mmol) in

DMF (1.0 mL) was microwave irradiated at 120 °C for 1h. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded N-((1H-benzo[d]imidazol-2-yl)methyl)-4-(2-chloro-4-methoxyphenoxy)pyridin-2-amine (**1933**). LC/MS: (ESI) (M + H)⁺ = 381.7.

**1960**

[0389] **1960** was synthesized using (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine in General Procedure 26. LC/MS: (ESI) (M + H)⁺ = 400.6.

Scheme 63


**1941**

Reagents and conditions (a) CuI, Cs₂CO₃, dioxane, μ w, 100 °C, 1h; (b) Fe, AcOH (c) KI, EtOH, benzimidazole.

[0390] A solution of 1-iodo-3-nitrobenzene (24.8 mg, 0.1 mmol), 2-chloro-4-methoxyphenol (31.7 mg, 0.2 mmol), CuI (1.91 mg, 0.01 mmol), cesium carbonate (65.2 mg, 0.2 mmol) in 1,4-dioxane (1.0 mL) was heated at 100 °C for 1 h under microwave. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (5 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography (5-10 % ethyl acetate in hexane) afforded the biaryl ether. The biaryl ether (13.6 mg, 0.05 mmol) was treated with Fe (11.2 g, 0.2 mmol), NH₄Cl (11.0 mg, 0.2 mmol) in 1 mL EtOH, and 0.5 mL H₂O was heated at 75 °C for 4 h. After the reaction completed, the mixture was filtered, neutralized with 1 M NaOH and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was chromatographed (10-15 % ethyl acetate in hexane) to afford the amine as a yellow solid. A mixture of benzimidazoles (7.5 mg, 0.045 mmol), substituted aniline (7.5 mg,

0.03 mmol) and KI (9.9 mg, 0.06 mmol) in 1.0 mL of ethanol was heated under reflux. After 6 h, KOH (0.1 mmol in 1.0 mL of water) was added with continuous stirring and heating for 2 h. After the reaction completed, the mixture was extracted with ethyl acetate. The organic fractions were dried and concentrated under vacuum. The residue was chromatographed to give **1941** as a yellow solid. ^1H NMR (500 MHz, CD_3OD): δ = 7.50 (dd, J = 8.5 Hz, 3.0 Hz, 2H), 7.20-7.24 (m, 2H), 7.02 (t, J = 8.0 Hz, 1H), 6.91 (d, J = 3.0 Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 6.63 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 6.37 (dd, J = 8.0 Hz, 3.0 Hz, 1H), 6.16 (dd, J = 8.0 Hz, 2.0 Hz, 1H), 6.06-6.07 (m, 1H), 4.53 (s, 2H), 3.78 (s, 3H) ppm.

Scheme 64



Reagents and conditions (a) DMF, Cs_2CO_3 , μW , 80 °C, 20min; (b) 2-chloro-4-methoxyphenol, CuI, Cs_2CO_3 , dioxane, μW , 160 °C, 2h; (c), NaOH, MeOH, μW , 80 °C, 8min; (d) EDC, pyridine; (e) HOAc, 60 °C


[0391] A solution of 2-bromo-4-fluoropyridine (35 mg, 0.2 mmol), methyl 2-aminoacetate (0.4 mmol), cesium carbonate (0.50 mmol) in DMF (2.0 mL) was heated at 80 °C for 20min under microwave. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded methyl 2-(2-bromopyridin-4-ylamino)acetate. The solution of the methyl 2-(2-bromopyridin-4-ylamino)acetate (24.6 mg, 0.1 mmol), 2-chloro-4-methoxyphenol (0.2 mmol), CuI (0.01 mmol) and cesium carbonate (0.3 mmol) in dioxane (2ml) was heated at 160 °C for 2h under microwave. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded methyl 2-(2-(2-chloro-4-methoxyphenoxy)pyridin-4-ylamino)acetate.

[0392] The solution of methyl 2-(2-(2-chloro-4-methoxyphenoxy)pyridin-4-ylamino)acetate (0.1mmol) in 1ml of 2N NaOH and 1ml of MeOH was microwave irradiated at 80 °C for 8 min.

[0393] After most of solvents were removed, the residue was neutralized with 1 N HCl and extracted with ethyl acetate (3 x 50 mL). The organic fractions were dried and concentrated under vacuum. The residue was dissolved in pyridine and EDC (0.12mmol), benzene-1,2-diamine (1,2 mmol) were added. The solution was stirred at room temperature overnight. The residue was dissolved in acetic acid (1ml). The solution was heated at 60 °C for 3h. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried and concentrated under vacuum.

[0394] The residue was chromatographed to give N-((1H-benzo[d]imidazol-2-yl)methyl)-2-(2-chloro-4-methoxyphenoxy)pyridin-4-amine (**1950**). LC/MS: (ESI) (M + H)⁺ = 381.7.

Scheme 65




1924

Reagents and conditions (a) acetonitrile, K₂CO₃, μ W, 100 °C, 1h; (b) 2,2-diethoxyethanamine, MW 120 °C, 10min; (c), NaOH, MeOH, μ W 80 °C, 8min; (d) benzene-1,2-diamine, EDC, pyridine; (e) HOAc, 60 °C

General Procedure 27(1924, 1918):

[0395] A solution of 2,6-dichloropyridine (29 mg, 0.2 mmol), 2-chloro-4-methoxyphenol (0.4 mmol), potassium carbonate (0.60 mmol) in acetonitrile (2.0 mL) was heated at 100 °C for 1h under microwave. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded 2-(2-chloro-4-methoxyphenoxy)-6-chloropyridine. The solution of 2-(2-chloro-4-methoxyphenoxy)-6-chloropyridine (20 mg, 0.075 mmol) in 2,2-diethoxyethanamine (1ml) was heated at 120 °C for 10 min under microwave. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL), filtered. The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded 6-(2-chloro-4-methoxyphenoxy)-N-(2,2-diethoxyethyl)pyridin-2-amine. The solution of 6-(2-chloro-4-methoxyphenoxy)-N-(2,2-diethoxyethyl)pyridin-2-amine (0.05mmol) in 0.4 ml of acetone

and 1ml of 2 N HCl was stirred at room temperature for 3h. After most of solvents were removed, the residue was neutralized with 1 N NaOH and extracted with ethyl acetate. The organic fractions were dried and concentrated under vacuum. The residue was dissolved in 1 ml of DMF and NaHSO₃ (0.05mmol), benzene-1,2-diamine (0.05 mmol) were added. The solution was stirred at 100 °C for 3h. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give N-((1H-benzo[d]imidazol-2-yl)methyl)-6-(2-chloro-4-methoxyphenoxy)pyridin-2-amine (1924). LC/MS: (ESI) (M + H)⁺ = 381.7.




1918

[0396] 1918 was synthesized using 3,3-diethoxypropan-1-amine in General Procedure 27.

LC/MS: (ESI) (M + H)⁺ = 395.6.

Scheme 66




Reagents and conditions: (a) PPA, 180 °C, 4h; (b) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN, r.t., 3h.

[0397] 4-chlorobenzene-1,2-diamine (1 eq) and 3-aminobenzoic acid (1 eq) in PPA was heated to 180 °C for 4h. Cold NaOH aq (5 M) was added to the reaction mixture to adjust the pH to 10.0. Extracted with DCM, washed with brine, concentrated under vacuum and purified via flash column chromatography to yield 3-(6-chloro-1H-benzo[d]imidazol-2-yl)aniline. 3-(6-chloro-1H-benzo[d]imidazol-2-yl)aniline reacted with 3,5-dichlorobenzaldehyde following the general reductive amination condition in Scheme 1 yields 1952. LC/MS: (ESI) (M + H)⁺ = 403.5

[0398] 3-(6-chloro-1H-benzo[d]imidazol-2-yl)aniline reacted with 3,5-dichlorobenzoic acid to produce product **1953**. LC/MS: (ESI) (M + H)⁺ = 417.6

Scheme 67



Reagents and conditions: (a) EDC, pyridine, r.t. overnight; (b) Propionic acid, Microwave 180 °C, 1h; (c) HCl (aq), Microwave 120 °C, 1h; (d) 3,5-dichlorobenzaldehyde, MeOH, NaBH₃CN, r.t., 3h.


[0399] 6-chloropyridine-2,3-diamine (0.5 mM) and 3-((tert-butoxycarbonyl)amino)benzoic acid (0.5 mM) in pyridine (2 mL) was added EDC (144 mg, 0.75 mM). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous sodium bicarbonate to the residue, the mixture was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave intermediate tert-butyl (3-((2-amino-6-chloropyridin-3-yl)carbamoyl)phenyl)carbamate.

[0400] Intermediate tert-butyl (3-((2-amino-6-chloropyridin-3-yl)carbamoyl)phenyl)carbamate was microwave irradiated in 3 mL propionic acid at 180 °C for 1 hours. The reaction was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave N-(3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)propionamide.

[0401] The suspension of N-(3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)propionamide in concentrated HCl was microwave irradiated at 120 °C for 1h. Evaporated off the solvent got 3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)aniline as yellow solid, which was used for the next step directly.

[0402] 3-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)aniline reacted with 3,5-dichlorobenzaldehyde following the general reductive amination condition in Scheme 1 yields **1966**. LC/MS: (ESI) (M + H)⁺ = 404.7

Scheme 68




Reagents and conditions (a) HOBt, EDC; (b) DCM, TFA; (c) tert-butyl 2-(isocyanatomethyl)-1-Boc-1H-benzo[d]imidazole-1-carboxylate, DCM; (d) DCM, TFA ; (e) Des-Martin reagent; (f) HCOOH, 50 °C.

[0403] To a solution of (S)-2-Boc-amino-3-(2,4-dichlorophenyl)propanoic acid (245 mg, 0.735 mmol) in DCM (15 mL) was added HOBt (123 mg, 0.8 mmol) and EDC (154 mg, 0.8 mmol). The mixture was stirred for 30 min and then concentrated under vacuum. The residue was dissolved in THF (15 mL) and NaBH₄ (56mg, 1.47 mmol) was added at 0 °C. Then the mixture was added 0.5ml of water. The resulting mixture was stirred at 0 °C for 30 min and quenched with MeOH (5 mL). After most solvents were removed, EtOAc (25 mL) was added. The organic phase was washed with 10% citric, saturated NaHCO₃, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give (S)-2-Boc-amino-3-(2,4-dichlorophenyl)propan-1-ol⁸. (S)-2-Boc-amino-3-(2,4-dichlorophenyl)propan-1-ol (96mg, 0.3mmol) was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was completely evaporated under vacuum. The residue was dissolved in anhydrous DCM containing DIPEA (0.4mmol). The solution was cooled to 0° C and tert-butyl 2-(isocyanatomethyl)-1H-benzo[d]imidazole-1-carboxylate (0.3mmol) in DCM was added slowly. The reaction was performed at room temperature for 1h. The solution was diluted with DCM and washed with water, brine, dried over Na₂SO₄.

After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 1-((1-Boc-1H-benzo[d]imidazol-2-yl)methyl)-3-((S)-3-(2,4-dichlorophenyl)-1-hydroxypropan-2-yl)urea. 1-((1-Boc-1H-benzo[d]imidazol-2-yl)methyl)-3-((S)-3-(2,4-dichlorophenyl)-1-hydroxypropan-2-yl)urea was dissolved in 10 ml of DCM. To the solution, 3 ml of TFA was added dropwise. The solution was stirred for 40 min at room temperature. The reaction mixture was completely evaporated under vacuum to give 1-((1H-benzo[d]imidazol-2-yl)methyl)-3-((S)-3-(2,4-dichlorophenyl)-1-hydroxypropan-2-yl)urea (**1935**) LC/MS: (ESI) (M + H)⁺ = 394.5. Compound **1935** (50mg, 0.127mmol) was dissolved in THF and Des-Martin reagent (0.15 mmol) was added. The mixture was stirred at room temperature overnight. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with saturated NaHCO₃, brine, dried and concentrated under vacuum. Purification by chromatography afforded (S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)-N-methoxy-N-methylpropanamide to give (4S)-1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(2,4-dichlorobenzyl)-5-hydroxyimidazolidin-2-one (**1934**) LC/MS: (ESI) (M + H)⁺ = 392.4. Compound **1934** was dissolved in formic acid and heated at 50 °C overnight to give 3-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorobenzyl)-1H-imidazol-2(3H)-one (**1907**). LC/MS: (ESI) (M + H)⁺ = 374.5.


Scheme 69



Reagents and conditions (a) NaBH₄, EtOH

[0404] To a solution of compound **1754** (58mg, 0.15 mmol) in ethanol (15 mL) was added NaBH₄ (1.5 mmol). The mixture was stirred at room temperature overnight. After most solvents were removed, EtOAc (25 mL) was added. The organic phase was washed with water, brine, dried over Na₂SO₄. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give **1906** (5S)-3-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorobenzyl)imidazolidine-2,4-diol, LC/MS: (ESI) (M + H)⁺ = 395.5.

Scheme 70




Reagents and conditions (a) HATU, methoxymethanamine, DMF (b) LiAlH_4 , THF, 0°C ; (c) MeOH, HCl, μw , 80°C , 10min; (d) DBU, ethyl acetate; (e) triphosgene, DIPEA, DCM, (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine; (f) 2 N HCl, 80°C , 10min

[0405] A solution of (S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)propanoic acid (228mg, 0.5mmol), N-methoxymethanamine HCl (58mg, 0.6mmol), HATU (0.6mmol) and DIPEA (1.2mmol) in 5ml of DMF was stirred at room temperature overnight. The solvent was then removed under vacuum. The residue was dissolved in EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried and concentrated under vacuum. Purification by chromatography afforded (S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)-N-methoxy-N-methylpropanamide.

(S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)-N-methoxy-N-methylpropanamide (200mg, 0.4mmol) in anhydrous THF was slowly added LiAlH_4 (0.5mmol) at 0°C . The mixture was stirred for 1h, then water was added slowly. The mixture was extracted into ether (3 times), and the combined organic layer was washed with brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give (S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)propanal. (S)-2-Fmoc-amino-3-(2,4-dichlorophenyl)propanal (150mg, 0.34mmol) was dissolved and concentrated HCl (30 μl) was added. The solution was microwave irradiated at 80°C for 10min. After the solvent was removed, the residue was dissolved in ethyl acetate and washed with saturated NaHCO_3 . The organic layer was treated with DBU (0.35mmol) for 10min with stirring. The organic layer was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was dissolved in anhydrous DCM. The solution was added DIPEA (0.4mmol) and triphosgene (0.12mmol) at 0°C . The solution was stirred at 0°C for 1h and room temperature for 2h, then (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (0.35mmol)

was added. The reaction was performed at room temperature for 1h. The solution was diluted with DCM and washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 1-((S)-3-(2,4-dichlorophenyl)-1,1-dimethoxypropan-2-yl)-3-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)urea. 1-((S)-3-(2,4-dichlorophenyl)-1,1-dimethoxypropan-2-yl)-3-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)urea (50mg, 0.11mmol) was dissolved in 2ml of acetone and 4 ml of 2N HCl. The solution was microwave irradiated at 80 °C for 10min. After the solvent was removed, the residue was dissolved in ethyl acetate and washed with saturated NaHCO_3 , brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to 5-(2,4-dichlorobenzyl)-3-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)-1H-imidazol-2(3H)-one (**1962**). ^1H NMR (500 MHz, MeOD) δ 8.04 (t, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.31 (m, 2H), 6.93 (dd, J = 18.1, 8.8 Hz, 1H), 6.23 (s, 1H), 5.04 (s, 2H), 3.83 (s, 2H). LC/MS: (ESI) ($M + H$) $^+$ = 393.5.

Scheme 71



Reagents and conditions (a) $\text{CF}_3\text{COOH}/(\text{CF}_3\text{CO})_2\text{O}$, NH_4NO_3 ; (b) NH_3/MeOH ; (c) H_2/Pd , MeOH


Synthesis of 6-fluoropyridine-2,3-diamine. Trifluoroacetic anhydride (8.8 ml) was slowly added to a solution of 5-amino-2-fluoropyridine (1.0 g) dissolved in trifluoroacetic acid (15.2 ml) at 0 °C. After stirred in 5 min, the clear solution was added ammonium nitrate (1.43g) portionally. The mixture was stirred at 0 °C for 4h. After solvents were removed, the residue was dissolved in EtOAc, washed with brine three times, dried over Na_2SO_4 . The orange residue was purified via silica gel column with EtOAc/hexane elution to obtain 1.4 g of 2,2,2-trifluoro-N-(6-fluoro-2-nitropyridin-3-yl)acetamide in yellow oil. ^1H NMR (500 MHz, MeOD) δ 8.60 (t, J = 10.5 Hz, 1H), 7.61 (d, J = 3.4 Hz, 1H).

[0406] Ammonia (7 N solution in methanol, 2.0 eq.) was slowly added to a solution of 2,2,2-trifluoro-N-(6-fluoro-2-nitropyridin-3-yl)acetamide (0.82 g) in 10 ml of methanol. After stirred at rt for overnight, the solvent was removed. The residue was purified via silica gel column (30-50 % EtOAc in hexane) to afford the 6-fluoro-2-nitropyridin-3-amine as yellow solid. LC/MS: (ESI) ($M + H$) $^+$ = 159.2.

[0407] 6-fluoro-2-nitropyridin-3-amine (157 mg, 1.0 mmol) was dissolved in 5 ml of MeOH and reduced with H_2 balloon in the presence of 0.2 eq of 10% Pd/C for 2 h at rt. The

solution was filtered through a celite pad. After the solvent was removed, the residue was purified via silica gel column (30-50 % EtOAc in hexane) to obtain 6-fluoropyridine-2,3-diamine as pink solid. ^1H NMR (500 MHz, MeOD) δ 7.00 (dd, $J = 7.9, 7.2$ Hz, 1H), 6.07 (dd, $J = 8.0, 2.2$ Hz, 1H). LC/MS: (ESI) $(\text{M} + \text{H})^+ = 128.8$.

Scheme 72




Reagents and conditions (a) MeOH, HOAc, NaBH_3CN ; (b) TFA/DCM; (c) ethyl 2,2,2-trifluoroacetate; (d) Boc_2O ; (e) NaOH, MeOH; (f) CS_2 , Boc_2O ; (g) 6-fluoropyridine-2,3-diamine; (h) DIC; (i) HCl, dioxane

General Procedure 28 (1614, 1708, 1829, 1849, 1850):


[0408] Tert-butyl 3-aminopropylcarbamate (1.29g, 7.42mmol) was dissolved in 20 ml of MeOH, 1.0 ml of AcOH and 3,5-dichlorobenzaldehyde (1.3 g, 7.42 mmol) was added. After the mixture was stirred for 30 min, NaBH_3CN (14.8 mmol) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH) to give 1.6 g of tert-butyl 3-(3,5-dichlorobenzylamino)propylcarbamate. Tert-butyl 3-(3,5-dichlorobenzylamino)propylcarbamate (1.0 g, 3.0mmol) was dissolved in DCM (20ml) and TFA (10ml) was added. The mixture was stirred at room temperature for 1h and the solvent was removed completely in vacuum. The residue was added anhydrous DCM (50ml) and treated with DIPEA to basic. The solution was added ethyl 2,2,2-trifluoroacetate (3.6mmol) in 10 ml of DCM over 30min at 0 °C. The solution was stirred at room temperature overnight, following by adding Boc_2O (4.5mmol) and DIPEA (4.5mmol). The mixture was stirred at room temperature overnight, then washed water, and brine. It was then dried over

anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography to afford tert-butyl 3-(2,2,2-trifluoroacetamido)propyl3,5-dichlorobenzylcarbamate. To the solution of tert-butyl 3-(2,2,2-trifluoroacetamido)propyl3,5-dichlorobenzylcarbamate (1.0g, 2.33mmol) in 20 ml of MeOH, NaOH (466mg, 11.65mmol) in 10 ml of water was added. The solution was stirred at room temperature overnight. After the solvent was removed, the residue was dissolved in ethyl acetate. The organic layer was washed water, and brine. It was then dried over anhydrous sodium sulfate and evaporated under vacuum. The residue was purified by flash column chromatography (MeOH/NH₄OH/DCM) to afford tert-butyl 3,5-dichlorobenzyl3-aminopropylcarbamate.


[0409] The synthetic procedure was based on the reference¹⁰. To the solution of tert-butyl 3,5-dichlorobenzyl-3-aminopropylcarbamate (0.71g, 2.13 mmol) in 5 ml of anhydrous EtOH, 1.283 ml CS₂ (20.13mmol) and DIPEA (2.13 mmol) were added. The solution was stirred at room temperature for 1h. At 0 °C, Boc₂O (2.024mmol) in 1ml of ethanol was added, following immediately adding DMAP (0.0426mmol) in ethanol. The solution was stirred at 0 °C for 5 min, then room temperature for 2h. After the solvent was removed, the residue was purified by flash column chromatography (MeOH/NH₄OH/DCM) to afford tert-butyl 3,5-dichlorobenzyl3-isothiocyanatopropylcarbamate in 84% yield. To the solution of tert-butyl 3,5-dichlorobenzyl3-isothiocyanatopropylcarbamate (0.733g, 1.95 mmol) in 20 ml anhydrous acetonitrile was added 6-fluoropyridine-2,3-diamine (1.95mmol). The mixture was refluxed for 20h. After the solvent was removed, the residue was recrystallized in EtOAc/hexane twice to give tert-butyl 3,5-dichlorobenzyl3-(3-(2-amino-6-fluoropyridin-3-yl)thioureido)propylcarbamate. To solution of tert-butyl 3,5-dichlorobenzyl3-(3-(2-amino-6-fluoropyridin-3-yl)thioureido)propylcarbamate (487 mg 0.98 mmol) in 25 ml of anhydrous acetonitrile (warm to dissolve), DIC (19.6 mmol) was added. The solution was refluxed for 10h. After cooling down, the white precipitate was collected by filtration to give tert-butyl 3,5-dichlorobenzyl3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate. To the solution of tert-butyl 3,5-dichlorobenzyl3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propylcarbamate (0.15 mmol) in dioxane (20 ml), excess 4 N HCl in dioxane was added. The precipitate was formed in 5 min. The mixture was continued to stir overnight. The solid was collected and washed with dioxane to obtain the white solid of **1614** in HCl form. ¹H NMR (500 MHz, MeOD) δ 7.87 (m, 1H), 7.59 (s, 2H), 7.56 (s, 1H), 6.97 (s, 1H), 4.27 (s, 2H), 3.59 (t, *J* = 6.9 Hz, 2H), 3.24 (m, 2H), 2.16 (m, 2H). LC/MS: (ESI) 369.5 [M+H]⁺.

**1708**


[0410] **1708** was synthesized using tert-butyl 3-amino-2,2-difluoropropylcarbamate and pyridine-2,3-diamine in General Procedure 28. ^1H NMR (500 MHz, MeOD) δ 7.96 (d, J = 4.0 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.28 (s, 2H), 7.25 (s, 1H), 6.99 (m, 1H), 3.93 (t, J = 13.6 Hz, 2H), 3.81 (s, 2H), 2.95 (t, J = 13.9 Hz, 2H). LC/MS: (ESI) 386.9 $[\text{M}+\text{H}]^+$. LC/MS: (ESI) $(\text{M}+\text{H})^+$ = 387.6.

**1829**

[0411] **1829** was synthesized using tert-butyl 2-aminoethylcarbamate and 4-chlorobenzene-1,2-diamine in General Procedure 28. LC/MS: (ESI) $(\text{M}+\text{H})^+$ = 370.5.


**1849**

[0412] **1849** was synthesized using tert-butyl 2-aminoethylcarbamate and 6-chloropyridine-2,3-diamine in General Procedure 28. LC/MS: (ESI) $(\text{M}+\text{H})^+$ = 371.5.

**1850**

[0413] **1850** was synthesized using tert-butyl 2-aminoethylcarbamate and 5-chloropyridine-2,3-diamine in General Procedure 28. LC/MS: (ESI) $(\text{M}+\text{H})^+$ = 371.5.

Scheme 73



Reagents and conditions: (a) NaBH_3CN , MeOH/AcOH , r.t., overnight; (b) Ac_2O , DIPEA, DCM, r.t., 2h; (c) TFA, DCM, r.t., overnight; (d) CS_2 , Boc_2O ; then 6-fluoropyridine-2,3-diamine; (e) DIC, reflux, overnight.


[0414] 3,5-dichlorobenzaldehyde (1 eq) and tert-butyl (2-aminoethyl)carbamate (1 eq) were dissolved in MeOH , AcOH (2 eq) and NaBH_3CN (2 eq) were added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/ MeOH) to give tert-butyl (2-((3,5-dichlorobenzyl)amino)ethyl)carbamate.

[0415] To a solution of tert-butyl (2-((3,5-dichlorobenzyl)amino)ethyl)carbamate (1 eq) in DCM was slowly added DIPEA (1.5 eq) and acetic anhydride (1.2 eq) in DCM at 0°C . The mixture was stirred overnight and then diluted with DCM. The organic phase was washed with water, brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with EA/hexane to give tert-butyl (2-(N-(3,5-dichlorobenzyl)acetamido)ethyl)carbamate.

[0416] Tert-butyl (2-(N-(3,5-dichlorobenzyl)acetamido)ethyl)carbamate was dissolved in DCM, and TFA (5 eq) was added, the mixture was stirred at r.t. over night. The solvent was removed under vacuum to get the deprotected intermediate N-(2-aminoethyl)-N-(3,5-dichlorobenzyl)acetamide which was used for next step without further purification.

[0417] Steps d and e were conducted following General Procedures 28 to get the final product N-(3,5-dichlorobenzyl)-N-(2-((5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)amino)ethyl)acetamide (1897) LC/MS: (ESI) $(\text{M} + \text{H})^+ = 397.2$.

Scheme 74




Reagents and conditions: (a) K_2CO_3 , DMF, 60 °C, 3h; (b) hydrazine, MeOH, reflux, 3h; (c) CS_2 , Boc_2O ; then 6-fluoropyridine-2,3-diamine; (d) DIC, reflux, overnight.

[0418] 4,6-dichloro-1H-indole (1 eq) was dissolved in DMF, K_2CO_3 (3eq) and 2-(3-bromopropyl)isoindoline-1,3-dione (1.1 eq) was added and the mixture stirred at 60 °C for 3 h. Solvent was removed and extracted with DCM. The organic extract was washed with water, brine and dried over Na_2SO_4 . The residue was purified via flash chromatography on silica gel to obtain 2-(3-(4,6-dichloro-1H-indol-1-yl)propyl)isoindoline-1,3-dione.

[0419] 2-(3-(4,6-dichloro-1H-indol-1-yl)propyl)isoindoline-1,3-dione was dissolved in MeOH, hydrazine (3 eq) was added and the mixture refluxed for 3 h. Solvent was removed and the residue was purified via flash chromatography on silica gel to get 3-(4,6-dichloro-1H-indol-1-yl)propan-1-amine.

[0420] 3-(4,6-dichloro-1H-indol-1-yl)propan-1-amine reacted with 6-chloropyridine-2,3-diamine following the general procedure for making benzimidazole ring to get compound 1996. LC/MS: (ESI) $(M+H)^+ = 395.0$

Scheme 75



1673

Reagents and conditions (a) KI, EtOH; (b) Boc_2O ; (c) CH_3SO_2Cl ; (d) NaN_3 ; (e) PPh_3/H_2O ; (f) CS_2/Boc_2O ; (g) 6-fluoropyridine-2,3-diamine; (h) DIC, acetonitrile; (i) HCl/dioxane

General Procedures 29 (1673, 1655)


[0421] A mixture of 3,5-dichlorobenzylamine (1.5 mmol) and (R)-(-)-3-bromo-2-methyl-1-propanol (0.5 mmol), DIPEA (0.5 mmol) and trace amount of KI in ethanol (1.0 ml) was

microwave irradiated at 90 °C for 30 min. The solution was added (Boc)₂O (1.25 mmol) and DIPEA (1.5 mmol) in 2 ml of acetonitrile at room temperature overnight. After solvents were removed, the residues were dissolved in ethyl acetate, washed with water, brine and dried over Na₂SO₄. The organic extract was purified via flash chromatography on silica gel to obtain (S)-3-(N-(3,5-dichlorobenzyl)-N-Boc-amino)-2-methylpropan-1-ol in 50% yield. m/z: 371.0 ([M+Na]⁺)

[0422] The solution of (S)-3-(N-(3,5-dichlorobenzyl)-N-Boc-amino)-2-methylpropan-1-ol (0.25 mmol) in 20 ml of dry DCM at -10 °C was added DIPEA (0.45 mmol) and methanesulfonyl chloride (0.38 mmol). The mixture was stirred at -10 °C for 30 min. After solvent was removed, the residue was dissolved in 5 ml of DMF and NaN₃ (0.50 mmol) was added. The mixture was stirred at 40-45 °C overnight. Solvent was removed and extracted with ethyl acetate. The organic extract was washed with water, brine and dried over Na₂SO₄. The residue was purified via flash chromatography on silica gel to obtain tert-butyl 3,5-dichlorobenzyl(S)-3-azido-2-methylpropylcarbamate. ¹H NMR (500 MHz, CDCl₃) δ 7.28 (m, 1H), 7.10 (s, 2H), 4.37 (s, 2H), 3.24 (m, 4H), 2.04 (br, 1H), 1.48 (m, 9H), 0.97 (d, *J* = 6.7 Hz, 3H). m/z: 395.8 [M+Na]⁺

[0423] A mixture of tert-butyl 3,5-dichlorobenzyl(S)-3-azido-2-methylpropylcarbamate (0.083 mmol), PPh₃ (0.25 mmol) in 1 ml of THF and 15 μl of water was stirred at room temperature overnight. Purification was performed via flash chromatography on silica gel to obtain (R)-N1-(3,5-dichlorobenzyl)-N1-Boc-2-methylpropane-1,3-diamine. m/z: 347.8 [M+H]⁺

[0424] Following the general synthetic procedure of 1614, compound 1673 was synthesized using (R)-N1-(3,5-dichlorobenzyl)-N1-Boc-2-methylpropane-1,3-diamine. ¹H NMR (500 MHz, MeOD) δ 7.93 – 7.83 (m, 1H), 7.64 (s, 2H), 7.56 (s, 1H), 6.97 (d, *J* = 8.4 Hz, 1H), 4.30 (q, *J* = 13.3 Hz, 2H), 3.58 – 3.38 (m, 2H), 3.28 (m, 1H), 3.10 – 2.96 (m, 1H), 2.42 (s, 1H), 1.20 (d, *J* = 6.7 Hz, 3H). m/z: 383.5 ([M+H]⁺).




1655

[0425] 1655 was synthesized using pyridine-2,3-diamine in General Procedure 29. ¹H NMR (500 MHz, MeOD) δ 8.03 (m, 1H), 7.56 (s, 2H), 7.46 (s, 1H), 7.32 (m, 1H), 7.00 (m, 1H),

4.59 (m, 2H), 3.63 (m, 2H), 3.40 (m, 2H), 2.20 (m, 1H), 1.28 (m 3H). LC/MS: (ESI) 365.5 [M+H]⁺.

Scheme 76



1717

Reagents and conditions (a) 100 °C, 2h; (b) PPA, CH₃SO₃H; (c) (R)-(+)-tert-butylsulfonamide, Ti(OEt)₄; (d) NaBH₄; (e) HCl, dioxane; (f) 6-fluoropyridine-2,3-diamine, acetonitrile, heating; (g) DIC, acetonitrile, heating; (h) HCl, acetone; (i) MeOH, HOAc, NaBH₃CN

[0426] A mixture of 2,4-dichloroaniline(1.032g) and acrylic acid (2ml) was heated to 100 °C for 2 h. After the reaction was completed, the reaction mixture was slowly added into 500 ml of water with strongly stirring. The solid was collected by filtration and dissolved in ethyl acetate. The organic layer was washed with water three time, brine and dried over Na₂SO₄. After solvent was removed, 3-(2,4-dichlorophenylamino)propanoic acid was obtained and directly used .

[0427] A mixture of 3-((2,4-dichlorophenyl)amino)propanoic acid (1.0 mmol) in polyphosphoric acid (PPA) (3 mL) and CH₃SO₃H (1.0 mL) was mechanically stirred at 100 °C for 10 h. After cooling to 0°C, ice-water was added into the reaction mixture. The aqueous phase was basified to pH = 12 with solid NaOH at 0°C. The aqueous layer was extracted with ethyl acetate. The organic layer were dried over anhydrous Na₂SO₄, filtered, and evaporated

under reduced pressure to give a crude product which was purified by column chromatography (petroleum ether: ethyl acetate=5:1) to give 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one as yellow solid. m/z : 217.4 ($[M+H]^+$)

[0428] To a stirred solution of 6,8-dichloro-2,3-dihydroquinolin-4(1H)-one (0.3 mmol) in DCE (5 mL) was added $Ti(OEt)_4$ (2.0 eq.), and (R)-(+)-tert-butylsulfinamide (0.33 mmol) then heated to 80 °C for 12 hours¹¹. The reaction mixture was cooled and concentrated under vacuum, diluted with EtOAc (80 mL) and brine (100mL) then the mixture was filtered through a pad of celite. The organic phase was separated, dried (Na_2SO_4) and concentrated under vacuum. The residue was subjected to flash silica chromatography, gradient elution (0 to 50 %) hexane /ethyl acetate to furnish N-((R)-(+)-tert-butylsulfyl)-6,8-dichloro-2,3-dihydroquinolin-4(1H)-imine.


[0429] A solution of N-((R)-(+)-tert-butylsulfyl)-6,8-dichloro-2,3-dihydroquinolin-4(1H)-imine (0.1 mmol) in THF (2 mL) and water (20 μ L) was cooled in an CH_3COCH_3 /dry ice bath to -50 °C. Upon equilibration to bath temperature, solid sodium borohydride (4.0 eq.) was added¹². The resulting mixture was allowed to warm to rt over 4 h. The solvent was evaporated and the residue taken up in DCM, dried over anhydrous $MgSO_4$, the insoluble material was removed via filtration and the solvent was evaporated to afford colorless oil. The residue was purified by chromatography on silica using ethyl acetate/hexane as the eluent to give (R)-N-(tert-butylsulfyl)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine. ^1H NMR(500 MHz, $CDCl_3$) δ 7.32 (m, 1H), 4.57 (br, 1H), 4.42-4.46 (m, 1H), 4.30-4.35 (m, 1H), 3.34 (s, 1H), 2.13-2.17 (m, 2H), 1.26 (s, 9H). m/z : 323.0 ($[M+H]^+$)

[0430] To a solution of (R)-N-(tert-butylsulfyl)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine (0.05 mmol) in methanol (2 mL) was added 4.0 M of hydrochloric acid in 1,4-dioxane (5.0 eq.). The reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated to give (R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine and used without further purification.

[0431] A solution of (R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-amine HCl salt (0.1 mmol) in 5 ml of methanol was added DIPEA (0.1 mmol), 0.15 ml of HOAc and 3-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-ylamino)propanal (0.12 mmol). The mixture was stirred at room temperature for 30 min, $NaBH_3CN$ (0.2 mmol) was added. The reaction mixture was stirred at 50 °C for 2 days. After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM and further purified by using preparative HPLC to give compound 1717 in TFA salt. Conversion of TFA salt to HCl was performed via adding HCl

in methanol and removing solvent to give a white solid. m/z : ^1H NMR (500 MHz, MeOD) δ 7.43 (m, 1H), 7.15 (m, 2H), 6.48 (d, $J = 8.2$ Hz, 1H), 3.92 (m, 1H), 3.47 (m, 4H), 2.85 (m, 2H), 2.20 (d, $J = 17.5$ Hz, 1H), 1.97 (m, 3H). LC/MS: (ESI) 410.4 $[\text{M}+\text{H}]^+$.

Scheme 77




1709

Reagents and conditions (a) NaOH, H_2O , 100°C ; (b) oxalyl chloride, AlCl_3 ; (c) (R)-(+)-tert-butylsulfinamide, $\text{Ti}(\text{OEt})_4$; (d) NaBH_4 ; (e) HCl, dioxane; (f) 6-fluoropyridine-2,3-diamine, acetonitrile, heating; (g) DIC, acetonitrile, heating; (h) HCl, acetone; (i) MeOH, HOAc, NaBH_3CN

[0432] A solution of 2,4-dichlorophenol (10 mmol) and NaOH (10 mmol) in 20 mL of water was heated at 100°C for 20min. A solution of 3-bromopropionic acid (20 mmol) and NaOH (20 mmol) in 10 ml of water was added slowly to the above hot solution. The mixture was heated at 100°C overnight, cooling to room temperature. The reaction mixture was made acidic with concentrated HCl. The mixture was extracted into ether (3 times), and the combined organic layer was extracted with saturated NaHCO_3 . The water layer was made acidic and extracted with ether (3 times). The combined organic layer was washed with brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 3-(2,4-dichlorophenoxy)propanoic acid in white solid.

[0433] Oxalyl chloride (5.2 mmol) was added to the solution of 3-(2,4-dichlorophenoxy)propanoic acid (2.6 mmol) in 20 mL of anhydrous DCM followed by a drop of DMF. After 1.5 hours, the solution was cooled in an ice-water bath. AlCl_3 (2.86 mmol) was added and the dark red solution was allowed to slowly reach room temperature and stirred overnight. The mixture was poured into ice and the organic layer was separated. The aqueous layer was extracted with ethyl acetate twice. The combined organic layers were washed with 1 N NaOH, brine, dried over Na_2SO_4 and concentrated. Flash chromatography of this residue eluted with hexane and EtOAc provided 6,8-dichloro-2,3-dihydrochromen-4-one in white solid. m/z : 218,2 $[\text{M}+\text{H}]^+$


[0434] Following the synthetic procedure of compound 1717, compound 1709 was synthesized using (R)- 6,8-dichloro-2,3-dihydrochromen-4-one. ^1H NMR (500 MHz, MeOD) δ 7.91 (m, 1H), 7.62 (d, $J = 1.9$ Hz, 1H), 7.54 (d, $J = 1.8$ Hz, 1H), 7.00 (d, $J = 8.3$ Hz, 1H), 4.68 (m, 1H), 4.51 (m, 2H), 3.66 (m, 2H), 3.45 (m, 2H), 2.54 (m, 1H), 2.51 (m, 1H), 2.25 (m, 2H). LC/MS: (ESI) 411.3 $[\text{M}+\text{H}]^+$.



1711

[0435] Following the synthetic procedure of compound 1717, compound 1711 was synthesized using (S)- 6,8-dichloro-2,3-dihydrochromen-4-one produced by L-Selectride¹². LC/MS: (ESI) 411.3 $[\text{M}+\text{H}]^+$.

Scheme 78



Reagents and conditions: (a) K_2CO_3 , CH_3CN , r.t. over night; (b) H_2NNH_2 , CH_3OH , MW, 70 °C, 20min, (c) 3,5-dichlorobenzaldehyde, MeOH, NaBH_3CN .


[0436] 5-chloro-1H-imidazo[4,5-b]pyridine-2(3H)-thione (1eq), 2-(2-bromoethyl)isoindoline-1,3-dione (1eq) were dissolved in CH_3CN , K_2CO_3 (4eq) was added and the resulting mixture was stirred at room temperature over night. After the mixture was

extracted with DCM, washed with brine, concentrated under vacuum and purified via flash column chromatography (10% MeOH in DCM) to yield the intermediate 2-(2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)ethyl)isoindoline-1,3-dione.

[0437] 2-(2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)ethyl)isoindoline-1,3-dione was dissolved in MeOH, hydrazine (2eq) was added, the mixture was then microwave irradiated at 70 °C for 20min. The solvent was evaporated off and residue was purified via flash column chromatography directly eluting with 20% MeOH in DCM to yield the deprotected intermediate.

[0438] 2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)ethanamine was dissolved in MeOH, 3,5-Dichlorobenzaldehyde (1.1 equiv) was added, then AcOH was added (2 eq). After the mixture was stirred for 30 min, NaBH₃CN (2 equiv) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding compound **1896** as white solid. LC/MS: (ESI) 388.8 [M+H]⁺.

Scheme 79




Reagents and conditions: (a) ethyl 2-bromoacetate, K₂CO₃, CH₃CN, r.t. over night; (b) LiOH, CH₃OH/H₂O, r.t. overnight, (c) (3,5-dichlorophenyl)methanamine, HATU, DIPEA, DMF, r.t. 3h.

[0439] 5-chloro-1H-imidazo[4,5-b]pyridine-2(3H)-thione (1eq) was dissolved in CH₃CN, K₂CO₃ (4 eq) was added and the resulting mixture was stirred at r.t. for 10 min. Ethyl 2-bromoacetate (1eq) dissolved in CH₃CN was added dropwise. After the mixture was stirred at r.t. overnight, the solvent was evaporated off under reduced pressure. The residue was extracted with DCM, washed with brine, concentrated under vacuum to produce the product ethyl 2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)acetate which was used for the next step without further purification.

[0440] The ethyl ester group of intermediate ethyl 2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)acetate was hydrolyzed following the procedure of step b in Scheme 2 to get the free acid and used for the next step without purification.

[0441] 2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)acetic acid (1eq), DIPEA (3 eq), (3,5-dichlorophenyl)methanamine (2 eq) were dissolved in DMF, then HBTU (2 eq) was added, the resulting mixture was stirred at r.t. for 3h. The solvent was removed under vacuum and the residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding compound **1951**. m/z: 402.8 ([M+H]⁺)

Scheme 80



Reagents and conditions: (a) CH₃CN, reflux, over night; (b) HgO, S, EtOH, reflux, overnight; (c) LiOH, MeOH/H₂O, r.t., 3h; (d) (3,5-dichlorophenyl)methanamine, EDC, HOBt, DIPEA, DMF.

[0442] 6-chloropyridine-2,3-diamine (1 eq), ethyl 2-thiocyanatoacetate (1 eq) in CH₃CN was refluxed over night. The solvent was removed under vacuum and the residue was dissolved in DCM and washed with brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH), yielding ethyl 2-(3-(2-amino-6-chloropyridin-3-yl)ureido)acetate.


[0443] To solution of ethyl 2-(3-(2-amino-6-chloropyridin-3-yl)ureido)acetate in EtOH, HgO (2 eq) and cat. S were added. The solution was refluxed overnight. The reaction mixture filtered through celite, washed with MeOH. The filtrate was collected, dried, purified by flash column chromatography (DCM/MeOH), yielding ethyl 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetate.

[0444] LiOH·H₂O (3 eq) was added to the solution of ethyl 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetate in CH₃OH/H₂O (CH₃OH:H₂O=3:1). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was used for next step without further purification.

[0445] 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)acetic acid (1 eq) was dissolved in DMF and EDC (1.5 eq), HOBt (1.5 eq), DIPEA (2.0 mmol), (3,5-

dichlorophenyl)methanamine (1 eq) were added. The solution was stirred at room temperature overnight and then removed solvent under vacuum. The residue was dissolved in DCM. The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give 2-((5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)amino)-N-(3,5-dichlorobenzyl)acetamide (**1970**). LC/MS: (ESI) (M + H)⁺ = 385.5.

Scheme 81




Reagents and conditions: (a) acetone, NaOH, 0 °C; (b) DMF, (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine, 110 °C, 30min; (c) DMF, 2-(piperazin-1-yl)pyrazine, 110 °C, 15min

[0446] Compound **1796** was synthesized according to the reference¹³. To a solution of 2,4,6-trichloropyrimidine (76m g, 0.42 mmoles) in 2 mL of acetone at 0°C, was slowly added a solution of 2-chloro-4-methoxyphenoxide (0.46 mmoles) and stirred at rt for 3 hours. After the solvent was removed, the residue was extracted with ethyl acetate. The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give 4-(2-chloro-4-methoxyphenoxy)-2,6-dichloropyrimidine. The solution of 4-(2-chloro-4-methoxyphenoxy)-2,6-dichloropyrimidine(0.2mmol), (5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methanamine (0.24mmol) and DIPEA (0.4mmol) in 1 ml of DMF was microwave irradiated at 110 °C for 30min. After the solvent was removed, the residue was extracted with ethyl acetate. The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to give 6-(2-

chloro-4-methoxyphenoxy)-2-chloro-N-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)pyrimidin-4-amine (**1796**). LC/MS: (ESI) (M + H)⁺=436.4.

[0447] To a solution of 6-(2-chloro-4-methoxyphenoxy)-2-chloro-N-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)pyrimidin-4-amine (0.1 mmol), 2-(piperazin-1-yl)pyrazine (0.2mmol) and DIPEA (0.2mmol) in 1 ml of DMF was microwave irradiated at 110 °C for 15min. After the solvent was removed, the residue was extracted with ethyl acetate. The organic layer was washed with water, brine (25 mL), dried and concentrated under vacuum. The residue was chromatographed to 6-(2-chloro-4-methoxyphenoxy)-N-((5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)methyl)-2-(4-(pyrazin-2-yl)piperazin-1-yl)pyrimidin-4-amine (**1797**). LC/MS: (ESI) (M + H)⁺=564.1.

Scheme 82




[0448] Reagents and conditions: (a) MeOH, HOAc, NaBH₃CN; (b) TFA/DCM; (c) MeOH, HOAc, NaBH₃CN, indole-3-carboxaldehyde

[0449] 1-Boc-piperazine (50mg, 0.269mmol) was dissolved in 2 ml of MeOH, 0.1 ml of AcOH and 2,4-dichlorobenzaldehyde (47mg, 0.269 mmol) was added. After the mixture was stirred for 30 min, NaBH₃CN (0.54 mmol) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH) to give 1-(2,4-dichlorobenzyl)-4-Boc-piperazine. 1-(2,4-dichlorobenzyl)-4-Boc-piperazine (60mg, 0.174mmol) was dissolved in DCM (4ml) and TFA (2ml) was added. The mixture was stirred at room temperature for 1h and the solvent was removed completely in vacuum and the residue was co-distilled 2× with methylene chloride. The residue was dissolved in 3 ml MeOH, neutralized with DIPEA, and 0.15 ml AcOH, indole-3-carboxaldehyde (1.1 equiv) were added. After the mixture was stirred for 30 min, NaBH₃CN (2 equiv) was added. The mixture was stirred overnight and the solvent was removed under vacuum. The residue was dissolved in EtOAc (50ml) and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH),

yielding 2-((4-(2,4-dichlorobenzyl)piperazin-1-yl)methyl)-1H-indole (**1608**). LC/MS: (ESI) $(M+H)^+=375.5$.


Scheme 83



Reagents and conditions: (a) LiAlH_4 , THF

[0450] To a solution of **1907** (50mg, 0.134mmol) in anhydrous THF at 0 °C was added LiAlH_4 (5mg, 0.134mmol). After the mixture was stirred at 0 °C overnight, then water was added slowly. The mixture was extracted into ether (3 times), and the combined organic layer was washed with brine, dried over Na_2SO_4 . After solvent was removed, the residue was chromatographed via silica gel, eluted with MeOH/DCM to give 3-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorobenzyl)-2,3-dihydro-1H-imidazol-2-ol (**1936**). LC/MS: (ESI) $(M+H)^+=376.3$.


Scheme 84



Reagents and conditions: acetaldehyde, NaBH_3CN , AcOH, CH_3OH , r.t. overnight.

[0451] Compound **1856** (4.1 mg, 0.01 mmol) was dissolved in 1 ml of MeOH, 5 μL AcOH and acetaldehyde (4 mg, 0.03 mmol) was added. After the mixture was stirred for 30 min, NaBH_3CN (1.4 mg, 0.02 mmol) was added. The mixture was stirred at r.t. overnight and the solvent was removed under vacuum. The residue was dissolved in DCM and washed with sat. sodium bicarbonate and brine. The organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash column chromatography (DCM/MeOH) to give the target compound (S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)-N-ethylpiperidin-3-amine (**1955**). LC/MS: (ESI) $(M+H)^+=439.8$.

Scheme 85



Reagents and conditions: (a1) (a2) NaBH_3CN , AcOH , CH_3OH , r.t. overnight; (b) ethyl 2-bromoacetate, NaH , DMF , 0°C –r.t., 2h; (c) LiOH , $\text{CH}_3\text{OH}/\text{H}_2\text{O}$, r.t. overnight; (d) benzene-1,2-diamine, EDC , pyridine, r.t. overnight; (e) (I) AcOH , 60°C , 3h,

General procedures 30:

[0452] (a) 2-chlorobenzaldehyde (0.2 mM) and piperazin-2-one (0.2 mM) were dissolved in CH_3OH , then AcOH (0.3 mM) and NaBH_3CN (0.4 mM) were added. The mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) to give 4-(2-chlorobenzyl)piperazin-2-one.


[0453] (b) The solution of 4-(2-chlorobenzyl)piperazin-2-one (1eq) in DMF was cooled to 0°C , NaH (1.2 eq) was added and the resulting solution stirred at 0°C for 10 min. Ethyl 2-bromoacetate (1.2eq) was then added in dropwisely at 0°C , and the mixture stirred at r.t. for 2 hours. The solvent was removed under reduced pressure and the residue was extracted by EA. The organic phase was dried over sodium sulfate. Remove solvent in vacuum and purify through flash chromatography on silica gel eluted with EA-hexane to give ethyl 2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetate.

[0454] (c) $\text{LiOH} \cdot \text{H}_2\text{O}$ (3 eq) was added to the solution of ethyl 2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetate in $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ ($\text{CH}_3\text{OH}:\text{H}_2\text{O}=3:1$). The reaction mixture was stirred at r.t. overnight. The solvent was evaporated under reduced pressure, the residue 2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetic acid was used for the next step without further purification.


[0455] (d) 2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetic acid (1 eq) and benzene-1,2-diamine (1 eq) in pyridine was added EDC (1.5 eq). The mixture was stirred at r.t. overnight, and pyridine was then removed under reduced pressure. After addition of saturated aqueous

sodium bicarbonate to the residue, the mixture was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave N-(2-aminophenyl)-2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetamide.


[0456] (e) N-(2-aminophenyl)-2-(4-(2-chlorobenzyl)-2-oxopiperazin-1-yl)acetamide in glacial acetic acid was heated at 60 °C for 3 hours. The reaction mixture was concentrated in vacuum and the residue partitioned between saturated sodium bicarbonate and DCM. The organic extract was dried over anhydrous sodium sulfate, and concentrated in vacuum. Purification through flash chromatography on silica gel eluted with MeOH-DCM (0.5% ammonia hydroxide) gave in 5 mL glacial acetic acid (**1735**). LC/MS: (ESI) (M + H)⁺=356.0.

**1736**


[0457] **1736**: 1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(3-chlorobenzyl)piperazin-2-one was synthesized using 3-chlorobenzaldehyde in General Procedure 30. LC/MS: (ESI) (M + H)⁺=355.8.

**1747**

[0458] **1747**: 1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(2,4-dichlorobenzyl)piperazin-2-one was synthesized using 2,4-dichlorobenzaldehyde in General Procedure 30. LC/MS: (ESI) (M + H)⁺=390.5.

**1748**

[0459] **1748**: 1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(3,5-dichlorobenzyl)piperazin-2-one was synthesized using 3,5-dichlorobenzaldehyde in General Procedure 30. LC/MS: (ESI) (M + H)⁺=390.4.



[0460] 1760: 1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(3,5-dichlorobenzyl)piperazin-2-one-1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(2-naphthoyl)piperazin-2-one was synthesized using 2-naphthoyl chloride in General Procedure 30. LC/MS: (ESI) (M + H)⁺ = 385.5.

***T. brucei* MetRS aminoacylation assay.**

[0461] Test compounds (assayed in triplicate in serial 3 dilutions) were pre-incubated for 15 minutes at room temperature with 10 nM of *T. brucei* MetRS (PMID: 21282428), 0.1 mM ATP, 240 nM ³H[L]-methionine (83 Ci/mmol) 0.1 U/mL pyrophosphatase (I1643; Sigma-Aldrich), 0.2 mM spermine, 0.1 mg/mL bovine serum albumin, 2.5 mM dithiothreitol, 25 mM HEPES-KOH (pH 7.9), 10 mM MgCl₂, 50 mM KCl, and 2% DMSO (PMID: 22720744, PMID: 25163684, PMID: 21282428). Reactions (75 µL/well) were started with the addition of 400 µg/mL bulk *E. coli* tRNA (R4251; Sigma-Aldrich or the equivalent activity of 10109550001; Roche) and incubated at room temperature for 120 minutes in 96-well filter plates with Durapore membranes (MSHVN4B10; Millipore). Reactions were quenched by adding 100 µL/well of ice cold 10% trichloroacetic acid and washed three times with 300 µL/well of ice cold 10% trichloroacetic acid. The plates were dried, 25 µL/well of scintillation fluid added, and the counts quantified using a scintillation plate reader. Percent inhibition was calculated by comparing the signal of wells with test compounds to that of wells without test compounds. Every assay also included wells without bulk *E. coli* tRNA and test compounds to measure background signal. IC₅₀ values were calculated in Prism 3.0.

Growth inhibition assays of *T. brucei* cell cultures.

[0462] *T. brucei* (bloodstream form strain 427 from K. Stuart, Seattle Biomedical Research Institute, Seattle, WA) was cultured in HMI-9 medium containing 10% fetal bovine serum, penicillin, and streptomycin at 37°C with 5% CO₂. Drug sensitivity of the *T. brucei* strain was determined in 96 well microtiter plates in triplicate with an initial inoculum of 1 x 10⁴ trypomastigotes per well. Compound stock solutions were prepared in DMSO at 20mM and added in serial dilutions for a final volume of 200 µL/well. Parasite growth was quantified at 48 h by the addition of Alamar Blue (Alamar Biosciences, Sacramento, CA).

Pentamidine isethionate (Aventis, Dagenham, UK) was included in each assay as a positive control. Standard errors within assays were consistently less than 15%.

Biological Data

[0463] The compounds of the present disclosure were tested against **A)** MetRS (T. brucei) ATP depletion assay using Kinase-Glo, IC₅₀ (nM); **B)** T.brucei EC₅₀ (nM); **C)** T.cruzi EC₅₀ (nM); **D)** MetRS (Giardia) aminoacylation assay with modified cpd dilution method IC₅₀ (nM); **E)** Giardia intestinalis (ATCC 50580) EC₅₀ (nM); **F)** L. amaz EC₅₀ (nM); **G)** P.fal (3D7) EC₅₀ (nM); **H)** MetRS (S. aureus) ATP depletion assay using Kinase-Glo with modified cpd dilution method, IC₅₀ (nM); **I)** S.aureus (ATCC 29213) MIC/EC₅₀, MIC (ug/ml); **J)** S.aureus MRSA (ATCC 43300) MIC/EC₅₀, MIC (ug/ml); **K)** E.faecalis (ATCC 29212) MIC/EC₅₀, MIC (ug/ml); **L)** E.faecium (ATCC 51559) MIC/EC₅₀, MIC (ug/ml); **M)** MetRS (Brucella) ATP depletion assay using Kinase-Glo, IC₅₀ (nM). The results are listed in Tables 1 and 2:

[0464] Table 1:

No.	A	B	C	D	E	F
1575	9	9.36, 7.64	192.96	36	> 10000.0, 4500.0, 8000.0	> 10000.0
1576	109	402.68				
1599	45.00, 59.00	661.89	2912.02			
1608	> 1000	4234.73				
1614	16	6.22, 4.43, 1.81	39.45, 35.68	9	3423.0, 1978.0	> 1000, > 1000
1627	61	> 9.08, 4.60	623.09			
1634	133	121.06	9759.25			
1641	< 49.00, 138.00	7654.28, 8351.62				
1655	43	11.34, 7.97	709.29			6740.1
1671	1271	> 20000				
1673	11	7.58, 1.23	1536.16			7862.9, 5711.0, 8284.6
1674	23019	> 20000				
1675	8228	> 20000				
1683	74	8831.12	> 10000	> 1000	> 2000, > 2000	> 1000
1699	13100	> 10000				
1701	5	1293.71	8747.24			
1702	9.00, 11.00	4974.05				
1703	12068	> 10000				
1704	280	8610.96				
1705	100	8839.47				
1706	38	2761.15				
1708	11	1561.50, 892.78	> 5000			> 1000
1707	26	1608.28	> 10000			> 1000
1709	8	1.70, 0.18, 0.05	> 4.57, 5.05	2	664.0, 492.0	1301.2, 1134.2

1711	752	2822.86				
1716	51	373.64	1048.87			> 1000
1717	28	> 0.91, 0.67, 0.06, 0.41	> 4.57, 3.72	3	590.0, 316.0	2852.4
1720	70	848.39	3704.39			
1726	2378	8023.6				
1727	5088	> 20000				
1728	> 10000	> 20000				
1729	17	119.43	> 5000			> 1000
1730	142	722.52				
1731	5000	> 20000				
1732	288	> 5000				
1733	926	8810.04				
1734	60	1396.88	4909.57			
1735	> 10000	> 20000				
1736	> 10000	> 20000				
1737	47	> 1000				
1738	> 10000	> 20000				
1739	1452	> 10000				
1740	549	> 10000				
1741	132	4223.16				
1744	184	3260.27				
1745	812	4602.62				
1746	138	3333.74				
1747	> 10000	> 10000				
1748	> 10000	> 10000				
1752	1364	> 10000				
1753	73	2328.63	> 5000			
1754	> 10000	5894.39	> 5000			
1755	1390	> 10000				
1756	3718	> 10000				
1757	3500	> 10000				
1758	31	4645.85				
1759	> 10000	> 10000				
1760	> 10000	> 10000				
1761	54	995.78	> 5000			
1762	28	1058.06				
1763	168	12657.66				
1764	> 10000	> 20000				
1765	> 10000	> 20000				
1766	297	3525.77	> 5000			
1767	51	626.61	2929.69			
1768	18	70.23	1689.02			> 1000
1769	11	1071.12	> 5000			
1779	> 10000	> 20000				
1780	67.00, 36.00	1162.97, 1061.52				
1785	> 10000	> 20000				
1786	310	5673.64				
1787	267	2683.83				
1788	124	358.76	4174.3			
1789	89	2810.59	4985.76			
1790	105	2695.33				
1791	8477	> 20000				
1792	150	2682.05				
1793	> 10000	6375.52				
1794	31.00, 17.00, 72.00, 70.00	1332.84, 1873.14,	5229.23			

		1840.56				
1795	> 10000	12335.27				
1796	17	49.85, > 9.08	521.12			> 1000
1797	23	22.23, > 9.08	432.26			> 1000
1798	> 10000	1228.86				
1799	2063	8308.97				
1800	663	961.47				
1801	533.00, 569.00	27.16, 71.92	252.47			
1802	4291	> 20000				
1803	> 10000	> 20000				
1804	389	14979.7				
1805	56.00, 27.00	1692.64	5614.27			
1806	7628.00, 9885.00	3330.66				
1807	1553	3729.23				
1808	> 10000	17417.37				
1809	43	821.2	3461.75			
1810	361	4526.85				
1811	8	81.76	2512.78			
1812	> 10000	3762.72				
1813	247	1375.15				
1814	3397	7213.32				
1815	> 10000	4086.56				
1816	> 10000	8786.35				
1817	> 10000	2055.91				
1818	7951	> 20000				
1819	7233	8903.31				
1820	290	3142.7				
1821	54	1670.28				
1822	1493	3574.4				
1823	2294	4557.37				
1824	160	2240.02				
1825	1558	3645.45				
1826	454	2932.6				
1827	390	5021.49				
1828	> 10000	7405.91				
1829	85	538.71	3042.29			
1830	> 10000	> 20000				
1831	> 10000	8002.72				
1832	243	2154.33				
1833	> 10000	> 20000				
1835	23	873.42	> 20000			
1836	1433	7630.29				
1837	119	1336.92				
1838	> 10000	8567.89				
1839	3677	2318.59				
1840	580	1952.34				
1841	6301	3687.05				
1842	> 10000	8577.61				
1844	60	597.58	5424.02			
1845	47	1538.61				
1846	1637	11030.23				
1847	696	9012.74				
1848	847	10588.34				
1849	33	60.73	1812.42			

1850	385	3868.81				
1851	81	3375.75				
1852	75	5543.34				
1853	> 10000	> 20000				
1854	106	580.1				
1855	192	998.64				
1856	19	38.73	1471.8			4347.7
1857	72	1475.76				
1858	340	1888.4				
1859	1429	> 20000				
1860	6900	8565.45				
1861	1471	4439.75				
1862	31	343.15	4924.81			
1863	> 10000	3289.78				
1864	2166	> 20000				
1865	> 10000	6633.56				
1866	> 10000	> 20000				
1867	4970	> 20000				
1868	77	1081.21				
1869	52	1699.67				
1870	54	457.53	2608.61			
1871	447	5435.64				
1872	> 10000	8341.99				
1873	98	5498.13				
1874	51	3653.7				
1875	38	1895.51	13103.6			
1876	375	> 20000				
1877	191	8678.69				
1878	195	7516.95				
1879	416	11214.45				
1880	214	8397.97				
1881	35	306.62	5870.45			
1882	87	1024.25				
1883	39	5620.25, 3665.62	17446.4			
1884	24	55.94	772.85			
1885	1510	5871.08				
1886	14	299.07	5157.74			
1887	6657	> 20000				
1888	> 10000	> 20000				
1889	> 10000	> 20000				
1890	78	6221.13				
1891	3904	> 20000				
1892	33	1547.62				
1893	8	14.84, 28.19	339.9			3784.3
1894	179	2892.72				
1895	17	569.06				
1896	1054	1399.07				
1897	16	652.55				
1898	196	8801.76				
1899	89	> 9.08, 56.50	259.67			
1900	27	127.66, > 200.00	2237.11			
1901	692	5097.58				
1902	18	354.05				
1903	682	1813.45				
1904	> 10000	> 20000				

1905	4308	> 20000				
1906	2942	6228.96				
1907	19	346.06	7668.95			> 1000
1908	15	85.21				
1909	20	333.54				
1910	19	39.52	934.37			
1911	21	356.93				5146.6
1912	8	70.6	2248.41			7726.2
1913	26	113.02				> 1000
1914	18	252.1				
1915	170	3104.67				
1916	58	479.71				9546.3
1917	21	> 0.91, 4.02	15.66			663.2
1918	1114	9556.51				
1919	15	6.31, 9.45	88.77			1639.4
1920	16	110.76				
1921	25	240.64				
1922	140	2762.19				
1923	32	566.36				
1924	165	3284.35				
1925	15	314.17				
1926	20	75.52	1332.62			
1927	47	826.99				
1928	21	325.55				
1929	29	510.83				
1930	389	3115.19				
1931	305	1703.03				
1932	518	8908.51				
1933	22	102.11	1709.13			
1934	118	2001.52				
1935	> 10000	9358.82				
1936	65	1827.98				
1937	19	229.79				
1938	36	> 9.08, 30.53	266.04			
1939	73	29.64, 68.14	175.74			
1940	42	359.36				
1941	273	3132.75				
1942	20	145.42				
1943	2130.00, 3540.00	418.74, 388.60				
1944	535	11671.86				
1945	> 10000	13696.23				
1949	18	79.92, 85.47	1305.66			
1950	50	867.21, > 200.00				
1951	288	663.62				
1952	2283.00, 1737.00	186.83, 367.34				
1953	> 10000, > 10000	903.42, 812.43				
1954	61	368.97, 564.94				
1955	286	1736.37				
1956	325	1549.17				
1957	11	14.52, 30.10				
1958	13	62.37, 33.09				
1959	16	39.30, 51.15				

1960	21	21.52, > 9.08				
1961	121	3763.17				
1962	19	12.92				
1963	21	97.37				
1964	17	36.65				
1965	345.00, 322.00	96.2				
1966	72	1034.47				
1967	88	2301.41				
1968	1856	> 20000				
1969	782	7959.94				
1970	69	2979.12				
1971	13	62.28, 40.40				
1972	27	58.00, 25.21				
1973	11	90.99, 43.27				
1974	7	38.82, 10.52				
1990	17	2040.3				
1991	18	2066.58				
1992	14	110.82	2130.39			
1994	59	1414.46				
1996		5299.9				

[0465] Table 2:

No.	G	H	I	J	K	L	M
1575	7005.6	35				0.625	
1614	7710.9	37	1.25		0.625	1.25	490
1655		171	10	10			
1673		113	5	5			
1701		67	> 10	> 10			
1705		1693					
1706		83					
1708		88					
1707		37					
1709		19				> 0.04	
1711		368			> 10, > 10	> 10	
1716							
1717		28	0.157	0.157	> 0.04, 0.079	> 0.04	
1720		181	> 10	> 10			
1729		27				> 10	
1734		2443	> 10	> 10			
1753		1095				> 10	
1758		1041	> 10	> 10			
1761		1912	> 10	> 10			
1762		2884	> 10	> 10			
1767		> 1000	> 10	10			
1768		30	> 10	> 10			
1769		95	> 10	> 10			
1794		22581					
1796		55					
1797		2					
1805		> 1000					
1811		709					
1849		3109					
1856		365					

1862		754					
1870		837					
1883		333					
1884		122					
1886		505					
1893		296					
1895		445					
1897		606					
1899		323					
1900		303					
1907		54					
1908		155					
1910		22					
1913		691					
1914		303					
1917		137					
1919		328					
1921		1575					
1923		504					
1925		266					
1926		172					
1933		40					
1938		1260					
1939		271					
1942		104					
1949		606					
1950		797					
1954		928					
1957		424					
1958		381					
1959		12					
1960		12					
1962		17					
1963		348					
1966		5734					
1967		> 1000					
1970		1078					
1971		85					
1972		140					

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/46357

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 403/12, 471/04, 487/04 (2015.01)

CPC - C07D 235/30, 401/12, 403/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C07D 403/12, 471/04, 487/04 (2015.01)

CPC: C07D 235/30, 401/12, 403/12 USPC: 514/303, 393, 394

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PATSEER (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, Other Countries (INPADOC), RU, AT, CH, TH, BR, PH); ProQuest; Google Scholar; IP.com; SureChEMBL; KEYWORDS: inhibit*, MetRS, methionyl RNA synthetase, treat* bacteri* infect*, imidazo 4 5 b pyridin 2 yl, propane 1 3 diamine, 3 5 dichlorobenzyl, gram positive, Staphylococc*, crystal* structure, model*, dock*, binding pocket

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y — A	US 2007/0213362 A1 (BERGE, J et al.) 13 September 2007; paragraphs [0007]-[0014], [0017], [0021], [0029], [0031], [0047], [0061], see Example 1	1 — 36-42, 43/36-41 — 4-8, 10/5-8, 32
X — A	PUBCHEM CID 73012917, pages 1-10, Create Date: 2014-03-07; Modify Date: 2015-10-10; page 3; [retrieved on 2015-10-14]. Retrieved from the Internet: <URL: http://pubchem.ncbi.nlm.nih.gov/compound/73012917 >	53 — 54
Y — A	WO 00/71522 A1 (SMITHKLINE BEECHAM) 30 November 2000; page 1, lines 3-5, 27-35; page 2, lines 1-15, 20-32; page 4, line 27	1-3, 9 — 4-8, 10/5-8, 32
Y	KIM, SY et al., 3-D-QSAR Study and Molecular Docking of Methionyl-tRNA Synthetase Inhibitors, Bioorganic & Medicinal Chemistry 11, pages 5325-5331, 2003; <DOI: 10.1016/j.bmc.2003.09.044>; abstract; page 5328, column 2; paragraph 2; page 5329, figures 3b-c; column 1; paragraph 1; page 5331, column 1, paragraphs 1-2	1-3, 9, 36-42, 43/36-41
A	US 2012/0264943 A1 (BJORK, S et al.) 18 October 2012; page 6, Scheme 2, see compound 5	54
A	US 2004/0019037 A1 (ASKEW, BC et al.) 29 January 2004; page 18, Scheme 5, see compound 5-2	54



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

15 October 2015 (15.10.2015)

Date of mailing of the international search report

01 DEC 2015

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/46357

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 11-31, 33-35 and 44-52
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.